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 1 
Summary 
Breast cancer is the most frequently diagnosed malignancy among women. Due to its molecular 
heterogeneity, a generalized therapy is not possible. Nuclear estrogen receptor-α (ER-α) is 
overexpressed in the majority of breast tumors. ER-positive patients benefit from endocrine therapy 
that abrogates estrogen-induced tumor growth. However, approximately half of the patients do not 
respond or relapse due to de novo or acquired resistance against therapy. Occurrence of resistance is 
a drawback for long-term efficacy of endocrine therapy and leads to poor prognosis. The mechanisms 
underlying acquisition of endocrine therapy resistance, however, remain elusive. Recently, epigenetic 
reprogramming has been proposed as a means to render the tumor cells refractory to treatment. 
Therefore, the aims of this project were to uncover novel targets that confer resistance and to 
elucidate the involvement of epigenetics in this process. To this end, two ER-positive cell lines 
(MCF7 and T47D) were utilized to recapitulate endocrine therapy resistance in vitro by treating them 
either with tamoxifen (TAMR) or depriving them of estrogen (LTED). I identified GLYATL1 
(glycine-N-acyltransferase like 1) as a highly de-regulated gene as revealed by RNA-seq and ATAC-
seq integrative analysis comparing resistant cell lines to the sensitive parental. GLYATL1 encodes for 
an enzyme that catalyzes the transfer of an acyl group to glutamine. I showed that knockdown of 
GLYATL1 sensitizes resistant cell lines while GLYATL1 overexpression renders sensitive luminal 
cells resistant to endocrine therapy. Furthermore, I found GLYATL1 is involved in acetylation of 
histone residues H3K9 and H3K14 since the knockdown of GLYATL1 led to a decrease in these two 
histone marks in resistant MCF7 cells. Moreover, I showed the expression of GLYATL1 to be 
regulated in these cells by methylation, growth factor receptor HER2, and transcription factors ERα, 
GATA3 and p300. CRISPR/dCas9-mediated epigenetic editing method was adopted to validate the 
involvement of methylation in GLYATL1 regulation. This method is a repurposed version of 
CRISPR/Cas9 system where Cas9 is catalytically inactive and fused to catalytic domain of epigenetic 
enzymes. Combined with sgRNAs, these effectors can be recruited to target regions to modulate the 
epigenetic landscape, thereby altering gene expression. Furthermore, I utilized this method of 
epigenetic editing to investigate endocrine therapy resistance involvement of other genes such as 
CD44 and BAMBI, expression of which were also found to be elevated in resistant cells compared to 
parental. I showed that targeting promoter regions of CD44 and BAMBI with dCas9-p300 yielded 
upregulation of both genes whereas dCas9-G9a combination led to a downregulation which resulted 
in retarded proliferation in LTED cells. Moreover, altering expression of BAMBI elicited similar 
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changes in CD44 expression further proving CD44 as a direct target gene of the Wnt signaling 
pathway, for which BAMBI acts as an activator. In conclusion, my results demonstrate the 
importance of GLYATL1 in initiation and maintenance of endocrine therapy resistance and identify 
its involvement in H3K9 and H3K14 acetylation. This study demonstrates the potential of epigenetic 
reprogramming mediated regulation of target gene expression as a novel method of therapeutic 
intervention. 
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Zusammenfassung 
Brustkrebs ist die am häufigsten diagnostizierte Krebskrankheit bei Frauen. Aufgrund der 
molekularen Heterogenität ist eine generalisierte Therapie nicht möglich. Der nukleäre 
Östrogenrezeptor α (ERα) ist bei der Mehrheit aller Brusttumoren überexprimiert. ER-positive 
Patienten profitieren von einer endokrinen Therapie die Östrogen-induziertes Tumorwachstum 
unterbindet. Allerdings spricht ungefähr die Hälfte der Patienten nicht an oder rezidiviert aufgrund 
von de novo oder erworbener Therapieresistenz. Das Auftreten von Resistenz ist ein Rückschritt für 
die Langzeiteffizienz von endokriner Therapie und führt zu einer schlechten Prognose. Die 
Mechanismen die dem Erwerb der endokrinen Therapieresistenz unterliegen sind jedoch unbekannt. 
Kürzlich wurde epigenetische Reprogrammierung als Mittel vorgeschlagen, welches Tumorzellen 
unempfänglich für die Therapie macht. Daher waren die Ziele dieses Projekts neue Zielmoleküle zu 
entdecken die Resistenz vermitteln und die Rolle der Epigenetik in diesem Prozess aufzuklären. Zu 
diesem Zweck wurden zwei ER-positive Zelllinien (MCF7 und T47D) verwendet um die endokrine 
Therapieresistenz in vitro zu rekapitulieren indem die Zellen entweder mit Tamoxifen (TAMR) 
behandelt wurden oder indem ihnen das Östrogen entzogen wurde (LTED). Ich identifizierte 
GLYATL1 (glycine-N-acyltransferase like 1) als ein stark dereguliertes Gen wie die integrative 
Analyse von RNA-Seq und ATAC-Seq, die resistente Zelllinien mit sensitiven parentalen Zelllinien 
verglich, zeigte. GLYATL1 kodiert ein Enzym das den Transfer einer Acylgruppe auf Glutamin 
katalysiert. Ich konnte zeigen, dass Knockdown von GLYATL1 resistente Zelllinien sensibilisiert, 
während die Überexpression von GLYATL1 sensitiven luminalen Zellen Resistenz gegen endokrine 
Therapie verleiht. Des Weiteren fand ich heraus, dass GLYATL1 in die Acetylierung der Histonreste 
H3K9 und K3K14 involviert ist, da Knockdown von GLYATL1 zur Abnahme der beiden 
Histonmodifikationen in resistenten MCF7 Zellen führte. Außerdem zeigte ich, dass die Expression 
von GLYATL1 in diesen Zellen durch Methylierung, den Wachstumsfaktor-Rezeptor HER2 und die 
Transkriptionsfaktoren ERα, GATA3 und p300 reguliert wird. CRISPR/dCas9-vermittelte 
epigenetische Editierung wurde eingesetzt um die Beteiligung von Methylierung an der GLYATL1 
Regulation zu validieren. Diese Methode ist eine umfunktionierte Version des CRISPR/Cas9 
Systems bei dem Cas9 katalytisch inaktiv ist und an die katalytische Domäne epigenetischer Enzyme 
fusioniert wird. In Kombination mit sgRNAs können diese Effektoren zu Zielregionen rekrutiert 
werden um die epigenetische Landschaft zu modulieren und dadurch die Genexpression zu 
verändern. Darüber hinaus verwendete ich diese Methode der epigenetischen Editierung um die 
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Beteiligung anderer Gene an der endokrinen Therapieresistenz zu untersuchen. Zum Beispiel CD44 
und BAMBI, deren Expression in resistenten Zellen im Vergleich zu parentalen Zellen ebenfalls 
erhöht war. Ich zeigte, dass epigenetische Modulierung der Promotorregionen von CD44 und BAMBI 
mit dCas9-p300 zur Hochregulierung beider Gene führte, wohingegen die Kombination dCas9-G9a 
zu einer Herunterregulierung führte, die in verlangsamter Proliferation von LTED Zellen resultierte. 
Außerdem rief eine Änderung der BAMBI Expression ähnliche Änderungen der CD44 Expression 
hervor, was CD44 als direktes Ziel des Wnt Signalweges, für den BAMBI als Aktivator agiert, 
bestätigte. Abschließend zeigen meine Ergebnisse die Bedeutung von GLYATL1 in der Initiierung 
und Erhaltung von endokriner Therapieresistenz und identifizieren seine Beteiligung an der 
Acetylierung von H3K9 und H3K14. Diese Studie demonstriert das Potential der durch epigenetische 
Reprogrammierung vermittelte Regulation der Expression von Zielgenen als neue Methode für die 
therapeutische Intervention.  
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1. Introduction 
1.1 Breast Cancer 
 
Breast cancer is the most frequently diagnosed malignancy among women worldwide (Siegel et 
al., 2019). According to Global Cancer Observatory (GLOBOCAN) statistics, in 2018, there 
were more than two million new cases of breast cancer (24.2% of all cancer entities affecting 
females) and more than 600,000 deaths which accounts for 15% of cancer related decease among 
females (Bray et al., 2018). Breast cancer is a highly heterogeneous disease rendering a 
generalization of therapy impossible. Depending on the status of hormone receptors, estrogen 
(ER) and progesterone (PR) receptors, and the receptor tyrosine kinase (RTK) HER2/neu breast 
cancer can be subdivided into clinical subtypes including Luminal A, Luminal B, HER2-
enriched, Triple-Negative (X. Dai et al., 2015). Luminal subtypes are positive for expression of 
ER and/or PR, the HER2-enriched subtype is characterized by overexpression of the HER2 
RTK, whereas the triple-negative subtype is negative for these three receptors (Neve et al., 
2006). Receptor status is mostly assessed by  immunohistochemistry (IHC) and ERBB2 (the gene 
encoding for HER2) amplification is verified by fluorescence in situ hybridization (FISH). Status 
for ER, PR and HER2 stratifies the patient according to the subtype of the disease and indicates 
the treatment strategies combined with clinical indicators such as tumor size, grade and lymph 
node status. A number of studies have investigated large patient cohorts with the use of state-of-
the-art large-scale screening technologies to identify perturbations in genomic, epigenomic and 
proteomic levels that drive breast cancer initiation and metastasis. These studies have revealed 
intrinsic subtypes within the classified molecular subtypes that  require more precise treatment 
approaches (Lehmann et al., 2011, 2016; Rueda et al., 2019) 
1.1.1 Molecular Subtypes of Breast Cancer 
 
In 2001, Sørlie et al published their study which paved the way for classifying breast carcinomas 
by identifying five molecular breast cancer subtypes (Luminal A, Luminal B, HER2-enriched, 
Basal, Normal-like) with different clinical prognosis depending on gene expression patterns 
(Sørlie et al., 2001). This subtype classification has been re-identified with some moderations by 
Introduction 
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different gene signatures by different groups such as PAM50, MammaPrint and OncoTypeDX 
(Bernard et al., 2009; Cristofanilli, 2005; Mook et al., 2007). 
Luminal 
Luminal breast cancer is the most common subtype. Nuclear estrogen receptor-α (ERα) is 
overexpressed in the majority (up to 70%) of breast tumors. Luminal tumors are sub-classified 
into Luminal A and Luminal B. 
Luminal A tumors are characterized as ER-positive (ER+) and/or PR-positive (PR+), HER2-
negative with low Ki67 (fraction of Ki67-positive tumor cells<14%), a marker for proliferation 
index. Luminal B tumors also express ER (ER+) and/or PR (PR+), however can be either HER2-
negative with high Ki67 (≥14%) or HER2-positive with any Ki67 (Fulawka & Halon, 2017; 
Gnant et al., 2011). Luminal A breast tumors are generally lower-grade with slow growth 
tendencies compared to luminal B and other subtypes. Luminal B subtype has typically higher 
proliferative index compared to luminal A.  
Luminal A subtype is characterized by the elevated expression of ER-responsive genes such as 
ESR1, FOXA1, GATA3, XBP1. GATA3, FOXA1 code for transcription factors and are termed as 
‘pioneer factors’ facilitating the transcription of ER-responsive genes by binding to condensed 
chromatin and changing the chromatin architecture allowing other TFs to bind (Manavathi et al., 
2014). Genomic mutations of common pathway related genes are often observed in Luminal A 
subtype such as MAP3K1, MAP2K4 of RAS/RAF/MEK/ERK and JNK stress-response signaling 
pathways, respectively (Koboldt et al., 2012). Mutations in tumor suppressor TP53 may also 
contribute to aberrant growth of these tumors. TP53 mutation rate is higher in luminal B subtype 
compared to luminal A, providing further explanation for their more aggressive phenotype 
(Bertheau et al., 2013; Koboldt et al., 2012). 
Given their ER+ status and their dependency on estrogen for growth, the standard therapy for the 
luminal subtypes is endocrine therapy. The luminal A subtype has the best prognosis among all 
molecular subtypes in terms of overall survival. Patients affected by the luminal B subtype also 
benefit from endocrine therapy, however, require supplemental chemotherapy. Still, they exhibit 
less favorable overall prognosis compared to patients with luminal A BCa.  
Introduction 
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HER2-enriched 
Her2-enriched subtype is hormone receptor negative and typically characterized by ERBB2 gene 
amplification and HER2 protein overexpression. These tumors tend to have higher grade and 
patients have worse clinical prognosis compared to those presenting with the luminal A subtype. 
HER2 is a member of the epidermal growth factor receptor (EGFR) family. Overexpression of 
HER2 renders these tumors susceptible to targeted therapies against this receptor tyrosine kinase. 
Discovery of several drugs targeting HER2  increased the survival rate of the patients suffering 
from Her2-enriched subtype of breast cancer (Slamon et al., 2001). These drugs are mostly 
comprised of monoclonal antibodies targeting HER2 homodimers and HER2 heterodimers with 
other EGFR family members (i.e. EGFR, HER3, HER4) such as trastuzumab and pertuzumab, 
respectively (Ataseven, 2012). However, resistance to these approaches resulted in modification 
of existing drugs by conjugating them with cytotoxic components, as seen in trastuzumab 
emtansine (T-DM1) case, which is basically an antibody-drug conjugate between trastuzumab 
and DM1 (Verma et al., 2012). 
Triple Negative 
Triple negative subtype (TNBC) is characterized as ER-negative, PR-negative and HER2-
negative, based on IHC stainings. Basal-like and triple negative breast cancers are often used to 
define the same molecular subtype as TNBC is largely comprised of basal-like (BL) tumors. 
However, Prat et al nomenclature subdivides TNBCs into BL and non-basal-like (NBL) (Prat et 
al., 2013). In short, not all TNBCs are basal-like (although the majority are) and not all basal-like 
tumors are TNBC. A recent sub-classification of the TNBC subtype by revealed four sub-
subtypes: mesenchymal (M), basal-like 1 and basal-like 2 (BL1 and BL2), and luminal androgen 
receptor (LAR) (Lehmann et al., 2016). Regardless of various different nomenclatures, TNBC 
tumors are highly aggressive and metastatic. High frequency for PI3KCA, BRCA1/2 and/or TP53 
mutations are observed for this subtype (L. Yang et al., 2019). 
The lack of three targetable receptors renders this subtype ineligible for conventional targeted 
therapy approaches such as endocrine therapy or therapeutic antibodies, like trastuzumab. 
Patients mostly receive neo-adjuvant chemotherapy with taxanes and platinum salts. These 
Introduction 
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tumors are highly aggressive and due to the unavailability of a generalized targeted therapy, they 
have the worst prognosis compared to other molecular subtypes. 
Sørlie et al nomenclature also defines normal-like breast cancer as an intrinsic molecular subtype 
which is characterized by elevated expression of genes related to non-epithelial tissues with 
reduced expression of luminal signature genes (Sørlie et al., 2001). 
Treatment strategy for breast cancer can either be in neo-adjuvant or adjuvant setting in which 
therapy administration is either before or after surgery, respectively. Treatment approach is 
largely determined by the molecular profile of the tumor.  Endocrine therapy, targeted therapy or 
chemotherapy constitute standard systemic treatment regimen.  
1.1.2 Endocrine  Therapy 
 
Endocrine therapies are commonly applied to treat ER+ patients and come in mostly three ways: 
Tamoxifen is a selective ER modulator (SERM) and blocks estrogen-induced ERα activation by 
competitive inhibition of estrogen binding. Fulvestrant is a selective ER downregulator (SERD) 
that leads to degradation of the receptor. Aromatase inhibitors (AIs) block synthesis of estrogen, 
depriving ER from its ligand estrogen (Ali et al., 2011). 
Since its approval by the US Food and Drug Administration (FDA) in the 1970s, tamoxifen has 
been the backbone of endocrine therapy lowering the breast cancer mortality rates considerably 
(Smith, 2014). It has been widely used to treat early breast cancer in pre-menopausal females in a 
5 year long adjuvant setting (Yeo et al., 2014). Aromatase inhibitors are the choice of endocrine 
therapy for post-menopausal women. Aromatase is a monooxygenase that converts the steroid 
testosterone into estrogen. Determining factor for the choice of endocrine therapy agent is the 
status of ovarian function. Ovaries are the main source of estrogen in pre-menopausal women 
whereas estrogen production takes place primarily in adipose tissue, bones and muscle after 
menopause catalyzed by aromatase enzyme in both states. AIs are not effective in pre-
menopausal women. This can be explained by the high level production of aromatase in pre-
menopausal ovaries. In fact, the exposure to AI brings about a decrease in estrogen produced by 
peripheral tissues which leads to an increase in gonadotrophin secretion. Secreted gonadotropin, 
in turn leads to stimulation of ovaries to induce production of more estrogen. In short, AI 
Introduction 
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administration leads to even increased estrogen levels in pre-menopausal women (Scharl & 
Salterberg, 2016). AIs are given to pre-menopausal women with the addition of gonadotropin 
releasing hormone (GnRH) agonists/antagonists (Zelnak & O’Regan, 2015). Tamoxifen 
treatment can also be accompanied by ablation of ovarian function with gonadotropin releasing 
hormone (GnRH) agonists/antagonists in pre-menopausal patients (Robertson & Blamey, 2003). 
With the introduction of aromatase inhibitors (AIs) such as anastrozole, examestane, letrozole in 
1990s, they constitute the first line of therapy for post-menopausal patients or second line 
therapy for relapsing/non-responding tumors in pre-menopausal women (Rugo et al., 2016). 
Aromatase inhibitors can be subclassified into two classes: non-steroidal ones which bind 
reversibly to aromatase and steroidal ones which binds irreversibly (Schneider et al., 2011). 
Examestane is the sole representative of the steroidal AI among third generation AIs. Switch 
between non-steroidal to steroidal AIs occur in case of recurrence depending on prior therapy. 
Fulvestrant is commonly used as second line therapy for resistant tumors (Chia et al., 2008). 
De-regulation of cell cycle and activation of alternative growth pathways such as 
PI3K/AKT/mTOR are major hallmarks of endocrine therapy resistance and disease relapse 
(Araki & Miyoshi, 2018; A. Gao et al., 2018). Therefore, metastatic or relapsed luminal breast 
cancers can also be treated with cell cycle inhibitors such as CDK4/6 inhibitor palbociclib as an 
additional therapy (Cristofanilli et al., 2016; X. Fu et al., 2013; Lu, 2015; Pang et al., 2014) 
Everolimus, an mTOR inhibitor, provides another alternative to overcome endocrine therapy 
resistance. It is used in combination with examestane in cases of non-responsive non-steroidal AI 
treatments (Gnant et al., 2013)(Liedtke & Kolberg, 2016) (Figure 1). 
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Figure 1: Treatment guidelines for endocrine therapy of ER-positive breast cancer in post-menopausal 
women. Modified from American Society of Clinical Oncology Guidelines (Rugo et al., 2016). AI:aromatase 
inhibitor, (a) Early relapse: ≤12 months after adjuvant endocrine therapy; late relapse: > 12 months after endocrine 
therapy  AI:aromatase inhibitor.  
1.1.3. Endocrine Therapy Resistance 
Although luminal A subtype has better prognosis when compared to triple-negative breast 
cancer, approximately half of the patients do not respond or relapse due to de novo or acquired 
resistance against endocrine therapy, respectively (Early Breast Cancer Trialists’ Collaborative 
Group (EBCTCG) et al., 2011; Osborne & Schiff, 2011) Occurrence of resistance is a limiting 
drawback for long-term efficacy of endocrine therapy and leads to poor prognosis 10-20 years 
after first diagnosis and treatment. Development of resistance against endocrine therapy is a 
long-term process where genetic and epigenetic changes play a predominant role (Badia et al., 
2007; García-Becerra et al., 2012) (Figure 2). 
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Resistance to hormone therapy may occur due to many factors: 
 Aberrant regulation of cell cycle or cell survival molecules 
 Mutations of ESR1 (Hyperactive estrogen signaling) 
 Aberrant regulation of ER coactivators/corepressors 
 Loss of ERα expression due to (epi)genetic modifications  
 Alternative growth pathways (Increased estradiol-independent estrogen signaling) 
De novo endocrine therapy resistance occurs primarily due to loss or modification of ERα 
expression. This can occur via epigenetic repression (methylation of CpG island or histone 
deacetylation) on ESR1 expression. It has been shown that use of HDAC and DNMT1 inhibitor 
resulted in re-expression of ESR1 in ER-negative breast cancer cell lines and rendered them 
susceptible to endocrine therapy (J. Fan et al., 2008; Milani, 2014). 
Deficiency of cytochrome P450 2D6 (CYP2D6) in the liver has been proposed as an alternative 
mechanism for intrinsic resistance. CYP2D6 encodes the enzyme that is responsible for 
metabolizing tamoxifen to 4-hydroxy-tamoxifen (4-OHT) which is by about 100 fold more 
potent to inhibit ER. Testing of the CYP2D6 status has become a companion diagnostic for 
luminal BCa patients as this status determines the dose of tamoxifen that needs to be 
administered. CYP2D6 also catalyzes formation of 4-hydroxy-N-desmethyltamoxifen 
(endoxifen), active metabolite of tamoxifen with high affinity to ER (Desta, 2004). Lacking this 
enzyme renders these patients refractory to tamoxifen treatment (Hoskins et al., 2009).  
Mutations in the ESR1 locus can also be accounted for the refractory state of the tumor to 
endocrine therapy. However loss of function mutations are found in less than 1% of primary 
breast tumors (Riggins et al., 2007). Activating ESR1 mutations, which mostly occur in the 
ligand binding domain may result in hyperactive ER signaling even in the absence of the ligand 
and have been found mostly in relapsed tumors (W. Fan et al., 2015). Atypical expression levels 
of ER-coregulators have also been shown to confer therapy resistance as under-expression of co-
repressors and/or over-expression of co-activators would contribute to augmented ERα signaling 
(Zhou et al., 2007). 
De-regulation of the cell cycle caused by overexpression of positive regulators (e.g. Myc or 
Cyclin D1) or by a reduction of cyclin-dependent kinase (Cdk) inhibitors (e.g. p21, p27) might 
Introduction 
12 
enable tumor cells to evade cytostatic effects exerted by endocrine therapy drugs (Chu et al., 
2008; Jansen et al., 2005; Span et al., 2003).  
Activation of alternative growth factor pathways may bypass the effect of estrogen-dependent 
growth of tumor cells, thereby leading to endocrine therapy resistance. ERα is shown to be 
activated by growth factor receptors EGFR, HER2 and IGF1R in a ligand-independent fashion 
(Schiff et al., 2004). This leads to activation of PI3K/AKT/mTOR and MAPK downstream 
signaling (DeGraffenried et al., 2004; Faridi et al., 2003; Musgrove & Sutherland, 2009). ERBB2 
amplification, loss of PTEN, activating mutations of PI3K can account for aberrant activity of 
these signaling pathways (Arpino et al., 2008; Riggins et al., 2007).  
According to the literature, alteration of metabolism (e.g. cholesterol biosynthesis) and activation 
of alternative signaling pathways (e.g. Notch and Wnt/β-catenin signaling pathway) can also 
contribute to development of endocrine resistance and have intricate cross-talk mechanisms in 
this process (Magnani et al., 2013; Nguyen et al., 2015; Riggins et al., 2007)  
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Figure 2: Mechanisms of endocrine therapy resistance. Schematic representation of factors playing a role in 
acquired endocrine therapy resistance (García-Becerra et al., 2012).  
It has been recently shown that tumor cells having acquired a selective advantage against 
endocrine therapy do not cease proliferating due to genome-wide epigenetic reprogramming 
(Magnani et al., 2013) (S. V. Sharma et al., 2010) (Nguyen et al., 2015). Epigenetic 
reprogramming refers to any alteration in the epigenome such as DNA methylation, histone 
modification and chromatin compaction. Although there are epigenetic drugs available for 
endocrine resistance-reversal, they lack specificity and act on the whole genome (Cherblanc et 
al., 2012) (Steele et al., 2009). Identification and targeting of specific (epi)genetic elements that 
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confer resistance in tumors and discovery of epigenome-based biomarkers to predict prognosis 
and treatment outcome are fundamental to combat endocrine-resistance.  
1.2 Epigenetics 
 
Epigenetics can be described as the study of the heritable, yet reversible, modifications on 
chromatin that alter gene expression, with no change in genomic content (Marx, 2012). Three 
fundamental epigenetic mechanisms include non-coding RNAs, histone modifications and DNA 
methylation (Allis & Jenuwein, 2016).  
1.2.1 DNA methylation 
 
DNA methylation is defined as addition of a methyl group to the fifth carbon of cytosine residue 
which results in 5-methyl-cytosine (5mC). The methyl group donor is typically S-adenosyl 
methionine (SAM). This reaction is catalyzed by DNA methyltransferases (DNMTs). In 
eukaryotes, DNMT3a and DNMT3b are de novo DNMTs that can introduce methylation to 
unmethylated DNA whereas DNMT1 is responsible from methylation maintenance during DNA 
(Moore et al., 2013; Okano et al., 1999; Suetake et al., 2004; S. Xie et al., 1999) DNMT3L, 
although devoid of a catalytic domain, can interact with de novo DNMTs and enhance their 
methyltransferase activity (Aapola et al., 2000; Hata et al., 2006; Jia et al., 2007; Suetake et al., 
2004). 
Genomic imprinting, X chromosome inactivation and tissue-specific gene expression regulation 
is established by DNA methylation. DNA methylation is also important for silencing of retroviral 
and transposable elements that could jeopardize genomic integrity unless inactivated (Michaud et 
al., 1994; W. Xie et al., 2012) 
DNA methylation exerts its effect on the genome in a region-dependent manner. CpG islands are 
DNA stretches that are 500-1500 bp long with a higher CG ratio compared to the rest of the 
genome. CpG islands typically contain most of the gene promoters and are often not methylated 
(Illingworth et al., 2010; Saxonov et al., 2006). A recent publication stated that when combined 
with particular TF motifs the presence of high CpG abundance within CpG islands is enough to 
enhance transcriptional activity independent of methyltransferase activity (Hartl et al., 2019)  
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Methylation of CpG islands leads to gene repression (Mohn et al., 2008). Methylation of CpG 
islands located in gene promoters mostly exhibit tissue specificity unlike intragenic or gene body 
CpG islands (Eckhardt et al., 2006; Ghosh et al., 2010; Maunakea et al., 2010; Meissner et al., 
2008; Rakyan et al., 2004). Tissue specific methylation is also observed in CpGs located 2 kb 
upstream or downstream of CpG islands, collectively termed as CpG island shores, where 
methylation is inversely correlated with gene expression (Irizarry et al., 2009). On the other 
hand, gene body methylation correlation with gene expression is more complicated. In 
methylation nomenclature, gene body is defined as the region following the first exon (Brenet et 
al., 2011). Elevated gene expression is observed for dividing cells after gene body methylation 
(Aran et al., 2011; Ball et al., 2009; Hellman & Chess, 2007). No correlation was found between 
expression of a gene and methylation of its gene body in dormant slowly dividing cells (Guo et 
al., 2011). There has been recent studies suggesting gene body methylation is closely associated 
to alternative splicing and loss of gene body methylation leads to aberrant splicing (Flores et al., 
2012; Maunakea et al., 2013, 2010)  
The interplay between DNA methylation and histone modifications dictate the chromatin 
accessibility for DNA binding proteins such as transcription factors thereby permitting or 
hindering transcription of a gene. For example, H3K4 tri-methylation (H3K4me3), a permissive 
histone mark, impede binding of DNMTs. Histone marks associated with closed chromatin such 
as H3K9 or H3K27 methylation attract or favor DNMT binding, thereby establishing a more 
inaccessible chromatin landscape (Vaissière et al., 2008). 
DNA demethylation can arise either in an active or passive manner. Passive demethylation is 
closely related with the lack of or a decrease in DNMT activity. It is associated with DNA 
replication where methylation marks are lost with increasing number of cell cycles in the absence 
of maintenance methylation. Active demethylation can be orchestrated by three enzyme families. 
Ten-eleven translocation (TET) enzymes catalyze hydroxylation of 5mC resulting in 5-
hydroxymethylcytosine (5hmC) which can be further oxidized to 5-formylcytosine (5fC) and 5-
carboxylcytosine (5caC). AID/APOBEC family of enzymes catalyzes deamination of 5mC or 
5hmC to 5-methyluracil (5mU) or 5-hydroxymethyluracil (5hmU), respectively. 5mU, 5hmU or 
5caC are further catalyzed by TDG/SMUG1 (base excision repair glycosylases) to form cytosine, 
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therefore concluding active DNA demethylation (Bhutani et al., 2011; Kohli & Zhang, 2013) 
(Figure 3). 
 
Figure 3: Mechanisms of DNA demethylation. Schematic representation of active and passive DNA 
demethylation (Bhutani et al., 2011). 
1.2.2 Histone modifications 
 
Post-translational modifications of histones are diverse in many ways. These modifications can 
be present on all five histones: H2A, H2B, H3, H4 and the linker histone H1. They are 
commonly introduced at the N-terminal tail of histone proteins. Several types of post-
translational modifications of histones have been reported, including acetylation, methylation, 
phosphorylation, ubiquitination, succinylation, sumoylation, citrunnilation, propionylation, 
butyrylation, formylation and ADP ribosylation (Lennartsson & Ekwall, 2009; Ruthenburg et al., 
2007). Moreover, the amino acid residues that are modified may vary. Some residues may only 
allow one type of modification while others are prone to several. For instance, while 
phosphorylation is the only mark that is found on serine, threonine or tyrosine residues, lysine 
residues can be modified by acetylation, biotinylation, methylation, ribosylation and 
ubiquitination. Additionally, a methylation mark may be present in a mono-, di- or tri-methylated 
state (H. Dai & Wang, 2014). A recent study revealed 67 novel histone modifications such as 
lysine crotonylation by mass spectrometry which expands the histone code considerably (Castillo 
et al., 2017; Tan et al., 2011)  
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While DNA methylation is a rather stable modification, histone marks undergo constant change 
by epigenetic modifiers. The histone modifying enzymes that introduce the modifications are 
termed “writers”, while “erasers” are responsible for removing the marks. This epigenetic code is 
then read by the “readers”, which specifically bind to certain epigenetic marks and depending on 
the composition of the epigenetic landscape, either recruit repressive or activating complexes to 
the gene, thereby modifying gene expression (X. J. Yang & Seto, 2007). While the effect of 
some epigenetic marks is context dependent, meaning depending on the presence of other 
epigenetic modifications, histone acetylation is generally associated with transcriptional 
activation. Positive charge of lysine is neutralized by acetylation thereby the interaction between 
histone tail and negatively charged DNA is weakened which leads to opening up the chromatin 
structure and making it accessible for transcription factors or the transcription machinery.  The 
composition of the histone modifications make up the so-called ‘histone code’ which pertains to 
regulation of gene expression via changes in the chromatin architecture (Carlberg et al., 2018; 
Turner, 2000, 2007)   
 
Figure 4:  Histone modifications of core histones and histone code. Schematic depiction of modifications that 
may occur on core histone tails and their implications on activating or repressing gene expression (H. Dai & Wang, 
2014). 
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1.2.2.1. Histone Acetyl Transferases (HATs) and Histone Deacetylases 
(HDACS) 
Histone acetylation is mediated by Histone Acetyl Transferases (HATs). HATs can be either 
nuclear (Type A) or cytoplasmic (Type B) (Richman et al., 1988). Nuclear HATs are subdivided 
into five families. MYST HATs (MOF, MOZ, MORF, HBO1 and TIP60) typically contain a 
chromodomain and/or a PHD finger domain in addition to MYST domain, which is composed of 
zinc finger and acetyl CoA-binding domains (Avvakumov & Côté, 2007). Gcn5-related N-
acetyltransferases (GNATs) family is composed of GCN5 (KAT2A) and PCAF (KAT2B) in 
humans. They are characterized by the presence of bromodomain in addition to HAT domain (Z. 
Nagy & Tora, 2007). p300/CBP (CREB-binding protein) HATs constitute another HAT family 
which are composed of two transcriptional co-activators. Harboring a chromodomain, 
bromodomain or PHD finger domain enables these enzymes to recognize and bind modified 
histone residues thereby rendering them as epigenetic “readers” adding to their designated 
epigenetic “writer” status due to HAT activity (Yun et al., 2011; T. Zhang et al., 2015). 
Transcription factor-related HATs (TFIIIC, TAF1) and nuclear receptor co-activators (SRC, 
ACTR, P160, CLOCK) are other HAT families (Doi et al., 2006; Torchia et al., 1998). 
HATs (mostly as part of multisubunit HAT complexes) exert their catalytic activity on 
preferential histone lysine residues. As an example, GCN5/PCAF can acetylate H3K9 and 
H3K14 in SAGA or ADA complexes and MYST family member MOF acetylates H4K16 (Jin et 
al., 2011; Krebs et al., 2011; Lee & Workman, 2007; G. G. Sharma et al., 2010). Histone 
modifications are dynamic and transient processes. Abnormal histone acetylation patterns are 
closely related to malignancies such as cancer (Di Cerbo & Schneider, 2013). 
Post-translational acetylation of a histone lysine residue can be deacetylated by a histone 
deacetylase (HDAC) (Seto & Yoshida, 2014). Reversible nature of this modification results in 
transcriptional regulation. Being devoid of DNA-binding domain, HDACs can interact with their 
targets through binding to coactivators or repressors of transcription (Wang et al., 2009) Hence, 
the repertoire and range of the available interaction partners for HDACs determine their effect on 
gene expression regulation (Turner, 2000). Histone deacetylation is commonly associated with 
closed chromatin and reduced gene expression. However, there is growing evidence suggesting 
HDACs might also play a role in transcriptional initiation and progression via ‘erasing’ 
Introduction 
19 
acetylation marks which can obstruct elongation (C. B. Greer et al., 2015; Nusinzon & Horvath, 
2005) 
There are 11 classical HDACs which are further subdivided into four families: Class I, IIa, IIb 
and IV. They are differing from each other in function, structure and expression. Class III 
HDACs (sirtuins) deviate from classical HDACs since they depend on nicotine adenine 
dinucleotide (NAD
+
) for their enzymatic activity (Haberland et al., 2009; RUIJTER et al., 2003). 
HDACs are notoriously de-regulated in cancer. HDACs are generally found to be elevated in 
tumorigenesis. Class I HDACs are associated with increased proliferative and invasive 
phenotype. Breast, prostate and gastrointestinal cancers have reportedly elevated levels of 
HDAC1 (Choi et al., 2001; Halkidou et al., 2004; Nakagawa et al., 2007). HDAC inhibitors have 
been used to combat cancer entities of differing origin in pre-clinical and clinical trials in an 
attempt to attenuate proliferation, angiogenesis and invasion of tumor cells.  
Inhibition of HDACs results in cell cycle arrest and apoptosis in vitro due to increased levels of 
p21 and induction of proapoptotic genes (Bak, Bax), respectively (Marchion & Münster, 2007). 
Efficacy of HDAC treatment in humans is limited. They are effective in abrogating proliferation, 
angiogenesis, invasion and inflammation. However the drawback is their non-specificity. Anti-
angiogenesis effect of HDACs diminishes their delivery into solid tumors. Anti-inflammatory 
effect of HDACs depletes also the immune cells, therefore anti-tumor immune response (Ropero 
& Esteller, 2007; Somech et al., 2004).  
 
1.2.2.2. Histone methyltransferases and Histone demethylases  
Histone methyltransferases mediates methylation of lysine or arginine residues on histone tails. 
Depending on the methylated amino acid they can be divided into two groups: protein lysine 
methyltransferases (PKMT) and protein arginine methyltransferases (PRMT) (Dillon et al., 2005; 
Feng et al., 2002; Lachner & Jenuwein, 2002) PKMTs can be subdivided into SET (Su(var)3–9, 
Enhancer of Zeste, and Trithorax) domain containing and non-SET domain containing enzymes 
(Dillon et al., 2005). Much like in DNA methylation, SAM provides the methyl group for HMTs. 
There are two methylation states (mono-, di-methylation) for arginine while lysine residues can 
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be either mono-, di- or tri-methylated (Bannister & Kouzarides, 2011; Tiedeken & Chang, 2015) 
Unlike lysine acetylation, lysine methylation does not alter the side chain’s positive charge. For 
this reason, the effect of lysine methylation is generally context-dependent, meaning it depends 
on the position and state of methylation and the molecules that ‘read’ the histone code ‘written’ 
by HMTs (Martin & Zhang, 2005). Methylation of H3K4, H3K36 and H3K79 are histone marks 
associated with active transcription. H3K9, H3K27 and H4K20 methylation, on the other hand, 
comprise a repressive histone code (Hyun et al., 2017). Bivalent chromatins are characterized by 
their occupancy with opposing histone marks such as H3K4 methylation (activating) and H3K27 
methylation (repressing). Bivalency is crucial for maintaining poised state of transcription ready 
for activation or inactivation in stem cells (Vastenhouw & Schier, 2012). 
Methyl group removal from histone tail residues is catalyzed by histone demethylases. The 
discovery of jumanji protein domain (JmjC) responsible for demethylase activity led to an 
expansion in histone demethylases (Agger et al., 2008; Tsukada et al., 2006) 
Aberration in histone methylation patterns have been closely related to many maladies. That 
led to the consideration of histone methyltransferases, histone demethylases or methyl -lysine 
binding proteins as therapeutic targets (E. L. Greer & Shi, 2012; Song et al., 2016). 
Figure 5 provides a general overview of the ‚writers’ and ‚erasers’ of the histone methylation 
marks in different organisms, histone methyl transferases and histone demethylases, 
respectively (Hyun et al., 2017). 
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Figure 5: Histone methyltransferases and demethylases. Schematic representation of ´writers´ and ´erasers´ of 
histone methylation in different organisms with their respective choice of histone tail residues (Hyun et al., 2017). 
 
1.3 CRISPR/dCas9-mediated Epigenetic Editing 
 
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 
(Cas) system was introduced by Jennifer Doudna and Emmanuelle Charpentier in 2012 as one of 
the most ground-breaking scientific methods in recent years, and has since then revolutionized 
research in genome engineering (Doudna & Charpentier, 2014). It was discovered much earlier, 
as part of the research on the prokaryotic immune system, where this method is used as an 
adaptive defense mechanism against viruses or other foreign DNA (Horvath & Barrangou, 
2010).  
In bacteria, foreign DNA is at times fragmented and integrated as a spacer between short 
palindromic repeats in the CRISPR locus of the bacterial chromosome. The locus is then 
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transcribed into crRNA and associates with a so-called tracrRNA to form the guide RNA 
(gRNA). The gRNA will then in turn form a complex with a Cas protein. In case of invasion of 
the same foreign DNA, this complex is then guided by the crRNA spacer sequence being 
complementary to the foreign DNA. The complex binds and cleaves the target DNA through the 
endonuclease activity of the Cas protein in order to diminish foreign invasion (Jinek et al., 2012).  
Doudna and Charpentier have engineered a two component version of this system, that uses Cas9 
endonuclease and a fusion of the two RNA components, termed single guide RNA (sgRNA) 
(Sternberg & Doudna, 2015). In genome engineering, this system is utilized to introduce targeted 
double strand breaks at a genetic region of interest, guided by the choice of sgRNA. It makes use 
of the cellular repair mechanisms, which will repair the double strand break in one of two ways. 
Using non-homologous end joining (NHEJ), the break is ligated without a template, resulting in 
the occurrence of insertions or deletions (indel) (Figure 6a). Often, premature stop codons or 
frame shifts appear due to these indels, thereby causing a functional knock out of the gene. The 
other repair mechanism, homology directed repair (HDR) uses a template, such as the second 
chromosome or a template DNA, to repair the break (Gilbert et al., 2013; Knott & Doudna, 2018; 
Sternberg et al., 2014). By specifically adding a repair template to the cell, one is able to modify 
a genetic region of interest in a targeted fashion  
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Figure 6: Two distinct applications of CRISPR/Cas9 system. (a) Genome editing by CRISPR/Cas9 system where 
the targeted region of the genome is cut and repaired via NHEJ, introducing indels, thereby resulting in edited 
genome. (b) Epigenetic editing via CRISPR/dCas9, where catalytically dead Cas9 (dCas9) is fused to catalytic 
domains of epigenetic effectors and recruited to targeted regions of the genome to modulate the epigenetic 
landscape, thereby altering transcriptional status of target genes. 
The specificity and activity of the CRISPR/Cas9 system are conveyed by two elements, the 
target sequence and the Protospacer adjacent motif (PAM) sequence. In the sgRNA, the target 
sequence is a 20 nucleotide sequence that is complementary to the region of interest and guides 
the sgRNA/Cas9 complex to the targeted genomic locus. It is followed by the two to six 
nucleotide PAM sequence, which is specific for every Cas9 protein and essential in facilitating 
the binding of Cas9 to the DNA and enabling its endonuclease activity. The PAM sequence for 
Cas9 derived from Streptococcus pyogenes is NGG, with N being any base followed by two 
guanines (Kleinstiver et al., 2015; Knott & Doudna, 2018).   
Since the ground-breaking innovation of tailored genetic editing systems, like TALENs, Zinc 
Finger Nucleases (ZFNs) or the CRISPR/Cas9 system, research has concentrated on also 
utilizing these systems for other applications. Recently, CRISPR/dCas9 system has been 
repurposed for epigenetic editing of targeted region of the genome (Brocken et al., 2018; Vojta et 
al., 2016). It makes use of the CRISPR/Cas9 system’s advantage of specifically targeting a 
region of interest in the genome. The Cas9 nuclease here is catalytically dead (dCas9), and 
instead fused to effector domains of epigenetic enzymes (De Groote et al., 2012; X. Gao et al., 
2014) (Figure 6b). This approach is used to modify the epigenome at a specific locus, eg. a gene 
regulatory element, and thereby altering the expression of a gene of interest.  
 
 24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Aims 
25 
2. Aims 
The main focus of this project has been the identification of fundamental epigenetic changes that 
bring about endocrine therapy resistance and interfering with the epigenome to mimic resistance 
or achieve resistance-reversal and re-sensitization to endocrine therapy. This project has been 
part of EU funded EpiPredict Consortium (Horizon 2020). The research questions have been 
tackled in two parts in this thesis:  
PART I: Elucidating the Role of GLYATL1 in Endocrine Therapy Resistant Breast Cancer 
The aim of this part is to identify novel target gene(s) which confer resistance to endocrine 
therapy via: 
- profiling the changes in transcriptomics (RNA-Seq), methylome (EPIC array) and 
chromatin accessibility (ATAC-Seq) in resistant cell lines (MCF7 and T47D) compared 
to their sensitive counterparts 
- combining large scale screening techniques such as RNA-Seq and ATAC-Seq to reveal 
commonalities between distinct therapy resistance models has identified novel target 
GLYATL1 
- validating the contribution of GLYATL1 to endocrine therapy resistance development 
- elucidating (epigenetic) regulation of GLYATL1  
- utilizing established CRISPR/dCas9- mediated epigenetic editing approach in order to 
validate epigenetic regulation of GLYATL1. 
PART II: Establishing CRISPR/dCas9-mediated Epigenetic Editing Methodology to 
Modulate the Epigenetic Landscape of Endocrine Therapy Resistant Breast Cancer 
The aims of this part are: 
- to establish innovative CRISPR/dCas9-mediated epigenetic editing tools and to modulate 
expression of potentially endocrine therapy resistance related genes.  
- to elucidate the involvement of the epigenetic landscape and expression of SLC9A3R1, 
BAMBI and CD44 in the development and maintenance of endocrine therapy resistance in 
the parental and resistant cell lines 
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3. Materials and Methods 
3.1 Materials 
3.1.1 Instruments 
Bacterial Incubator (37°) Memmert (Schwabach, Germany) 
Bacterial shaking Incubator (37°) INFORS HAT (Surrey, UK) 
Biohit Proline multichannel pipette Sartorius (Göttingen, Germany) 
Cell culture hood HERA Safe  Thermo Fisher Scientific (Waltham, USA)  
Cell culture incubator  Heraeus (Hanau, Germany)  
Centrifuges  Eppendorf AG (Hamburg, Germany)  
Extracellular flow bioanalyzer (Seahorse 
XF96) 
Agilent Technologies (Santa Clara USA) 
Flow Cytometer FACS Canto II Becton Dickinson (New Jersey, USA)  
Flow Cytometer  LSRFortessa™ Becton Dickinson (New Jersey, USA) 
Fluorescent microscope Axiovert 40 CFL Carl Zeiss (Oberkochen, Germany) 
Freezer (-20°) Liebherr (Bulle, Switzerland) 
Freezer (-80°) Sanyo (Osaka, Japan) 
Fridge (+4°) Liebherr (Bulle, Switzerland) 
Gel documentation system  Herolab GmbH (Wiesloch, Germany)  
Glomax explorer plate reader  Promega (Wisconsin, USA) 
Molecular Devices Microscope IXM XLS  Molecular Devices (Sunnyvale, USA)  
Nanodrop ND-1000 spectrophotometer  Thermo Fisher Scientific (Waltham, USA)  
Neubauer cell counting chamber BRAND 
Odyssey Infrared Imaging System  Li-Cor Biosciences GmbH (Bad 
Homburg, Germany)  
Pipetboy acu pipette INTEGRA Biosciences (Fernwald, Germany) 
Pipetman
®
 pipette Gilson (Limburg, Germany) 
Protein Gel Apparatus MiniProtean II  Bio-Rad (Hercules, USA)  
SW41 Ti Rotor and Tubes  Beckman Coulter (Brea, USA)  
Thermocycler  Applied Biosystems (Foster City, USA)  
Thermomixer Eppendorf AG (Hamburg, Germany) 
Titramax 100 rocking platform Heidolph (Schwabach, Germany) 
  Materials and Methods 
28 
Trans-Blot Turbo Transfer  Bio-Rad (Hercules, USA)  
Tube Rotator VWR (Darmstadt, Germany) 
Ultracentrifuge, Beckman L8-70M  Beckman Coulter (Brea, USA)  
Vacuboy aspiration device INTEGRA Biosciences (Fernwald, Germany) 
Vortex mixer  neoLab (Heidelberg, Germany)  
 
3.1.2 Chemicals and Reagents 
(Z)-4-Hydroxytamoxifen ≥98% Sigma-Aldrich (Saint-Louis, USA) 
0.25% Trypsin EDTA Solution  Gibco (New York, USA)  
5-Aza-dC (5-Aza-2 deoxycytidine) Abcam (Cambridge, USA) 
Acetic Acid Sigma-Aldrich  (Saint-Louis, USA) 
Acrylamide/bisacrylamide 37.5:1  Carl Roth (Karlsruhe, Germany)  
Agar Sigma-Aldrich (Saint-Louis, USA) 
Ammoniumperoxodisulfate (APS)  Sigma-Aldrich (Saint-Louis, USA)  
Ampicillin Sigma-Aldrich (Saint-Louis, USA) 
Blasticidin Thermo Fischer Scientific (Waltham, 
USA) 
BSA Sigma-Aldrich  (Saint-Louis, USA) 
BsmBI restriction enzyme New England Biolabs (Massachusetts, 
USA) 
Charcoal Stripped Fetal Bovine Serum Sigma-Aldrich  (Saint-Louis, USA) 
cOmplete Mini Protease Inhibitor Cocktail Roche Diagnostics (Mannheim, Germany) 
Competent E.coli (DH5α) New England Biolabs (Massachusetts, USA) 
Crystal violet Sigma-Aldrich (Saint-Louis, USA) 
DMEM medium Gibco (New York, USA)  
DMSO  Sigma-Aldrich (Saint-Louis, USA)  
Doxycycline Sigma-Aldrich (Saint-Louis, USA) 
DPBS Gibco (New York, USA) 
EDTA  Sigma-Aldrich (Saint-Louis, USA)  
Ethanol  Sigma-Aldrich (Saint-Louis, USA)  
Fetal Bovine Serum Gibco (New York, USA)  
Geneticin Gibco (New York, USA) 
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Hoechst 33258 Sigma (Krefeld, Germany) 
Isopropanol  Greiner Bio-One International GmbH 
(Kremsmünster, Austria)  
LB Broth Sigma-Aldrich (Saint-Louis, USA) 
L-glutamine, 200mM  Gibco (New York, USA)  
Lipofectamine LTX Thermo Fischer Scientific (Waltham, 
USA) 
Lipofectamine RNAiMAX Thermo Fischer Scientific (Waltham, 
USA) 
Matrigel Corning (Corning, USA) 
Methanol  Greiner Bio-One International GmbH 
(Kremsmünster, Austria)  
NaCl  VWR International (Darmstadt, Germany)  
NaF Bernd Kraft (Duisburg, Germany) 
NaOH  Sigma-Aldrich (Saint-Louis, USA)  
NEB Buffer #3, #3.1 New England Biolabs (Massachusetts, 
USA) 
non-DEPC treated nuclease-free water  Thermo Fisher Scientific (Waltham, 
USA)  
Opti-MEM medium Gibco (New York, USA) 
Paraformaldehyde 16% Thermo Fisher Scientific (Waltham, 
USA) 
PBS  Gibco (New York, USA)  
Penicillin/Streptomycin (Pen/Strep) Gibco (New York, USA)  
PhosSTOP Phosphatase Inhibitor Cocktail Roche Diagnostics (Mannheim, Germany) 
primaQUANT 2x qPCR Probe Master Mix Steinbrenner Laborsysteme (Weinbach, 
Germany) 
Protein Marker Precision Plus Protein Dual 
Color 
Bio-Rad (Hercules, USA) 
Proteinase K  Sigma-Aldrich (Saint-Louis, USA)  
Puromycin Thermo Fischer Scientific (Waltham, 
USA) 
RIPA Lysis and Extraction buffer Thermo Fischer Scientific (Rockford, 
  Materials and Methods 
30 
USA) 
Rockland Blocking Buffer Rockland Immunochemicals Inc. (Limerick, 
USA) 
Roti
®
-Load 1, 4x sample loading buffer Carl Roth (Karlsruhe, Germany) 
SDS  Carl Roth (Karlsruhe, Germany)  
siRNAs  Dharmacon, Thermo Fisher Scientific 
(Waltham, USA)  
SOC Outgrowth Medium New England Biolabs (Massachusetts, 
USA) 
Sodium pyruvate, 100mM  Gibco (New York, USA)  
T4 DNA Ligase Thermo Fischer Scientific (Rockford, 
USA) 
TEMED  Carl Roth (Karlsruhe, Germany)  
Tris-base  Sigma-Aldrich (Saint-Louis, USA)  
Triton X-100  Sigma-Aldrich (Saint-Louis, USA)  
TrypLE Express Enzyme (1X, no phenol 
red) 
Thermo Fischer Scientific (Rockford, 
USA) 
Tween 20  Sigma-Aldrich (Saint-Louis, USA)  
β-estradiol Sigma-Aldrich  (Saint-Louis, USA) 
 
3.1.3 Assay Kits 
BCA Protein Assay Kit PierceTM  Thermo Fisher Scientific (Waltham, USA)  
CellTiter-Glo Luminescent assay Promega (Wisconsin, USA) 
Click-iT™ EdU Cell Proliferation Kit for 
Imaging, Alexa Fluor™ 647 dye 
Thermo Fisher Scientific (Waltham, USA) 
DNeasy Blood & Tissue Kit Qiagen (Hilden, Germany) 
Histone Extraction Kit  Abcam (Cambridge, USA) 
Histone H3 acetyl 14 ELISA Kit 
(H3K14) 
Active Motif (California, USA) 
Histone H3 acetyl 9 ELISA Kit (H3K9) Active Motif (California, USA) 
Infimium MethylationEPIC BeadChip Illumina (San Diego, USA) 
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NE-PER Nuclear Cytoplasmic Extraction 
Kit 
Thermo Fisher Scientific (Waltham, USA) 
primaQUANT 2x qPCR Probe Master 
Mix 
Steinbrenner Laborsysteme (Weinbach, 
Germany) 
Qiagen Plasmid Plus Midi Kit Qiagen (Hilden, Germany) 
RevertAid™ H Minus First Strand 
cDNA synthesis kit  
Fermentas, Thermo Fisher Scientific 
(Waltham, USA)  
RNeasy Mini Kit  Qiagen (Hilden, Germany)  
Total Histone H3 ELISA Kit Active Motif (California, USA) 
Trans-Blot Turbo mini PVDF Transfer 
Kit 
Bio-Rad (Hercules, USA) 
Universal Probe Library (UPL)  Roche Diagnostics (Mannheim, Germany)  
Wizard SV Gel and PCR Clean-up 
System 
Promega (Wisconsin, USA) 
 
3.1.4 Consumables 
Micro centrifuge tubes (1,5,2 and 5 ml)  Eppendorf AG (Hamburg, Germany)  
Petri dishes (100 mm and 150 mm)  Techno Plastic Products (TPP) AG 
(Trasadingen, Switzerland)  
Falcon tubes (15 ml and 50 ml)  Becton Dickinson (New Jersey, USA)  
Multi-well plates (6, 12, 24, 48-well), F-
bottom, transparent  
Thermo Fisher Scientific (Waltham, 
USA)  
96-well plate (F-bottom, transparent) Becton Dickinson (New Jersey, USA)  
96-well plate (F-bottom, white)  PerkinElmer (Waltham, USA)  
96-well plate (F-bottom, black)  Greiner Bio-One International GmbH 
(Kremsmünster, Austria)  
96-well Clear V-Bottom Deep Well Plate Corning (Corning, USA) 
384-well plates for TaqMan Applied Biosystems (Foster City, USA) 
Adhesive Optically Clear Plate Seal  Thermo Fisher Scientific (Waltham, 
USA)  
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Cell Culture Flasks, T-25, T-75, T-175  Greiner Bio-One International GmbH 
(Kremsmünster, Austria)  
Cell Scraper  Corning (Corning, USA)  
Cryo vials 1.8mL  Nunc, Thermo Fisher Scientific 
(Waltham, USA)  
FACS tubes Becton Dickinson (New Jersey, USA) 
Filter tips, 10μL, 20μL, 200μL, 1000μL  Neptune Scientific (San Diego, USA)  
4-15% Mini-PROTEAN®TGX™ Precast 
Protein Gels (10,12 and 15-well) 
Bio-Rad  (Hercules, USA) 
Oncyte
®
 Avid Nitrocellulose Film-Slide Grace Bio-Labs (Bend, USA) 
PCR strips  Steinbrenner Laborsysteme GmbH 
(Wiesenbach, Germany)  
PVDF membrane Immobilon-P  Merck Millipore (Darmstadt, Germany)  
Reservoirs 50ml Corning (Corning, USA) 
Round-Bottom polypropylene tubes 5ml Thermo Fisher Scientific (Waltham, 
USA) 
Serological pipettes 5mL, 10mL, 25mL, 
50ml  
Becton Dickinson (New Jersey, USA)  
Trans-well system (8.0μm pore size)  Corning (Corning, USA)  
Whatman 3 MM filter paper  GE Healthcare (Little Chalfont, United 
Kingdom)  
 
3.1.5 Software 
BD FACSDiva™ Software Becton Dickinson (New Jersey, USA) 
GraphPad Prism 5  GraphPad Software, Inc. (La Jolla, USA)  
FlowJo 10 Becton Dickinson 
Image Studio LI-COR Biosciences (Lincoln USA) 
Inkscape Software Freedom Conservancy, Inc. (NY 
USA) 
Molecular Devices Analysis Software  Molecular Devices (Sunnyvale, USA)  
Odyssey 2.1  LI-COR (Lincoln, USA)  
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QuantStudio  Applied Biosystems (Foster City, USA)  
Roche UPL Design Center Roche Diagnostics (Mannheim, 
Germany)  
SDS 2.2  Applied Biosystems (Foster City, USA) 
 
3.1.6 Database 
METABRIC mRNA data https://www.synapse.org/#!Synapse:syn1688369/wiki/27311  
TCGA mRNA data TCGA_BRCA_exp_HiSeqV2-2015-02-24 
GSE1456 (Pawitan dataset) https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1456 
 
3.1.7 Buffers and solutions  
EdU assay 
Fixation Buffer  4% PFA in ddH2O 
Permeabilization Buffer 0.5% Triton X-100 in PBS 
Washing Buffer 3% BSA in PBS 
Western Blotting 
Lysis Buffer RIPA Buffer 10ml 
1x tablet PhosSTOP Phosphatase Inhibitor 
1x tablet Complete Mini Protease Inhibitor Cocktail 
SDS-PAGE Running 
Buffer (1L) 
0.25 M Tris Base (30.3 g) 
1.92 M Glycine (144.1 g) 
0.1% SDS (w/v) 
Transfer Buffer 20% Trans-BlotR Turbo™ 5x Transfer Buffer 
20% EtOH 
60% ddH2O 
Blocking Buffer Rockland blocking Buffer:TBS (1:1) 
5mM NaF 
1mM Na3VO4 
Washing Buffer (1X TBST) 0.1% Tween®20 in TBS (TBST)  
 
10X TBS 1.37M NaCl 
200mM Tris 
pH 7.6 
FACS Buffer 2% FBS in PBS 
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3.1.8 Antibodies 
 
Primary antibodies 
Protein name Host Product ID (Company) Dilution 
  
β-Actin 
      Mouse Actin (clone C4) (MP 
Biomedicals USA) 
1:10000 
β-Actin Rabbit Actin 21-33 (Sigma Aldrich 
USA) 
1:10000 
GLYATL1 Rabbit HPA039501 (Human 
Protein Atlas) 
1:1000 
Lamin B1 Rabbit CST12586 (Cell Signaling 
Technology, USA) 
1:1000 
CD44-FITC 
(monoclonal,IM7) 
Rat / IgG2b, 
kappa 
11-0441-82 eBioscience, 
Thermo Fisher Scientific 
(Waltham, USA) 
1:100 
Rat IgG2b kappa Isotype 
Control-FITC (eB149/10H5) 
Rat / IgG2b, 
kappa 
11-4031-82 eBioscience, 
Thermo Fisher Scientific 
(Waltham, USA) 
1:100 
CD44-PE (monoclonal,IM7) Rat / IgG2b, 
kappa 
 
12-0441-82 eBioscience, 
Thermo Fisher Scientific 
(Waltham, USA) 
1:150 
Rat IgG2b kappa Isotype 
Control-PE (eB149/10H5) 
Rat / IgG2b, 
kappa 
12-4031-82 eBioscience, 
Thermo Fisher Scientific 
(Waltham, USA) 
1:150 
H3K-pan-ac [Histone 3 
(acetyl 
K9+K14+K18+K23+K27)] 
Rabbit ab47915 Abcam 
(Cambridge, USA) 
1:1000 
Histone 3 (total) Mouse 05-449 (Clone 6.6.2) 
(Merck, Germany) 
1:1000 
 
3.1.9 siRNAs 
siRNA Annotation Catalogue 
Number 
Target Sequence 
 
ON-
TARGETplus 
non-targeting 
Pool 
 
siCTRL 
 
D-001810-10 
UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUGUGUGA 
UGGUUUACAUGUUUUCUGA 
UGGUUUACAUGUUUUCCUA 
 
siON-
TARGETplus 
Set of 4 Upgrade 
siRNA 
GLYATL1 
 
siGLYATL1 
 
LU-010292 
AACCUAAUCUGUAUGGAUA 
GCCAUUGGAACUUGGAUUA 
ACCACUAAGGUGAGGAUUA 
GUGAAACUCCCAACUUUAA 
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siON-
TARGETplus 
Set of 4 Upgrade 
siRNA ERBB2 
 
siERBB2 
 
LU-003126 
UGGAAGAGAUCACAGGUUA 
GAGACCCGCUGAACAAUAC 
GGAGGAAUGCCGAGUACUG 
GCUCAUCGCUCACAACCAA 
 
siON-
TARGETplus 
Set of 4 Upgrade 
siRNA ESR1 
 
siESR1 
 
LU-003401 
GAUCAAACGUCUAAGAAG 
GAAUGUGCCUGGCUAGAGA 
GAUGAAGGUGGGAUACGA 
GCCAGCAGGUGCCCUACUA 
 
siON-
TARGETplus 
Set of 4 Upgrade 
siRNA EP300 
 
siEP300 
 
LU-003486 
 
siON-
TARGETplus 
Set of 4 Upgrade 
siRNA GATA3 
 
siGATA3 
 
LU-003781 
 
3.1.10 Primers 
Gene Primer Left Primer Right Probe # 
ACTB attggcaatgagcggttc ggatgccacaggactcca 11 
BAMBI cgccactccagctacatctt cacagtagcatcgaatttcacc 71 
CD44 gacaccatggacaagttttgg cggcaggttatattcaaatcg 13 
EP300 gcagcctgcaactccact gaggatttgatacctgtccttca 20 
ERBB2 gggaaacctggaactcacct agcgatgagcacgtagcc 4 
ESR1 gatgggcttactgaccaacc aaagcctggcaccctctt 24 
GATA3 ctacgtgcccgagtacagc acacactccctgccttctgt 3 
GLYATL1 cacatcaatcacgggaacc ccatgtcatcagtcatctcctg 72 
KAT2A gttgtgagcaccccttgg tctccacatccaccacca 3 
KAT2B tcccaatgatgatatttctggat aactgtggcacgttgcagt 76 
PUM1 tcacatggatcctcttcaagc cctggagcagcagagatgtat 86 
SLC9A3R1 cagttcatccggtcagtgg cttcccctccatgcagac 30 
ZMYND8 aaagaaacctggcttactgaaca agtaaaacggaccatgtcttagttc 68 
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3.2 Methods 
3.2.1  Cell Culture and Growth Conditions 
MCF7 and T47D cells were obtained from ATCC (LGC Standards GmbH, Wesel, Germany). 
Cell lines were regularly authenticated by Multiplexion GmbH (Friedrichshafen, Germany) and 
tested for mycoplasma contamination. The cell lines were cultured in DMEM media and 
incubated at 37
o
C with 5% CO2 in a humidified atmosphere. The growth media for each cell line 
is described in Table 1.  Cells were passaged when they reached 80% confluency under aseptic 
conditions in a laminar air-flow hood. Briefly, medium was aspirated from the flask and the cells 
were washed with PBS following which 0.25% trypsin-EDTA was added and the cells were 
returned to 37
o
C. Once the cells detached, growth medium was added to neutralize the trypsin. 
The cells were counted using the Neubauer cell counting chamber. Depending on their growth 
and cell size, 1-2 x 10
6
 cells were seeded into a 150 mm petri dish with a final volume of 15ml. 
Cell numbers to seed in other canisters were calculated according to the surface area. Cells were 
used up to passage number 20. 
 
MCF7 resistant cell lines were kindly provided by Magnani Lab at ICL (London, United 
Kingdom). MCF7 and T47D cell lines, model human breast cancer cell lines of the Luminal A 
subtype, were chosen to recapitulate the resistance development in vitro. In short, MCF7 cells 
were treated with 100nM 4-Hydroxytamoxifen (4-OHT), the active metabolite of tamoxifen, for 
more than one year to make them gain resistance, resulting in the MCF7 TAMR cell line. 
Depriving MCF7 cells from estrogen for over a year, on the other hand, resulted in MCF7 LTED 
(long term estrogen deprived) cells, which mimic aromatase inhibitor treatment. Double resistant 
cell line MCF7 LTEDTAMR was generated by treating LTED cell line with 100 nM 4-OHT for 
one more year (Nguyen et al., 2015). T47D resistant cells were generated in house in 
collaboration with PhD student Simone Borgoni. Same approach was adopted for T47D 
resistance acquisition where parental cells were treated with either 100 nM 4-OHT (T47D 
TAMR) or deprived from estrogen (T47D LTED) for a year. DNA, RNA and protein samples 
were collected at different time points to monitor changes during resistance acquisition.  
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Cell line Description Growth Media 
MCF7 
Breast cancer cell line of the Luminal A 
subtype 
DMEM media + 10%FCS +10
-8-
M 17--estradiol + 1%Penicillin/ 
Streptomycin (P/S) 
MCF7 TAMR MCF7 cell line, resistant to 100nM 4-OHT 
DMEM media + 10%FCS + 
1%P/S + 100nM 4-OHT  
MCF7 LTED (Long 
term estrogen 
deprivation) 
MCF7 cell line, resistant to the deprivation 
of estrogen. Mimicking the treatment with 
Aromatase inhibitors 
DMEM media without phenol 
red + 10% charcoal stripped 
(CS) FCS + 1%P/S 
MCF7 LTED TAMR 
MCF7 cell line, resistant to the deprivation 
of estrogen and 100 nM 4-OHT.  
DMEM media without phenol 
red + 10% charcoal stripped 
(CS) FCS + 1%P/S + 100 nM 4-
OHT 
MCF7 empty 
MCF7 cell line lentivirally transduced 
with pLX-304 vector without any ORF 
DMEM media + 10%FCS +10
-8-
M 17--estradiol + 1%Penicillin/ 
Streptomycin (P/S) + Blasticidin 
(1μg/ml) 
MCF7 GLYATL1 ox 
MCF7 cell line lentivirally transduced 
with pLX-304 vector with GLYATL1 ORF 
(ORFeome clone: HQ448152)  
DMEM media + 10%FCS +10
-8-
M 17--estradiol + 1%Penicillin/ 
Streptomycin (P/S) + Blasticidin 
(1μg/ml) 
T47D 
Breast cancer cell line of the Luminal A 
subtype 
DMEM media + 10%FCS +10
-8-
M 17--estradiol + 1%Penicillin/ 
Streptomycin (P/S) 
T47D TAMR T47D cell line, resistant to 100nM 4-OHT 
DMEM media + 10%FCS + 
1%P/S + 100nM 4-OHT  
T47D LTED 
T47D cell line, resistant to the deprivation 
of estrogen. Mimicking the treatment with 
Aromatase inhibitors 
DMEM media without phenol 
red + 10% charcoal stripped 
(CS) FCS + 1%P/S 
T47D empty 
T47D cell line lentivirally transduced with 
pLX-304 vector without any ORF 
DMEM media + 10%FCS +10
-8-
M 17--estradiol + 1%Penicillin/ 
Streptomycin (P/S) + Blasticidin 
(1μg/ml) 
T47D GLYATL1 ox 
T47D cell line lentivirally transduced with 
pLX-304 vector with GLYATL1 ORF 
(ORFeome clone: HQ448152)  
DMEM media + 10%FCS +10
-8-
M 17--estradiol + 1%Penicillin/ 
Streptomycin (P/S) + Blasticidin 
(1μg/ml) 
 
Table 1: Cell lines and culture conditions 
To freeze cell stocks, the trypsinized cells were centrifuged at 1200 rpm for 5min. Cell pellets 
were re-suspended in 1ml freezing media composed of 70% growth media, 20%FBS, 
10%DMSO and stored in 1.5 ml cryovials which were slowly cooled down in an isopropanol 
bath at -80
o
C for a minimum of 24h before transferring to a liquid nitrogen container for long 
term storage. 
Frozen vials of cells were recovered by thawing quickly in a 37
o
C water bath. The cell 
suspension was centrifuged at 1200 rpm for 5min in order to remove DMSO. Following 
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centrifugation, cells were re-suspended in fresh growth media and transferred into an appropriate 
culture flask or dish. Cells were allowed to attach overnight before changing the growth media. 
3.2.1.1 Generation of stable overexpressing cell lines 
 
For generation of lentiviral particles, HEK293FT cells (Thermo Fischer Scientific, Germany) 
were co-transfected with the lentiviral expression constructs (pLX-304 vector with or without 
GLYATL1 ORF) and 2nd generation viral packaging plasmids VSV.G (Addgene #14888) and 
psPAX2 (Addgene #12260). 48h after transfection, virus containing supernatant was removed 
and cleared by centrifugation (5min/500g). The supernatant was passed through a 0.45μm filter 
to remove remaining cellular debris. Target cells were transduced with lentiviral particles at 70% 
confluency in the presence of 10 μg/ml polybrene (Merck, Germany). 24h after transduction 
virus containing medium was replaced with selection medium for the respective expression 
constructs. Transduced cells were selected with the respective antibiotic concentration (geneticin, 
puromycin or blasticidin). 
3.2.2  siRNA Transfections 
 
Cells were seeded to a confluency of 80%. After overnight incubation, transfections were 
performed with RNAiMax® according to manufacturer’s instructions. Unless otherwise stated, 
siRNAs were used at a final concentration of 30nM.  
Plate Format Volume of 
OptiMEM added 
(µl) 
Volume of 
RNAiMax added 
(µl) 
Final 
concentration of 
siRNA(nM) 
Total volume of 
transfection mix 
(µl) 
96-well plate 9.6 0.4 30 20 
24-well plate 28.5 1.5 30 60 
12-well plate 57.5 2.5 30 120 
6-well plate 115 5 30 240 
 
Table 2: Volumes of reagents used for siRNA transfections 
A pre-mix of RNAiMax and Opti-MEM was prepared (Table 2), and in parallel siRNAs were 
diluted in Opti-MEM. The siRNA and RNAiMax pre-mix were mixed and incubated for 5 min. 
During this incubation, media was aspirated from the cells and replaced with fresh growth media 
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without antibiotics (Pen/Strep). Post incubation, the transfection mix was added to the cells. 
Cells were then incubated in 37
o
C, 5% CO2   humidified atmosphere for different time points 
depending on the assay being performed. 
3.2.3 Analysis of RNA expression 
 
3.2.3.1 mRNA isolation 
mRNA was isolated using the “RNeasy Mini” Kit from Qiagen according to manufacturer’s 
recommendations. Extracted RNA was eluted in 30-50µl of nuclease free water. RNA 
concentrations were determined by NanoDrop ND-100. 
3.2.3.2 cDNA synthesis 
Up to 1 μg of total RNA was reverse transcribed to cDNA using the RevertAid™ H minus First 
strand Kit. In short, RNA was mixed with 1µl OligodT primer to a total volume of 12µl. 
Following a 5min-long incubation at 70
o
C, 8µl of master mix composed of following ingredients 
were added per sample.  
Reaction Buffer (5X) 4µl 
10mM dNTP mix 2µl 
Ribolock (RNase inhibitor) 1µl 
Reverse Transcriptase 1µl 
 
After the addition of the master mix, samples were incubated in following conditions allowing 
reverse transcription. 
37
o
C 5 min 
42
o
C 60 min 
70
o
C 10 min 
 
3.2.3.3 Quantitative RT PCR 
 
Primers and probes were designed for Taqman® qRT-PCR using the Roche UPL Design Center 
(Refer to section 3.1.11 for primer sequences and corresponding probe numbers).  
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For the Taqman assay the cDNA was first diluted to 2ng/µl. 5µl of cDNA was pipetted into 384 
well plates in triplicate. For each gene, a master mix was prepared. 6µl of the master mix was 
pipetted into each well. 
primaQUANT   2x 
qPCR Probe Master Mix 
5.5µl 
Left Primer 0.11µl 
Right Primer 0.11µl 
Taqman probe 0.11µl 
H2O 0.17µl 
 
A plate layout document was prepared using the SDS or QuantStudio software and the PCR 
conditions were set as follows:  
50
o
C 2 min  
95
o
C 15 min  
95
o
C 15 sec  
45 cycles 60
o 
C 1 min 
 
Raw data was analysed using the SDS or QuantStudio software with the ΔΔCt method (Yuan et 
al., 2006). The Ct values were normalized to housekeeping genes PUM1 and ACTB. 
3.2.3.4 RNA Sequencing 
 
Total RNA was extracted using Qiazol (Qiagen, Germany). Quality control, library preparation 
and sequencing was done at DKFZ Genomics and Proteomics Core Facility using HiSeq 4000 
platform (paired-end 100 bp). Analysis of the sequencing data was performed by Maryam 
Soleimani-Dodaran and Perry Moerland (UvA, The Netherlands). Raw sequencing data were 
subjected to quality control using FastQC and trimmed using Trimmomatic (v0.32). Reads were 
aligned to the human reference genome (hg38) using HISAT2 (v2.0.4). Gene level counts were 
obtained using HTSeq (v0.6.1) and the human GTF from Ensembl (release 85). Statistical 
analyses were performed using the edgeR and limma R/Bioconductor packages. Genes with 
more than 1 count in 3 or more samples were retained. Count data were transformed to log2-
counts per million (logCPM), normalized by applying the trimmed mean of M-values method 
and precision weighted using voom. Differential expression between the conditions of interest 
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was assessed using an empirical Bayes moderated t-test within limma’s linear model framework 
including the precision weights estimated by voom. Resulting p-values were corrected for 
multiple testing using the Benjamini-Hochberg false discovery rate (FDR). Additional gene 
annotation was retrieved from Ensembl (release 90) using the biomaRt R/Bioconductor package. 
3.2.4  Analysis of protein expression 
 
3.2.4.1 Protein isolation 
 
Cells were washed with ice cold PBS after indicated experimental durations (e.g. transfection, 
treatment). Cells were lysed with appropriate amount (100µl per 10 cm petri dishes or 40µl per 1 
well of a 6-well plate) of RIPA lysis buffer supplemented with 1x Complete Mini Protease 
Inhibitor Cocktail and 1x Phospho-Stop phosphatase Inhibitor and detached by cell scraper. 
Lysate was transferred into an eppendorf tube, vortexed and incubated on ice for 30min with 
agitation. The lysate was tehncentrifuged at 13,000rpm for 10min and the supernatant was 
transferred to a new pre-chilled eppendorf tube. Lysates were stored at -80
o
C.  
3.2.4.2 Protein quantification 
 
Protein concentrations of the lysates were determined using the BCA™ protein assay kit 
according to manufacturer’s instructions. Briefly, BSA standards of different concentrations 
(2mg/ml, 1.5mg/ml, 1mg/ml, 0.75mg/ml, 0.5mg/ml, 0.25mg/ml, 0.125mg/ml, 0.025mg/ml and 
0mg/ml) were prepared by serial dilution in PBS. 25µl of each standard and 5µl of each sample 
were pipetted into a 96-well microplate in duplicates. BCA™ working reagent is prepared 
freshly for each assay by mixing Reagent A with Reagent be in a 50:1 ratio. 200µl of the 
working reagent was added to each well of the microplate. Following an incubation at 37
o
C for 
30 min in the dark, the absorbance at 562nm was measured on the GloMax explorer plate reader. 
A standard curve was prepared using BSA standards and protein concentrations of the samples 
were determined based on this curve. The obtained concentrations were multiplied by 5 to 
account for the dilution factor between samples and the standards.  
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3.2.4.3 Western Blotting 
 
Samples for gel electrophoresis were then prepared (20-30 µg per well) for gel electrophoresis 
by mixing with protein loading buffer (4X RotiLoad) in a 1:4 dilution and incubated at 95
o
C for 
5min for denaturation. Mini-PROTEAN TGX Precast Gels were loaded into the MiniProtean gel 
apparatus filled with 1x running buffer. After the removal of the comb, the gels were loaded with 
5 µl molecular weight marker and appropriate amount of samples depending on the well number 
of the gel. Electrophoresis was performed at 120V for 70min. 
After protein separation via SDS-PAGE, the proteins were transferred to a PVDF membrane 
using the Trans-BlotR Turbo Transfer System according to manufacturer’s instruction (mixed 
weight setting, 7min transfer). The membrane was then blocked for 1h at RT with Rockland 
blocking buffer and subsequently incubated with a target specific primary antibody diluted in 
blocking buffer overnight at 4°C on a rocking platform. The membrane was washed 3x 15 min in 
TBST followed by a 1h incubation with IRDye®680 or IRDye®800 conjugated secondary 
antibodies (1:15,000 diluted in TBST) depending on the host organism of the primary antibody. 
Following washing for 3x 20 min in TBST, the membrane was scanned at an excitation 
wavelength of 685nm or 800nm and a resolution of 84 µm using the Odyssey Infrared Imaging 
System. Western blot bands were normalized using loading controls β-Actin, LaminB1 or total 
Histone 3. 
3.2.4.4 Nuclear and Cytoplasmic Extraction 
 
Nuclear and cytoplasmic fractions were extracted with NE-PER Nuclear AND cytoplasmic 
extraction kit (Thermo Fisher Scientific) according to manufacturer’s instructions. Briefly, cell 
pellet of 2x10
6
 cells was resuspended in 200µl ice-cold CERI buffer and incubated on ice for 10 
min. 11µl CERII buffer was added to the mix and incubated for 1 min on ice. Following 
vortexing, the tube was centrifuged at 13,000 rpm for 5 min at 4
 o
C. Supernatant (cytopliasmic 
fraction was transferred into a pre-chilled eppendorf tube. Pellet was resuspended in 100µl NER 
buffer, vortexed and incubated on ice for 40 min with vortexing briefly every 10 min. Following 
the incubation, the tube was centrifuged at 13,000 rpm for 10 min at 4
o
C. Supernatant (nuclear 
fraction) was transferred into a pre-chilled eppendorf tube. Protein concentrations were 
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determined by BCA™ protein assay kit. Samples were stored at -80 oC. For western blotting, 
Lamin B1 and β-actin were used as loading controls for nuclear and cytoplasmic fractions, 
respectively.   
3.2.4.5 Histone Extraction 
Histones were extracted with Histone extraction kit (Abcam) according to manufacturer’s 
instructions. In short, cell pellet of approximately 1x10
7
 cells were resuspended in 1ml of 1X 
Pre-Lysis Buffer, incubated on ice for 10 min and centrifuged at 10,000 rpm for 1 min. Pellet 
was re-suspended in 200µl of Lysis Buffer and vortexed briefly. Following a 30 min-long 
incubation on ice, samples were centrifuged at 13,000 rpm for 10 min and supernatant was 
transferred to a new eppendorf tube. Approximately 60µl of Balance Buffer (with the addition of 
DTT) was added to the samples prior to protein concentration determination by BCA™ protein 
assay kit and long term storage at -80°C. 
 
3.2.4.6 Histone ELISA 
 
Histone ELISA was carried out according to manufacturer’s instructions. Histone ELISA for 
Total H3, H3K9ac and H3K14ac were performed in parallel with the same samples. Purified 
core histones were diluted (100 ng/well for total H3, 500 ng/well for H3K9ac and H3K14ac) in 
Assay diluent buffer 1X and pipetted into the wells of 96-well plates pre-coated with anti-H3 
(Total Histone 3) in duplicates. Recombinant histones were prepared with Assay diluent buffer 
1X as instructed and pipetted into the wells in duplicates and diluted as instructed serving as 
standards. Following pipetting of protein standard curve and samples, plates were incubated at 
room temperature for 1 h with agitation. Following 1 h incubation, the wells were washed 3 
times with 200µl Wash buffer 1X (diluted from 20X with distilled H2O). 50µl diluted primary 
antibody (1:1000 dilution for anti-total H3; 1:2000 dilution for anti-H3K9ac; 1:500 dilution for 
anti-H3K14ac were done in assay diluent buffer 1X) was added into each corresponding well. 
Plates were incubated at room temperature for 1 h with agitation. After the incubation, wells 
were washed 3 times with 200µl Wash Buffer 1X. 50µl diluted secondary antibody (1:2000 HRP 
conjugated anti-rabbit IgG) was added into each well. Plates were incubated at room temperature 
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for 1h without agitation. After the incubation, wells were washed 3 times with 200µl Wash 
Buffer 1X. After complete removal of the final wash, 100µl developing solution was added into 
each well. Plates were incubated for the optimal developing time (2 min for total H3, 3 min for 
H3K9ac, 9 min for H3K14ac) in the dark without agitation. After optimal incubation time, 100µl 
stop solution was added to each well and absorbances were measured on GloMax® microplate 
reader at 450 nm with a reference wavelength at 600 nm. Optical densities of standards were 
plotted in order to get the best fit for standard curve and quantify the modified histone abundance 
in samples. Each modified histone sample was normalized against its total Histone 3. 
3.2.4.7 Flow Cytometry 
 
Cells were cultured to 70 to 80% confluence and detached from the cell culture flasks using 
TrypLE express. Cell pellets were obtained and washed with FACS Buffer (2% FBS in PBS). 
All further steps were performed on ice and all centrifugation steps at 4°C. Monoclonal 
antibodies against human CD44 (FITC, eBioscience; CD44-PE, eBioscience) and their isotype 
controls were added to the cell suspension (in final volume of 100µl FACS Buffer) at 
concentrations recommended by the manufacturer and incubated on ice in the dark for 30 min. 
Unstained controls and stained cells were analyzed on FACS Canto II (BD Biosciences). Gating 
was set to relevant isotype control-labeled cells or unstained cells for each cell line. For 
transfection efficiency check, cells transfected with only transfection reagent and transfected 
with mCherry-tagged dCas9 (±effector domain) plasmid or GFP plasmid (pmax GFP) were 
analyzed on LSRFortessa™ (BD Biosciences).  
 
3.2.5  Functional assays 
3.2.5.1 Cell Counting Assay 
 
Cell growth under different treatment (siRNA, sgRNA and media) conditions were analyzed 
with a microscopy based nuclei counting method. Cells were seeded in clear-bottomed 96 well 
black plates and after overnight incubation they were transfected with siRNA or plasmids 
encoding dCas9+effector domain and sgRNAs. At different time points DNA was stained with 
  Materials and Methods 
45 
intercalating dye Hoechst-33258 (1:5000 dilution in growth media) for 30-45min. Subsequently, 
the plates were imaged with a molecular devices microscope IXM XLS.  All nuclei were defined 
by Hoechst signals within a certain size and intensity and were detected and counted by the 
Molecular Devices Software. The number obtained was considered as cell number. 
3.2.5.2 Cell Titer Glo Assay 
 
Cell titer Glo assay measures the ATP in cells as a proxy of the metabolic activity. The 
incubation with the assay reagent results in lysis of the cells which can then release its ATP. For 
this assay cells were seeded into black 96-well plates and treated with siRNA and/or the media 
containing either 4-OHT or estrogen deprivation media after overnight incubation. The assay 
was performed 72h or 7 days after treatment according to the manufacturer’s recommendation. 
Briefly, the components of the assay kit were mixed and added into the wells. The incubation 
with the reagents resulted in the lysis of the cells which released ATP. The plate was placed on a 
shaker for 2 min to help the lysis. Luciferin, catalyzed in the assay by UtraGlo Luciferase, and 
the ATP generated oxyluciferin, which was detected via luminescence measurement using the 
Glomax Explorer Plate Reader. 
3.2.5.3 Quantification of S-phase with EdU incorporation assay 
 
For quantification of cells in S-phase, Click-iT™ EdU Cell Proliferation Kit was used according 
to manufacturer´s instructions. Cells were seeded in a black 96-well plate. Cells were allowed to 
attach overnight before changing the growth media to endocrine therapy conditions. After 72h of 
incubation at 37°C with 5% CO2 EdU (5-ethynyl-2′-deoxyuridine) was added into the cells by 
replacing half of the media with freash media including 20µM EdU to reach final concentration 
of 10µM EdU in each well. Following 24h of EdU incorporation, media was aspirated and cells 
were washed twice with PBS. Then, 50µl of 4% PFA was added into each well and cells were 
fixed for 15 min at RT. After removing the fixative, cells were washed twice with 100µl 3% 
BSA in PBS. Following the removal of the washing solution, 100µl 0.5% Triton X-100 in PBS 
was added into each well and cells were incubated for 20 min at RT. Following the removal of 
the permeabilization buffer, cells were washed twice with 100µl 3% BSA in PBS. After washing, 
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50µl of freshly prepared Click-iT
®
 reaction cocktail (ingredients shown below) was added into 
each well and the plate was incubated for 30 min at RT protected from light.  
1X Click-iT
®
 reaction buffer 43µl per sample 
CuSO4 2µl per sample 
Alexa Fluor
®
 azide (Alexa Fluor 647) 0.12µl per sample 
Reaction buffer additive 5µl per sample 
Total Volume 50µl per sample 
 
Following the incubation, cells were washed once with 100µl 3% BSA in PBS and 100µl nuclear 
staining solution (Hoechst-33258 diluted 1:5000 in PBS) was added into each well. Plate was 
incubated for 30 min at RT protected from light before imaging with molecular devices 
microscope IXM XLS. All nuclei were defined by Hoechst signals within a certain size and 
intensity and were detected and counted by the Molecular Devices Software. Cells going through 
S-phase were defined by Alexa Fluor 647 staining. The ratio of Alexa Fluor 647-positive cells 
were obtained as percentage of total cell number determined by Hoechst staining. 
 
3.2.5.4 Determination of late apoptotic cells via Propidium Iodide (PI) 
 
Late apoptotic cells were determined via PI staining combined with Hoechst staining (Refer to 
Part 3.2.16.1). PI  (1:5000 dilution in growth media) was added into the wells of 96-well plate 5 
min before the end of Hoechst staining incubation time (30-45 min).  Plates were imaged with 
molecular devices microscope IXM XLS.  All nuclei were defined by Hoechst signals within a 
certain size and intensity and were detected and counted by the Molecular Devices Software. 
Late apoptotic cells were defined by PI staining. The ratio of late apoptotic cells were obtained 
as percentage of total cell number determined by Hoechst staining. 
 
3.2.5.5 Cell migration and invasion assay 
 
A cell suspension of 2x10
5
 cells in 200µl of DMEM media without FBS were seeded into each 
upper chamber of Transwell chamber (8-μm pore size, Corning Costar Corp, US), which was 
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pre-coated with or without 5 mg/ml matrigel. 500µl DMEM supplemented with 20% FBS was 
used in the lower chamber as chemoattractant.  After incubating for 24 h for migration and 72h 
for invasion at 37°C in a humidified incubator with 5% CO2, chambers were disassembled. Cells 
were swiped off the top off the upper chambers with a cotton swab and the lower chambers were 
by fixed incubating with 4% PFA for 10 min. Transwell inserts were then moved to a new 24 
wells plate and stained with crystal violet for 30 min. After staining the inserts were washed with 
PBS to remove the excess staining and dried overnight. 10% acetic acid was used to elute crystal 
violet and the absorbance of the dissolved crystal violet was measured at 490 nm using the 
Glomax Explorer Plate Reader. Absorbance values were normalized to values of parental (WT) 
cells. 
 
3.2.6 Determination of methylation changes via Illumina EPIC 850k array  
 
Total DNA was extracted using Qiagen DNeasy Blood and Tissue Kit (Qiagen, Germany). 
Methylation profiling was performed using the Illumina MethylationEPIC BeadChip platform. 
Analysis of the raw data was performed by Maryam Soleimani-Dodaran (UvA, The 
Netherlands). Pre-processing was performed using the R package minfi. Data were normalized 
using functional normalization. Detection p-values were calculated for each methylation probe. 
14947 probes showed an unreliable signal (p>0.01) in one or more samples and were removed. 
Probes corresponding to loci that contain a SNP in the CpG site or in the single-base extension 
site were removed. We also removed probes that have been shown to cross-hybridize to multiple 
genomic positions (Pidsley et al., 2016). The final data set comprised 781062 CpG loci. Using 
the resulting M-values CpG-wise linear models were fitted with coefficients for each condition 
(TAMR, LTED, LTEDTAMR, WT). Differential methylation between the conditions of interest 
was assessed using empirical Bayes moderated t-statistics (R package limma) and p-values were 
corrected using the Benjamini-Hochberg FDR. 
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3.2.7  Assay for Transposase Accessible Chromatin with High Throughput 
Sequencing  (ATAC-Seq) 
 
Libraries for ATAC-sequencing were prepared as previously published with modifications 
(Buenrostro et al., 2015). Briefly, cells were lysed by 1% NP40 and tagmented at 55°C for 8 
minutes in a reaction mix with 2.5µl of TDE1 (Nextera Illumina DNAKit), 25µl Tagmentation 
buffer (Nextera Illumina DNA Kit) and 25µl of lysed cells. Reaction was stopped by adding 10 
µl Guanidium (5 M) and samples were purified using AMpure Beads. Libraries were generated 
using NEBNext High Fidelity PCR Mix and sequenced on the Illumina HiSeq 2500 platform at 
DKFZ Genomics and Proteomics Core Facility. Sequencing reads were adaptor-trimmed using 
cutadapt (v. 1.10). Genomic alignments were performed against the human reference genome 
(hg19, NCBI build 37.1) using Bowtie2 (v. 2.3.0). The non- default parameters “-q 20 -s” were 
used. PCR duplicates were removed by Picard MarkDuplicates (v. 1.125; 
http://broadinstitute.github.io/picard). Signal tracks were generated using deepTools (v. 2.3.3). 
Peaks were called using Macs2 (v. 2.1.1.) with the parameters “--nomodel --shift -50 --extsize 
100 --qvalue 0.01”. All peaks were merged to create a common bed file with read counts before 
differential analysis using edgeR (v. 0.3.16). Gene annotations were made using ChIPpeakAnno. 
Sample and library preparation were carried out by me. Data analysis was carried out by Dr. 
Simin Oz (DKFZ). 
 
3.2.8  CRISPR/dCas9-mediated targeted epigenetic editing experiments 
 
For epigenetic editing editing experiments, a hit-and-run approach was adopted in which the 
cells were transiently transfected with both a sgRNA plasmid and another plasmid encoding 
dCas9 fused with an effector domain (epi-effector). The latter construct also has an mCherry tag 
to enable sorting to ensure enrichment of the transfected cells. dCas9-effector domain constructs 
were either provided by Mihaly Koncz (MTA-SZBK) and Marianne Rots (UMCG) or obtained 
from Addgene with appropriate MTAs. The general procedure of experimental setup involves 
transfection for 48h, collection and validation of epigenetic interference in mRNA level 
(TaqMan) and re-seeding of cells to assess long term effects.  
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3.2.8.1 Plasmids 
Name Description 
pMdCas9-P2A-mCherry 
Plasmid expressing the catalytically dead (D10A and H840A 
mutations) dCas9 without effector domain (dCas9-NED) and 
mCherry with a self-cleavage linker in between 
pMdCas9-p300-P2A-mCherry 
Plasmid expressing dCas9 fused to the histone acetyltransferase 
core of p300 and mCherry with a self-cleavage linker in between 
pMdCas9-G9a-P2A-mCherry 
Plasmid expressing dCas9 fused to catalytic domains of the 
methyltransferase G9a. Included are the SET domain, the PreSET 
domain and one ANK repeat domain. The fluorophore mCherry is 
also expressed from the plasmid 
pMdCas9-PRDM9-P2A-mCherry 
Plasmid expressing dCas9 fused to the histone methyltransferase 
core of PRDM9 and mCherry with a self-cleavage linker in 
between 
pMdCas9-DOT1L-P2A-mCherry 
Plasmid expressing dCas9 fused to the histone methyltransferase 
core of DOT1L and mCherry with a self-cleavage linker in 
between 
pMdCas9-M.SssI(Q147L)-P2A-
mCherry 
Plasmid expressing dCas9 fused to the reduced activity mutant 
(Q147L point mutation) of prokaryotic DNMT and mCherry with 
a self-cleavage linker in between 
pMdCas9-TET1-P2A-mCherry 
Plasmid expressing dCas9 fused to the DNA demethylase core of 
TET1 and mCherry with a self-cleavage linker in between 
MLM3636 
sgRNA backbone, for the expression of CD44 sgRNAs. 
MLM3636 was a gift from Keith Joung (Addgene plasmid 
#43860;http://n2t.net/addgene:43860;RRID:Addgene_43860) 
MLM 2.0 
sgRNA backbone, for the expression of BAMBI, GLYATL1, 
SLC9A3R1 sgRNAs; with two MS2 stem loops; derived from 
MLM3636 
pmax GFP 
Plasmid used to assess transfection efficiency of sgRNA plasmid 
(MLM2.0) due to similar size. 
pHAGE-TRE dCas9 
Lentiviral expression vector expressing Tet-inducible catalytically 
dead Cas9 (dCas9). Used as a backbone vector to produce 
inducible cell lines stably expressing dCas9+effector domain. 
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pHAGE TRE dCas9 was a gift from Rene Maehr & Scot Wolfe 
(Addgene plasmid # 50915 ; http://n2t.net/addgene:50915 ; 
RRID:Addgene_50915) 
 
3.2.8.2 Generation of cell lines expressing inducible stable dCas9+effector domain 
Stable cell line generation was done using pHAGE-TRE dCas9 (fused to indicated effector 
domains) lentiviral contructs as explained in section 3.2.1.1. The lentiviral constructs were 
generated by Mihaly Koncz (MTA-SZBK) using pHAGE-TRE dCas9 as a backbone. Generated 
cell lines were seeded in the presence of 2µg/ml doxycycline to induce expression of 
dCas9+effector domain and transfected with the sgRNA plasmid(s) next day. 
Name Description Growth Media 
 
MCF7 (dCas9-p300) 
MCF7 cell line stably expressing Tet-
inducible dCas9 fused to the histone 
acetyltransferase core of p300 
DMEM media + 10%FCS 
+10
-8
M 17--estradiol + 
1%Penicillin/ Streptomycin 
(P/S) + Neomycin (1µg/ml) 
 
MCF7 (dCas9-TET1) 
MCF7 cell line stably expressing Tet-
inducible dCas9 fused to the catalytic 
domain of DNA demethylase TET1 
DMEM media + 10%FCS 
+10
-8
M 17--estradiol + 
1%Penicillin/ Streptomycin 
(P/S) + Neomycin (1µg/ml) 
 
MCF7 TAMR (dCas9-
Q147L) 
MCF7 TAMR cell line stably expressing 
Tet-inducible dCas9 fused to the 
reduced activity mutant (Q147L point 
mutation) of prokaryotic DNMT 
DMEM media + 10%FCS + 
1%P/S + 100nM 4-OHT+ 
Neomycin (1µg/ml) 
 
MCF7 TAMR (dCas9-
G9a) 
MCF7 TAMR cell line stably expressing 
Tet-inducible dCas9 fused to catalytic 
domains of the methyltransferase G9a. 
Included are the SET domain, the 
PreSET domain and one ANK repeat 
domain. 
DMEM media + 10%FCS + 
1%P/S + 100nM 4-OHT+ 
Neomycin (1µg/ml) 
 
MCF7 LTED (dCas9-
MCF7 LTED cell line stably expressing 
Tet-inducible dCas9 fused to the 
DMEM media without phenol 
red + 10% charcoal stripped 
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Q147L) reduced activity mutant (Q147L point 
mutation) of prokaryotic DNMT 
(CS) FCS + 1%P/S+ 
Neomycin (1µg/ml) 
 
MCF7 LTED (dCas9-
G9a) 
MCF7 LTED cell line stably expressing 
Tet-inducible dCas9 fused to catalytic 
domains of the methyltransferase G9a. 
Included are the SET domain, the 
PreSET domain and one ANK repeat 
domain. 
DMEM media without phenol 
red + 10% charcoal stripped 
(CS) FCS + 1%P/S+ 
Neomycin (1µg/ml) 
 
MCF7 LTED (dCas9-
G9a) 
MCF7 LTED cell line stably expressing 
Tet-inducible dCas9 fused to catalytic 
domains of the methyltransferase G9a. 
Included are the catalytically inactive 
SET domain, the PreSET domain and 
one ANK repeat domain. 
DMEM media without phenol 
red + 10% charcoal stripped 
(CS) FCS + 1%P/S+ 
Neomycin (1µg/ml) 
 
3.2.8.3 Design and Cloning of sgRNAs 
3.2.8.3.1 Design of sgRNAs 
The sgRNAs were designed using the CRISPOR online tool (www.crispor.tefor.net) and cloned 
into the MLM2.0 vector (except for CD44 sgRNAs that were cloned in to MLM3636 backbone 
vector). Genomic locations with histone marker peaks and CpG islands (if existent) were taken 
into account while designing the sgRNAs. Promoter region of target genes are covered with 
sgRNAs targeting both upstream and downstream of transcription start site (TSS). Additionally, 
enhancer region of SLC9A3R1 gene was also covered with sgRNAs.  
sgRNA Sequence Genomic Orientation 
BAMBI #1 TCTCAAGGGGCGTGCTGACAAGG antisense 
BAMBI #2 AGTGTCGTCTCGTTGGCGCCGGG  sense 
BAMBI #3 AGGGTCTCCACAGCACGCAAGGG  antisense 
BAMBI #4 CGATCCATTGACGCCCCGCACGG antisense 
BAMBI #5 TGAGGGCACGCGGCAGCTACAGG  antisense 
BAMBI #6 TGTAGCACATCATCCTCGCTGGG  antisense 
CD44 #1    TATGATATTTCAATCTCAAAAGG sense 
CD44 #2 CGGATGGAAGGATATTTAGGAGG sense 
CD44 #3 GAGTTGGTGAATCTTCCAAGTGG antisense 
CD44 #4 ACGGAGGCACTGCGCCACCCAGG sense 
CD44 #5 TCACAGGATGTTGGATATCCTGG antisense 
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CD44 #6 TGGTGCAAGGTTTTACGGTTCGG sense 
CD44 #7 CACTGGCTTTCTTCTCCCGCTGG antisense 
CD44 #8 GGGGAACCTGGAGTGTCGCGGGG antisense 
CD44 #9 GCTGAGGCTGTAAATAATCGGGG antisense 
CD44 #10 TCGCTCCCTCCCTCCGTCTTAGG sense 
SLC9A3R1 #1 AGGCTGTTAAAACGTTGGCCAGG  sense 
SLC9A3R1 #2 AGTGATCCGAGATCGCGCCACGG  sense 
SLC9A3R1 #3 AATGGCCGGCGCCGTTCACCCGG  sense 
SLC9A3R1 #4 TGGGACGCTCAGACGCCGCGCGG  sense 
SLC9A3R1 #5 GCGCGACTTGGGGTTCCGATGGG antisense 
SLC9A3R1 #6 AGAAAAACGACGGCGGGCGCGGG  antisense 
SLC9A3R1 #7 CCACACCGCCCTGAGATGGTGGG antisense 
SLC9A3R1 #8 AGAAGAGGTTACTAGCCAGAAGG sense 
SLC9A3R1 #9 GATAAATGGGAGTGACGTCCAGG antisense 
SLC9A3R1 #10 CCCAATGGGTTGCCCCATTCTGG sense 
SLC9A3R1 #11 ACACGCAGATTTCGAGTGCTTGG antisense 
GLYATL1 #1 AGCCTCAATTAAGTTTACTCTGG antisense 
GLYATL1 #2 CACCATTGGAGCTAGCCTGCAGG antisense 
GLYATL1 #3 GTTAATTCCGCCTGGTGATTAGG sense 
GLYATL1 #4 GTGTAAGGACCGCTTTCATGAGG antisense 
GLYATL1 #5 CCTTCATAGCTTGCCTTACAAGG sense 
 
3.2.8.3.2 Oligoduplex formation 
In short sgRNA top and bottom strand oligos, containing a BsmBI digestion site, were 
resuspended to 100 M in H2O. 5l of top strand oligo and 5l of bottom strand oligo were 
mixed with 2 l 10x NEB Buffer #3 and 8 l of H2O and heated at 95°C for 5 minutes with 
subsequent cool down to 10°C at -5°C/minute, to ensure generations of oligo duplexes.  
Oligo Sequence 
BAMBI #1 forward ACACCGTCTCAAGGGGCGTGCTGACAG 
BAMBI #1 reverse AAAACTGTCAGCACGCCCCTTGAGACG 
BAMBI #2 forward ACACCGAGTGTCGTCTCGTTGGCGCCG 
BAMBI #2 reverse AAAACGGCGCCAACGAGACGACACTCG 
BAMBI #3 forward ACACCGAGGGTCTCCACAGCACGCAAG 
BAMBI #3 reverse AAAACTTGCGTGCTGTGGAGACCCTCG 
BAMBI #4 forward ACACCGCGATCCATTGACGCCCCGCAG 
BAMBI #4 reverse AAAACTGCGGGGCGTCAATGGATCGCG 
BAMBI #5 forward ACACCGTGAGGGCACGCGGCAGCTACG 
BAMBI #5 reverse AAAACGTAGCTGCCGCGTGCCCTCACG 
BAMBI #6 forward ACACCGTGTAGCACATCATCCTCGCTG 
BAMBI #6 reverse AAAACAGCGAGGATGATGTGCTACACG 
SLC9A3R1 #1 forward ACACCAGGCTGTTAAAACGTTGGCCG 
SLC9A3R1 #1 reverse AAAACGGCCAACGTTTTAACAGCCTG 
SLC9A3R1 #2 forward ACACCAGTGATCCGAGATCGCGCCAG 
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SLC9A3R1 #2 reverse AAAACTGGCGCGATCTCGGATCACTG 
SLC9A3R1 #3 forward ACACCAATGGCCGGCGCCGTTCACCG 
SLC9A3R1 #3 reverse AAAACGGTGAACGGCGCCGGCCATTG 
SLC9A3R1 #4 forward ACACCTGGGACGCTCAGACGCCGCGG 
SLC9A3R1 #4 reverse AAAACCGCGGCGTCTGAGCGTCCCAG 
SLC9A3R1 #5 forward ACACCGCGCGACTTGGGGTTCCGATG 
SLC9A3R1 #5 reverse AAAACATCGGAACCCCAAGTCGCGCG 
SLC9A3R1 #6 forward ACACCAGAAAAACGACGGCGGGCGCG 
SLC9A3R1 #6 reverse AAAACGCGCCCGCCGTCGTTTTTCTG 
SLC9A3R1 #7 forward ACACCCCACACCGCCCTGAGATGGTG 
SLC9A3R1 #7 reverse AAAACACCATCTCAGGGCGGTGTGGG 
SLC9A3R1 #8 forward ACACCAGAAGAGGTTACTAGCCAGAG 
SLC9A3R1 #8 reverse AAAACTCTGGCTAGTAACCTCTTCTG 
SLC9A3R1 #9 forward ACACCGATAAATGGGAGTGACGTCCG 
SLC9A3R1 #9 reverse AAAACGGACGTCACTCCCATTTATCG 
SLC9A3R1 #10 forward ACACCCCCAATGGGTTGCCCCATTCG 
SLC9A3R1 #10 reverse AAAACGAATGGGGCAACCCATTGGGG 
SLC9A3R1 #11 forward ACACCACACGCAGATTTCGAGTGCTG 
SLC9A3R1 #11 reverse AAAACAGCACTCGAAATCTGCGTGTG 
GLYATL1 #1 forward ACACCGAGCCTCAATTAAGTTTACTCG 
GLYATL1 #1 reverse AAAACGAGTAAACTTAATTGAGGCTCG 
GLYATL1 #2 forward ACACCGCACCATTGGAGCTAGCCTGCG 
GLYATL1 #2 reverse AAAACGCAGGCTAGCTCCAATGGTGCG 
GLYATL1 #3 forward ACACCGTTAATTCCGCCTGGTGATTG 
GLYATL1 #3 reverse AAAACAATCACCAGGCGGAATTAACG 
GLYATL1 #4 forward ACACCGTGTAAGGACCGCTTTCATGG 
GLYATL1 #4 reverse AAAACCATGAAAGCGGTCCTTACACG 
GLYATL1 #5 forward ACACCGCCTTCATAGCTTGCCTTACAG 
GLYATL1 #5 reverse AAAACTGTAAGGCAAGCTATGAAGGCG 
 
3.2.8.3.3 Digestion of plasmid backbone 
2 g of MLM2.0 vector backbone were mixed with 10l 10x NEB 3.1 buffer, 1l of BsmBI and 
H2O up to 100l and digested at 55°C for 4 hours. The digested plasmid was run on a 2% 
agarose gel and isolated using the Promega Wizard SV gel and PCR clean up system according 
to manufacturer’s instructions.  
3.2.8.3.4 Ligation 
For the ligation, 30ng of digested plasmid, 1 l of oligo duplex, 1 l 10x T4 DNA ligase bugger, 
0.5 l T4 DNA ligase (NEB) and H2O ad 10l were incubated at 24°C for 10 minutes and chilled 
on ice prior to transformation.  
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3.2.8.3.5 Transformation 
80l of competent E.coli were mixed with 1l of the ligated plasmid mixture and incubated on 
ice for 30 minutes. Following a heat shock at 42°C for 90 seconds, 800l of SOC (Super Optimal 
Broth with Catabolite repression) media were added and incubated shaking at 37°C for 1 hour. 
100 l of the transformed bacteria were spread on LB-Agar plates with Ampicillin (100g/ml) 
and incubated over night. Colonies were picked the next day for colony PCR.  
3.2.8.3.6 Colony PCR and Sanger sequencing 
PCR mix was as shown in the table 
Component Amount per sample 
10X Buffer 2.5l 
MgCl2 1.5l 
10mM dNTP 0.5l 
10M forward primer 0.5l 
10M reverse primer 0.5l 
Taq Polymerase 0.2l 
ddH20 19.3l 
 
Forward primer was the sequencing primer for MLM3636 plasmid. Reverse primer was the 
reverse oligo for the respective sgRNA. 
MLM3636 sequencing 
primer (OS280) 
     5’-CAGGGTTATTGTCTCATGAGCGG-3’ 
PCR conditions were as follows: 
94°C 3 min  
94°C 20 sec  
30 cycles Tm (depending on the primers) 20 sec 
72°C 20 sec 
72°C 7 min  
 
Following the agarose gel electrophoresis and validation of the fragment inserted, samples were 
sent for Sanger sequencing to ensure complete and correct insertion. 
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3.2.8.3.7 Plasmid Purification 
Bacteria were grown in LB-media with Ampicillin (100g/ml) and pelleted at 5,000 x g for 15 
minutes at 4°C. The plasmids were isolated using the Qiagen Plasmid Plus Midi Kit according to 
manufacturer’s instructions. In short, pellets were resuspended in 4ml of buffer P1, mixed with 
4ml of buffer P2 and incubated at room temperature for 3 minutes. 4ml of buffer S3 were added 
and the mixture was inverted 4-6 times. The lysate was transferred to the QIAfilter Cartridge and 
incubated at room temperature for 10 minutes. The lysate was filtered into a tube, using a 
plunger, and mixed with 2ml Buffer BB. The mixture was transferred to a QIAGEN Plasmid 
Plus spin column and drawn through the column with a vacuum pump. The column was washed 
with 0.7ml Buffer ETR and 0.7 ml Buffer PE and centrifuged at 10,000 x g for 1 minute to dry 
the membrane. The plasmid was eluted in 150 l H2O and stored at -20°C.  
3.2.8.4 Plasmid Transfection 
The transfection conditions are shown in table. Cells were seeded in P/S-free media and 
transfected 24 hours later. The corresponding amount of plasmid DNA (1:1 ratio sgRNA plasmid 
and dCas9 plasmid) was added to Opti-MEM (media) containing the appropriate amount of LTX 
and plus reagent (ThermoFisher Scientific) and incubated for 30 minutes at room temperature 
(Table 3). The transfection mix was then added dropwise on the cells. 
Culture 
vessel 
P/S-free 
media 
Cells per well 
Transfection 
mix 
DNA amount LTX reagent Plus reagent 
96 well plate 80 l 
1250 (MCF7 WT and TAMR) 
2000 (MCF7 LTED) 
20 l 100 ng 0.4 l 0.2 l 
48 well plate 160 l 20.000 40 l 200 ng 0.8 l 0.4 l 
24 well plate 400 l 40.000 100 l 500 ng 1.5 l 0.75 l 
12 well plate 800 l 80.000 200 l 1000 ng 2.5 l 1.25 l 
6 well plate 1500 l 150.000 500 l 2000 ng 5 l 2.5 l 
 
Table 3: Volumes of reagents used for plasmid transfections 
3.2.9  Dataset Analysis 
Publicly available METABRIC and TCGA datasets were downloaded from the website given in 
Section 3.1.7. METABRIC data comprised of mRNA expression microarray and clinical data of 
nearly 2000 patients with a follow up of 20 years. Box plots are represented as log2 transformed 
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gene expression data. Kaplan-Meier method was used to generate survival curves (Kaplan & 
Meier, 1958). 33.3% of the patients with the highest and lowest expression of GLYATL1 and 
25% of the patients with the highest and lowest expression of BAMBI were used to generate 
survival curves. Km plotter was used to generate survival curves (Á. Nagy et al., 2018). Survival 
curve for Pawitan dataset was obtained from Cancertool (Cortazar et al., 2018). TCGA data 
comprises of RNA-sequencing and clinical data of nearly 1200 patients. Box plots were 
generated using gene expression data represented as log2 (x+1) rsem.   
3.2.10 Statistical Analysis 
Unless otherwise mentioned, data are presented as mean ± SD and statistical analyses were 
performed by unpaired two-tailed Student’s t-test (with Welch’s correction) and p-values smaller 
than 0.05 were considered statistically significant. P values <0.05, <0.01, <0.001 and <0.0001 
are indicated with one, two, three and four asterisks respectively. 
3.2.11 Graphical Illustrations 
All graphs were generated using the GraphPad Prism Software and illustrated via Inkscape v 
0.91 
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4. Results 
4.1 Part I: Elucidating the Role of GLYATL1 in Endocrine 
Therapy Resistant Breast Cancer 
4.1.1 Establishment and characterization of endocrine therapy 
resistant breast cancer cell lines 
 
In this project, we are focusing on Luminal A subtype due to their ER
+
 status. I chose MCF7 as 
luminal model cell line of interest. Dr. Luca Magnani (Imperial College London) has kindly 
provided MCF7 cells resistant to 100 nM 4-OH-tamoxifen (TAMR), long term estrogen-
deprivation (LTED) which mimics aromatase inhibitor resistance, and LTED MCF7 cells which 
are also resistant to tamoxifen (LTEDTAMR) as well as a sensitive counterpart (WT) (Nguyen et 
al., 2015). MCF7 TAMR and LTED cells have been generated either via treatment with 100 nM 
4-OH-Tamoxifen (active metabolite of the drug) or deprivation from estrogen for one year, 
respectively. Treatment of LTED cells with 4-OH-tamoxifen for one more year resulted in 
LTEDTAMR cells, which is a model for double resistance (Figure 7a) (Nguyen et al., 2015). We 
have generated also a resistance acquisition model in T47D, another luminal A cell line, in 
collaboration with Simone Borgoni established via treatment with either 100 nM 4-OH-
tamoxifen (T47D TAMR) or long term estrogen deprivation (T47D LTED) for one year (Figure 
8a). For T47D resistance acquisition model, we collected DNA, RNA, supernatant and protein 
samples from the cells in different time-points for further analysis. We also monitored and 
validated resistance development over time with phenotypic assays such as proliferation, 
viability, drug response, migration and invasion.  
Tamoxifen resistance was validated by viability assays under treatment with increasing doses of 
4-OH-Tamoxifen (4-OHT). Tamoxifen resistant cells were found to be more viable compared to 
their sensitive counterparts under treatment with up to 500 nM 4-OHT, which is five times more 
than the amount of the drug dose that they have been used for development of resistance (Figure 
7b).  LTEDTAMR cells showed a similar trend in tamoxifen resistance. Resistant cells also 
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displayed more invasive phenotype compared to parental MCF7 cells that they are derived from 
(Figure 7c). 
 
Figure 7: Establishment and characterization of endocrine therapy resistant MCF7 breast cancer cell lines. 
(a) Scheme for establishment of endocrine therapy resistance acquisition experiment for MCF7 cells. (b-d) Invasion 
assay was performed at different time-points of resistance acquisition. (b) WT and TAMR cells were grown in the 
presence of either vehicle (EtOH) or 4-OHT and cell viability was measured after 72h with Cell Titer Glo Assay. (c) 
LTED and LTEDTAMR cells were grown in the presence of either vehicle (EtOH) or 4-OHT and cell viability was 
measured after 72h with Cell Titer Glo Assay. (d) Invasion assay of MCF7 cell repertoire. All values are represented 
as relative values normalized to WT. Data are presented as mean ± SD, for invasion assays n=3 (each with 3 
technical replicates), for cell viability assays n=2 (with 6 technical replicates). *** represents p < 0.001, ** 
represents p<0.01, * represents p<0.05. 
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The same approach was adopted in characterization of resistant phenotype and validation of 
resistance acquisition over time for T47D cell line. Large scale screening techniques such as 
RNA-sequencing and EPIC array was performed on samples acquired at months 1, 2, 5 and 7 of 
resistance acquisition to fully comprehend the changes occurring during immediate early, early. 
intermediate and late time-points of exposure to endocrine therapy conditions. T47D TAMR 
cells displayed resistance to 4-OHT starting from 5 months of drug exposure (Figure 8e). After 7 
months under 4-OHT treatment, the cells were even resistant to higher doses of 4-OHT than 100 
nM (Figure 8f,g). And similar to their MCF7 counterparts, T47D cells got more invasive 
phenotype as they acquired resistance to endocrine therapy conditions (Figure 8b-d).  
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Figure 8: Establishment and characterization of endocrine therapy resistant T47D breast cancer cell lines. (a) 
Scheme for establishment of endocrine therapy resistance acquisition experiment for T47D cells. The indicated 
time-points are marking the samples used for RNA-seq, EPIC array (except for month 12) and functional assays. (b-
d) Invasion assays were performed at different time-points of resistance acquisition. (e-g) WT and TAMR cells were 
grown in the presence of either vehicle (EtOH) or 4-OHT and cell viability was measured over time with Cell Titer 
Glo Assay. All values are represented as relative values normalized to WT. Data are presented as mean ± SD, for 
invasion assays n=1 for each time point (each with 3 technical replicates), for cell viability assays n=1 for each time 
point (with 6 technical replicates). *** represents p < 0.001, ** represents p<0.01, * represents p<0.05. 
4.1.2 Profiling of resistant cell line repertoire 
 
Resistant MCF7 cell lines and their sensitive counterpart were profiled with next-generation 
sequencing techniques in order to elucidate changes in transcriptome (RNA-Sequencing), 
chromatin accesibility (ATAC-Seq) and methylome (EPIC array) that could be accounted for the 
development of endocrine therapy resistance in these cells. The reason for inclusion of ATAC-
Seq and EPIC array was to assess and understand the level of epigenetic regulation of endocrine 
therapy resistance to a certain extent. RNA-Seq and EPIC array data were analyzed by Maryam 
Soleimani-Dodaran and Perry Moerland (UvA, The Netherlands). ATAC-Seq data initial 
analysis was performed by Dr. Simin Oz (DKFZ) and integration of ATAC-Seq and RNA-Seq 
data was done by Dr. Perry Moerland. 
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Figure 9: Correlation of RNA-Seq and ATAC-Seq for resistant MCF7 cell line repertoire. The number of 
genes in associated with gained (a) and lost (c) peaks around TSS (±2 kb) based on ATAC-Seq data and RNA-Seq 
volcano plots upregulated (b) and downregulated (d) genes in MCF7 resistant cell lines compared to parental. The 
genes from ATAC-Seq analysis are highlighted in red. (e) Gene set variation analysis (GSVA) comparing the subset 
of genelists based on gained and lost peaks of ATAC-Seq data with RNA-Seq results. (f) Top 5 up- and down-
regulated genes in all three resistant cell lines derived from parental MCF7. 
Integration of ATAC-Seq and RNA-Seq data revealed that gained ATAC-Seq peaks around the 
transcription start site (± 2 kbp TSS) in resistant cell lines were correlating with upregulated 
genes whereas lost peaks of ATAC-Seq data were belonging to the TSS of the genes that were 
downregulated in resistant cells compared to parental. This finding was verified via geneset 
variation analysis comparing the genesets based on gained and lost peaks of ATAC-Seq data 
with RNA-Seq (Figure 9a-e).  
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Among the genes common to all MCF7-derived resistant cell lines, top 5 upregulated genes with 
gained peaks from ATAC-Seq were GLYATL1, EGLN3, ACSL4, UPK2, ELF5 and top 5 
downregulated with lost peaks were IL24, IL20, GREB1, PGR and TRIM55 (Figure 9f). I chose 
GLYATL1 as target gene potentially implicated in therapy resistance, since this gene was found 
to be the most strongly upregulated one in MCF7 TAMR, LTED and LTEDTAMR.    
GLYATL1 (Glycine-N-acyltransferase Like 1/Glutamine-N-acyltransferase) encodes for an 
acyltransferase using L-glutamine as its substrate. This gene has been characterized in 2007 and 
suggested to be implicated in activation of heat shock pathway (H. Zhang et al., 2007). There are 
three known members of GLYATL family of enzymes: GLYATL1, GLYATL2 and GLYATL3. All 
encode for acyltransferases with differing substrates. GLYATL1 is highly expressed in liver and 
kidney, whereas GLYATL2 is enriched in salivary glands (Matsuo et al., 2012). GLYATL1 is 
considered to be a biomarker for prostate cancer since it has been shown to be significantly 
upregulated in two independent datasets comparing primary prostate cancer samples to healthy 
control (Barfeld et al., 2014). TCGA dataset comparison between normal and matched primary 
tumors also revealed that prostate cancer, colon cancer and breast cancer are the only cancer 
entities with significantly increased expression difference in tumor tissue. 
Interestingly, GLYATL1 has also been implicated in androgen independent prostate cancer 
refractory to androgen deprivation therapy as a candidate gene (Nalla et al., 2016). Moreover, 
GLYATL1 was the only gene common for two independent gene signatures for vascular invasion 
prediction in hepatocellular carcinoma (W. Liu et al., 2012; Mínguez et al., 2011) 
 
Figure 10: Changes in GLYATL1 expression during T47D resistance acquisition. RNA was extracted from 
T47D cells at different time-points of tamoxifen-exposure (TAMR) or estrogen deprivation (LTED). GLYATL1 
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levels were determined by RNA-Sequencing. All values are represented as relative values normalized to WT. Data 
are presented as mean of two biological replicates.  
GLYATL1 was also found to be upregulated in T47D resistant cells in mRNA level. T47D LTED 
cells had higher GLYATL1 expression compared to T47D TAMR. Detailed analysis of different 
time-points of T47D resistance acquisition revealed that GLYATL1 mRNA expression was 
elevated already at 1 month of both tamoxifen administration and estrogen-deprivation (Figure 
10). Even though it fluctuated in between, the expression got even higher for T47D LTED cells 
at 12 months (Figure 11c). I then continued with checking the protein levels of GLYATL1 in 
both MCF7 and T47D resistant cell line repertoire that we have. Western blotting results 
confirmed the gene expression data obtained via RNA-Seq and TaqMan qRT-PCR as resistant 
cells derived from both luminal cell lines showed higher levels of GLYATL1 in protein level 
(Figure 11). 
 
Figure 11: GLYATL1 increases both at mRNA and protein level in endocrine therapy resistant cells. (a) RNA 
and protein were extracted from resistant and sensitive MCF7 and T47D cells. GLYATL1 levels were determined 
by qPCR (a,c) and western blot (b,d) respectively. All values are represented as relative values normalized to WT. 
Data are presented as mean ± SD. Values for mRNA expression were first normalized to PUM1 and ACTB levels, 
n=3 (each with 3 technical replicates), Protein expression values were first normalized to actin levels. Data shown 
are representative of 3 independent experiments (n=3) ** represents p<0.01, * represents p<0.05. 
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4.1.3 Clinical Significance of GLYATL1 
 
Assessment of GLYATL1 expression among 42 different breast cancer cell lines revealed that 
breast cancer cell lines belonging to luminal or HER2-enriched subtype had higher GLYATL1 
expression compared to the ones of basal subtype (Figure 12a). Cell lines provide the 
opportunity to recapitulate endocrine therapy resistance acquisition in vitro. Established cell line 
models enable the researchers to shed more light into the intricate molecular mechanisms that 
bring about resistance to therapies and relapse in patients. However, it is of utmost importance to 
understand and evaluate the clinical relevance of in vitro findings. For this purpose, the 
expression patterns of GLYATL1 among breast cancer molecular subtypes were analyzed using 
two publicly available datasets TCGA (1200 patients) and METABRIC (2000 patients) (Collins, 
2007; Curtis et al., 2012). GLYATL1 expression was found to be significantly higher in the 
luminal and HER2-enriched subtype of breast cancer compared to basal in both datasets 
corroborating in vitro cell line data (Figure 12b). However, the MCF7 and T47D cell lines did 
not show elevated levels of basal GLYATL1 expression compared to cell lines of other subtypes. 
Interestingly, HER2-enriched subtype had the highest GLYATL1 expression among all subtypes 
in METABRIC dataset (Figure 12c).  
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Figure 12: GLYATL1 expression in breast cancer cell lines and patients.  (a) Comparison of GLYATL1 mRNA 
expression levels among 42 different breast cancer cell lines belonging to different subtypes Lum A (n=9), Lum B 
(n=4), HER2+ (n=10), Basal (n=19). (b) Comparison of GLYATL1 mRNA expression analysis [log2 (x+1) rsem] in 
the TCGA dataset among the intrinsic subtypes Lum A (n=421), Lum B (n=192), HER2+ (n=67) and Basal (n=141). 
(c) Comparison of GLYATL1 mRNA expression analysis (log2 a.u.) in the METABRIC dataset among the intrinsic 
subtypes Lum A (n=721), Lum B (n=492), HER2+ (n=240) and Basal (n=331). **** represents p<0.0001, *** 
represents p < 0.001, ** represents p<0.01, * represents p<0.05. 
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Figure 13: Correlation of GLYATL1 expression with patient survival.  (a) Tertile –based survival analysis of 
TCGA dataset of GLYATL1 low versus high gene expression (for each tertile n=363). (b) .  Recurrence-free survival 
analysis of METABRIC dataset of GLYATL1 low versus high gene expression for ER
+
 patients undergoing 
tamoxifen treatment (n=161). Plotted with Kaplan-Meier Plotter (Á. Nagy et al., 2018) 
As for the role of GLYATL1 on overall patient survival, TCGA dataset showed that high 
GLYATL1 expression was significantly correlated with poor patient prognosis (Á. Nagy et al., 
2018) (Figure 13a). Survival analysis of METABRIC dataset demonstrated a similar trend in 
recurrence-free survival (RFS) for patients with ER-positive tumors who are under tamoxifen 
treatment (n=161) indicating a proxy for GLYATL1 in the context of endocrine therapy resistance 
(Figure 13b). 
This trend was further confirmed in an independent cohort (n=159) where patients with higher 
GLYATL1 expression levels and disease-free survival were significantly inversely correlated 
(Cortazar et al., 2018; Pawitan et al., 2005). In this dataset, recurrence within 5 years was also 
monitored and GLYATL1 expression was found to be significantly higher in patients with 
recurred breast cancer compared to disease-free individuals (Pawitan et al., 2005)(Figure 14). 
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Figure 14: Correlation of GLYATL1 expression with disease-free patient survival. (a) Quartile–based survival 
analysis of Pawitan dataset of GLYATL1 low, moderate and high gene expression. (b) GLYATL1 expression 
difference between disease-free individuals and recurrence patients (Cortazar et al., 2018; Pawitan et al., 2005).  
4.1.4 GLYATL1 as a novel gene in endocrine therapy resistance 
context 
4.1.4.1 Effect of GLYATL1 knockdown on cell viability 
 
Integrative analysis of RNA-Seq and ATAC-Seq revealed GLYATL1 as one of the top 
differentially regulated genes in all resistant cell lines compared to their sensitive counterparts. In 
order to investigate the effect of GLYATL1 loss on both parental and resistant cell lines, RNAi 
approach was used. I used a pool of four siRNAs targeting GLYATL1 to transfect MCF7 cells 
and checked the viability of the cells after 7 days in their respective treatment conditions with 
Cell Titer Glo assay from Promega which measures the ATP production of the cells as a proxy 
for metabolic activity and therefore viability.  
Viability of parental MCF7 cells did not change after transfection. TAMR cells were found to be 
less viable under tamoxifen treatment compared to vehicle control when GLYATL1 was knocked 
down. LTED cells also showed less metabolic activity following siRNA transfection. 
LTEDTAMR cells showed sensitivity to both estrogen deprivation and tamoxifen treatment after 
GLYATL1 knockdown (Figure 15). 
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Figure 15: GLYATL1 knockdown affects resistant MCF7 cell viability. a-e, Cells were transfected with 
siGLYATL1 and cell viability was assessed after 7 days with the Cell Titer Glo assay. All values are represented as 
relative values normalized to non-targeting control siRNA (siCTRL).  Data are presented as mean ± SD, n=3 (each 
with 5 technical replicates) ** represents p < 0.01,* represents p<0.05 (n.s: not significant). 
T47D resistant cell lines displayed similar tendency in re-sensitization to endocrine therapy 
conditions upon GLYATL1 knockdown. T47D TAMR cells were significantly less resistant to 4-
OHT exposure and T47D LTED cells were less viable following siGLYATL1 transfection 
(Figure 16). 
 
Figure 16: GLYATL1 knockdown affects resistant T47D cell viability. T47D TAMR (a) and LTED (b) cells were 
transfected with siGLYATL1 and cell viability was assessed after 7 days with the Cell Titer Glo assay. All values 
are represented as relative values normalized to non-targeting control siRNA (siCTRL).  Data are presented as mean 
± SD, n=3 (each with 5 technical replicates) ** represents p < 0.01,* represents p<0.05 (n.s: not significant). 
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Deconvolution of the 4 siRNAs of the GLYATL1 pool revealed that all siRNAs show a 
significant decrease in GLYATL1 mRNA levels (Figure 17). Nuclei count of the cells transfected 
with individual and pool GLYATL1 siRNA showed all sgRNAs were able to significantly, albeit 
variably, inhibit cell growth.   
 
Figure 17: Knockdown efficiency and deconvolution of siGLYATL1 pool. MCF7 LTED cells were transfected 
with siGLYATL1 (pool and individual). (a) RNA was harvested 72 hours post-transfection and knockdown 
efficiency was determined by qRT-PCR. (b) Microscopy-based nuclei counting of the cells were performed 72h post 
transfection. All values were normalized to siCTRL. Values for mRNA expression were first normalized to PUM1 
and ACTB levels and are presented as mean ± SD, n=3 (each with 3 technical replicates). Proliferation data are 
represented as mean ± SD, n=3 (each with 5 technical replicates) ****represents p<0.0001, *** represents p < 
0.001, ** represents p<0.01, * represents p<0.05. 
In conclusion, knockdown of GLYATL1 resulted in significant decrease in cell viability under 
endocrine therapy conditions in resistant cell lines derived from both MCF7 and T47D.  
4.1.4.2 Effect of GLYATL1 overexpression on cell proliferation 
 
Following the observation that knockdown of GLYATL1 partially, albeit significantly, re-
sensitizes the resistant cells to endocrine therapy, I wanted to investigate whether overexpression 
of this gene would confer resistance to parental cells or not. In order to answer this research 
question, I used lentivirally transduced stable cell lines overexpressing GLYATL1 (MCF7 
GLYATL1 ox and T47D GLYATL1 ox) generated by Dr. Rainer Will (DKFZ). Overexpression 
of target gene and protein was validated by TaqMan qRT-PCR and Western Blotting, 
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respectively (Figure 18) for both cell lines comparing overexpressing cells (GLYATL1 ox) to 
their empty vector controls (MCF7 empty and T47D empty). The two bands observed in western 
blotting in GLYATL1 overexpressing cells suggest a post-translational modification for this 
protein. 
 
 
Figure 18: GLYATL1 overexpression in MCF7 and T47D cells. RNA and protein were harvested from 
GLYATL1 overexpresing cells (GLYATL1 ox) and empty vector controls (empty). GLYATL1 levels were 
determined by qRT-PCR (a,b) and western blotting (c,d). Values for mRNA expression were first normalized to 
PUM1 and ACTB levels. Data are presented as mean ± SD, n=2 for qRT-PCR (each with 3 technical replicates)., 
n=3 for western blotting.  
Cell proliferation assays were performed over a course of one week via microscopy-based nuclei 
count following Hoechst staining. Cell growth media was changed to endocrine therapy 
conditions 24 hours post-seeding to assess the effects of therapy conditions. The conditions were 
normal growth media supplemented with E2 (+E2), growth media with vehicle EtOH, growth 
media with 100 nM 4-OHT, estrogen deprivation media (-E2) or estrogen deprivation media with 
100 nM 4-OHT. For MCF7 cells, overexpression of GLYATL1 gave the cells a slight 
proliferation advantage in normal growth conditions (+E2). Moreover, MCF7 GLYATL1 ox 
cells grew significantly better in estrogen deprivation conditions compared to empty vector 
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control. Impressively, GLYATL1 overexpressing MCF7 cells suffered significantly less from 
tamoxifen treatment. They also coped better with both estrogen deprivation and tamoxifen 
treatment significantly than their empty vector counterparts (Figure 19). 
 
Figure 19: Effect of GLYATL1 overexpression on MCF7 cell proliferation under endocrine therapy 
conditions. (a-d) MCF7 GLYATL1 overexpressing (GLYATL1 ox) and empty vector control (empty) cells were 
seeded and treated with different growth media to simulate endocrine therapy conditions. Microscopy based nuclei 
counting was performed at different time points during 7 days. All values for proliferation assays were normalized 
to seeding controls. Data are presented as mean ± SEM, n=4 (each with 5 technical replicates). **** represents 
p<0.0001, *** represents p<0.001, ** represents p<0.01. 
The effect of GLYATL1 overexpression followed a similar trend for T47D cells. GLYATL1 
overexpressing T47D cells grew significantly better under tamoxifen treatment conditions and in 
estrogen deprivation conditions, especially at day 7 of treatment. T47D GLYATL1 
overexpressing cells did not show any significant change in proliferation dynamics when 
exposed to both tamoxifen and estrogen deprivation at the same time (Figure 20). 
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Figure 20: Effect of GLYATL1 overexpression on T47D cell proliferation under endocrine therapy 
conditions. (a-d) T47D GLYATL1 overexpressing (GLYATL1 ox) and empty vector control (empty) cells were 
seeded and treated with different growth media to simulate endocrine therapy conditions. Microscopy based nuclei 
counting was performed at different time points during 7 days. All values for proliferation assays were normalized 
to seeding controls. Data are presented as mean ± SEM, n=3 (each with 5 technical replicates). *** represents 
p<0.001, ** represents p<0.01. 
 
4.1.4.3 Effect of GLYATL1 overexpression on cell cycle 
 
In order to elucidate the changes in proliferation dynamics of GLYATL1 overexpressing cells 
compared to their empty vector controls, I decided to check the cell cycle of the these cells under 
normal growth conditions and growth conditions mimicking endocrine therapy. For this purpose, 
EdU incorporation assay (Click-iT EdU Imaging Kit) was utilized. This assay simply provides 
detection of cells undergoing S-phase of the cell cycle via fluorescent tagged antibodies targeting 
incorporated EdU. I could determine the percentage of the cells in S-phase via combining this 
assay with Hoechst staining of the cells. EdU incorporation was performed in order to 
distinguish any changes in cell cycle kinetics following a 24h pulse. In short, the percentages of 
the GLYATL1 overxpressing MCF7 cells undergoing S-phase was found to be slightly more in 
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normal growth conditions. While a decrease in the percentages of cycling cells was observed 
under tamoxifen treatment, estrogen deprivation or simultaneous administration of both, 
GLYATL1 overexpressing cells had significantly more cells cycling through S-phase (Figure 
21a).  
T47D cells demonstrated a similar trend, as the percentages of cells going through S-phase were 
found to be higher in GLYATL1 overexpressing cells under endocrine therapy conditions. 
However, the difference here was not significant (Figure 21b). 
 
Figure 21: Effect of GLYATL1 overexpression on cell cycle. MCF7 (a) and T47D (b) cells were pulsed with EdU 
for 24h. Percentages of EdU
+
 cells were determined by microscopy-based counting. Data are presented as mean ± 
SD, n=3. * represents p<0.05. 
4.1.4.4 Effect of GLYATL1 overexpression on apoptosis 
 
Next, I wanted to check the changes in apoptosis (namely late apoptosis), which could be 
accounted for the differential growth dynamics of overexpressing cells. For this purpose, 
percentage of cells undergoing late apoptosis was determined by PI addition to the cells before 
microscopic nuclei counting with Hoechst staining. Here, the percentage of late apoptotic cells 
for MCF7 empty vector were found to be increasing as the cells are introduced to tamoxifen, 
estrogen deprivation or both at the same time whereas GLYATL1 overexpressing cells had 
significantly less apoptotic cells under endocrine therapy conditions (Figure 22a). 
For T47D GLYATL1 overexpressing cells, a similar trend was observed regarding apoptosis. 
Percentage of late apoptotic cells was significantly less under tamoxifen treatment and estrogen 
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deprivation whereas no significant change was observed when GLYATL1 overexpressing cells 
were challenged with both endocrine therapy conditions at the same time (Figure 22b).  
 
Figure 22:  Effect of GLYATL1 overexpression on apoptosis. Percentage of late apoptotic cells were determined 
via PI staining combined with Hoechst-based microscopic nuclei count. Data are presented as mean ± SD, n=3 for 
MCF7 and n=2 for T47D (each with 4 technical replicates). **** represents p<0.0001, *** represents p<0.001, * 
represents p<0.05. 
Taken together, these data suggest overexpression of GLYATL1 confers resistance to estrogen 
deprivation and especially tamoxifen treatment as revealed with differing proliferation dynamics 
for both MCF7 and T47D cells. Assays assessing cell cycle kinetics and apoptosis further 
confirmed the changes in dynamics in overexpressing cells indicating they cope better with 
endocrine therapy conditions compared to their empty vector control.  
4.1.5 Investigating the role of GLYATL1 as a potential HAT 
 
The STRING database suggests KAT2A and KAT2B as potential interaction partners of 
GLYATL1 (Szklarczyk et al., 2019). KAT2A and KAT2B are histone acetyltransferases 
belonging to GCN5-related N-acetyltransferases (GNATs) (Figure 23).  
These HATs predominantly catalyze acetylation of H3 or H4 tail lysine residues with a 
preference for H3K9 and H3K14 (Howe et al., 2001; Jin et al., 2011). For this reason, first I re-
assessed the RNA-Seq data with a focus on expression levels of HATs. Among the probed 
HATs, KAT2B was found to be the one that was the most upregulated in all MCF7 resistant cells 
compared to parental. Interestingly, KAT2A expression was upregulated only in MCF7 TAMR 
and LTEDTAMR. In contrast, in T47D cells, although both HATs were downregulated, KAT6B, 
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a HAT from MYST family, was found to be upregulated for both resistance models (TAMR and 
LTED). KAT6A was found to be upregulated only at the latest time-point (7 months) probed for 
T47D resistance acquisition with RNA-sequencing. CREBBP and EP300 (p300/CBP HATs) 
were also found to be upregulated in later time-points for T47D and for MCF7 LTED and 
LTEDTAMR cells (Figure 24).   
 
Figure 23: Putative interaction partners of GLYATL1. Possible interaction partners of GLYATL1 were 
determined using STRING database (version 11.0, accessed on 21.06.2019) (Szklarczyk et al., 2019). 
 
  Results 
76 
 
Figure 24:  Expression patterns of histone acetyltransferases in resistant MCF7 and T47D cell lines. 
Expression levels for family members of HATs in MCF7 (a) and T47D (b) cells were determined via RNA-
Sequencing. All values are represented as relative values normalized to their respective WT.  
Given the putative function of GLYATL1 as a histone acetyltransferase (or taking part in a 
multi-subunit HAT complexes), I wanted to check whether there was a global increase in histone 
3 (H3) acetylation. For this purpose, histones were extracted and changes in pan-histone 3 
acetylation patterns were assessed by western blotting. Pan-acetylation of H3 was found to be 
increased especially in LTED cells compared to parental MCF7 (Figure 25). 
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Figure 25:  Pan-acetylation of H3 in MCF7 cell line repertoire. Pan-acetylation of histone 3 was determined via 
western blotting of purified core histones. Protein expression levels were normalized to total H3 levels (n=2). 
ZMYND8, a gene encoding the epigenetic reader of H3K14ac mark (Savitsky et al., 2016), also 
came out of the MCF7 ATAC-Seq and RNA-Seq correlation analysis as one of the top 
significantly gained peaks around TSS and upregulated genes. This gene was also found to be 
upregulated for T47D resistance acquisition samples (Figure 26). Intriguingly, KAT2A, KAT2B, 
KAT6A and KAT6B are also epigenetic readers of histone marks H3K9ac and H3K14ac in 
addition to their role as histone acetyltransferases introducing these marks (Gong et al., 2016). 
That is the reason why I chose to focus specifically on acetylation of these two histone tail 
residues. 
 
 
Figure 26:  ZMYND8 expression levels in MCF7 and T47D cell line repertoire. ZMYND8 mRNA levels in 
MCF7 (a) and T47D (b) were determined via qRT-PCR. Values for mRNA expression were first normalized to 
PUM1 and ACTB levels and are represented as mean ± SD, n=3 (each with 3 technical replicates). ** represents 
p<0.01, * represents p<0.05. 
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GLYATL1 has been reported to to localize to mitochondria (Matsuo et al., 2012) while the 
Human Protein Atlas suggests localization in the cytosol and Golgi (Uhlen et al., 2017) 
GeneCards and the compartments database annotate also the nucleus as subcellular location, 
based on a prediction by PSORT (Binder et al., 2014; Database GeneCards, 2017). In order to 
further investigate the potential role of GLYATL1 in histone acetylation, I next checked whether 
it localizes to the nucleus or not. Western blotting results of cytoplasmic and nuclear fractions 
from GLYATL1 overexpressing cells and their empty vector controls showed GLYATL1 both in 
cytoplasmic and nuclear fractions of MCF7 and T47D (Figure 27). This finding strengthened the 
hypothesis that GLYATL1 might indeed have a potential role in the nucleus, such as histone 
acetylation.  
 
Figure 27:  Nuclear and cytoplasmic localization of GLYATL1 in MCF7 and T47D.  GLYATL1 protein was 
detected in cytoplasmic and nuclear fractions of MCF7 (a) and T47D (b) GLYATL1 overexpressing (GLYATL1 ox) 
cell lines. Actin was used as a loading control for cytoplasmic fraction whereas Lamin B1 was a loading control for 
nuclear fraction (n=2). 
Next step was to assess the changes in acetylation of H3K9 and H3K14 residues in MCF7 cell 
repertoire. For this, core histones were purified and alterations in H3K9ac and H3K14ac marks 
were quantified by histone ELISA. Each histone modification mark was normalized to total H3 
levels to negate any fluctuation in the probed histone mark due to abundance of total histone 
proteins. Both histone acetylation marks were found to be increased in TAMR and LTED cells 
compared to parental MCF7 (Figure 28a,c). H3K14ac increase was significant for both TAMR 
and LTED, whereas H3K9 was significantly more acetylated only in LTED cells. Furthermore, 
GLYATL1 overexpressing cells showed increased acetylation for both histone marks (Figure 
28b,d). 
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Figure 28:  H3K9ac and H3K14ac levels in MCF7 and T47D cells. H3K9ac (a,b) and H3K14ac (c,d) levels were 
detected by Histone ELISA in purified core histones of MCF7 parental and resistant cell lines and MCF7 GLYATL1 
overexpressing cells, respectively. Values for each histone mark was normalized to total H3 levels detected. Data are 
represented as mean ± SD, n=3 (each with 2 technical replicates). ** represents p<0.01, * represents p<0.05. 
In order to link the increase in H3K9ac and H3K14ac to an increase in GLYATL1 levels, the 
changes in both marks were investigated via histone ELISA upon RNA interference. GLYATL1 
knockdown on both MCF7 TAMR and LTED cells resulted in significantly less H3K9 and 
H3K14 acetylation, confirming the role of GLYATL1 as part of the machinery introducing these 
marks (Figure 29). 
 
Figure 29: Effect of GLYATL1 knockdown on H3K9ac and H3K14ac levels in MCF7 TAMR and LTED cells. 
MCF7 TAMR (a) and LTED (b) cells were transfected with siGLYATL1 and non-targeting siRNA pool (siCTRL). 
Core histones were purified 96h post-transfection. H3K9ac and H3K14ac levels were determined by Histone 
ELISA. Values for each histone mark was normalized to total H3 levels detected. Data are represented as mean ± 
SD, n=3 (each with 2 technical replicates). ** represents p<0.01, * represents p<0.05. 
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Moreover, I wanted to check whether loss of GLYATL1 has an effect on expression of two 
family members of GCN5-related N-acetyltransferases (GNATs). Interestingly, KAT2B 
expression was significantly downregulated whereas a slight (albeit not significant) increase in 
KAT2A levels was observed upon GLYATL1 knockdown in MCF7 LTED cells. On the other 
hand, overexpression of GLYATL1 resulted in an opposite trend for these two HATs where 
KAT2A was significantly downregulated and KAT2B was significantly upregulated (Figure 30).  
 
Figure 30: Effect of GLYATL1 knockdown and GLYATL1 overexpression on KAT2A and KAT2B expression 
levels. (a) MCF7 LTED cells were transfected with siGLYATL1 and non-targeting siRNA pool (siCTRL). Total 
RNA were purified 72h post-transfection. KAT2A and KAT2B expression levels were determined from GLYATL1 
knockdown and overexpression samples (b) via qRT-PCR. Values for mRNA expression were normalized to PUM1 
and ACTB levels. Data are represented as mean ± SD, n=3 (each with 3 technical replicates). * represents p<0.05. 
Altogether, these findings suggest a possible role for GLYATL1 involving in introduction of 
histone marks H3K9ac and H3K14ac in MCF7 endocrine therapy resistant cell lines, possibly 
through interaction with GCN5-related HATs, especially KAT2B. 
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4.1.6  Regulation of GLYATL1 
4.1.6.1 Epigenetic Regulation 
The above results demonstrate the importance of GLYATL1 in the context of endocrine therapy 
resistance since knockdown of this gene results in partial re-sensitization of the MCF7 resistant 
cells and overexpression renders the sensitive cells more resistant to endocrine therapy 
conditions while hinting at the involvement of GLYATL1 in histone acetylation. To understand 
whether this gene itself might be under epigenetic regulation or not I next investigated the EPIC 
array data generated for resistant cell line repertoire. The analysis results for MCF7 cells 
(analysis done by Maryam Soleimani-Dodaran) indeed revealed significantly differentially 
methylated CpGs spanning the promoter region and the 1
st
 exon of GLYATL1. Majority of the 
differentially methylated CpGs were found to be hypomethylated (between 11.5% - 75.6% 
hypomethylation) in all MCF7 resistant cells compared to their sensitive counterpart (Figure 31). 
This hypomethylation could explain the observed increase in expression of this gene in resistant 
MCF7 cells.  
 
Figure 31: Methylation status of GLYATL1 promoter region. (a) Schematic depiction of methylation changes in 
MCF7 cell line repertoire in GLYATL1 differentially methylated region (DMR). Methylation of CpGs covering 
GLYATL1 promoter region and 1
st
 exon were determined via Illumina Methylation EPIC 850k array. (b) CpGs that 
are significantly differentially methylated are depicted with their genomic location (GRCh37/hg19 build) and 
changes in methylation levels (%) compared to parental MCF7. 
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In order to validate regulation of GLYATL1 via methylation, I first treated MCF7 and T47D 
parental cells with 5-Aza-dC (5-aza-2'-deoxycytidine), a global DNMT1 inhibitor, for 72 hours 
and checked the changes in expression levels for GLYATL1. Interestingly, GLYATL1 expression 
was significantly upregulated (approximately 600-fold increase) upon induction of DNA 
hypomethylation (Figure 32a). This increase was reminiscent of the increase in MCF7 TAMR 
cells compared to their sensitive counterpart. A moderate upregulation of GLYATL1 expression 
was also observed in T47D cells upon 5 μM 5-Aza-dC treatment (Figure 32b). However, EPIC 
array results did not indicate any significant methylation changes in probed CpGs between 
months 1-7 of resistance acquisition in T47D (data not shown). These results suggested that 
methylation might be responsible for regulation of GLYATL1 in MCF7 cells, however, not in 
T47D. 
 
Figure 32: Effect of 5-Aza-dC treatment on MCF7 and T47D parental cells. MCF7 (a) and T47D (b) cells were 
treated either with 5 μM 5-Aza-dC or vehicle control (water) for 72h. Total RNA was extracted and GLYATL1 
expresssion levels were determined via qRT-PCR. All values are normalized to vehicle control. mRNA expression 
values were first normalized to PUM1 and ACTB levels. Data are represented as mean ± SD, n=2 (each with 3 
technical replicates). 
In order to explore and elucidate the epigenetic layer of regulation on GLYATL1, 
CRISPR/dCas9-mediated targeted epigenetic editing method was adopted (establishment of this 
method is explained more in detail in Part II of results). For this purpose, I designed five 
different sgRNAs covering CpGs that were probed by EPIC array and that were found to be 
significantly hypomethylated (Figure 33). I then utilized dCas9 fused to the catalytic domain of 
DNA demethylase TET1 or reduced activity mutant of prokaryotic M.SssI DNA 
methyltransferase (M.SssI-Q147L). M.SssI is a bacterial methyltransferase with a high enzymatic 
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activity. However it has been recently shown that the enzymatic activity can be reduced (~10%) 
by a point mutation (Q147L) which renders the enzyme more specific for introducing 
methylation on target loci. This specificity thereby overcomes off-target methylation spreading 
effects of eukaryotic DNMTs (Lei et al., 2017). 
 
Figure 33: Designed sgRNAs for GLYATL1. Schematic depiction of location of sgRNAs designed to target 
GLYATL1 promoter region with CRISPR/dCas9-mediated epigenetic editing with their genomic locations and 
proximity to annotated differentially methylated CpGs in MCF7 resistant cell lines. Arrows point the PAM sequence 
and indicate the directionality of sgRNA binding. Arrow on the genome depicts TSS. 
Utilizing doxycycline-inducible MCF7 cells stably expressing dCas9 fused to the catalytic 
domain of TET1, I could verify an increase in GLYATL1 expression after 10 days of transfection 
with sgRNAs targeting differentially methylated CpGs. This increase was found to be significant 
for two individual sgRNAs used (Figure 34). Moreover, the upregulation was found to be higher, 
albeit not significant, when CpGs were targeted with the combination of 5 sgRNAs. 
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Figure 34: Effect of epigenetic editing on GLYATL1 expression in MCF7 cells. MCF7 cells stably expressing 
inducible dCas9 fused to TET1 were transfected with three individual sgRNAs as well as combination of all 
targeting CpGs of GLYATL1 and control sgRNA. (a) GLYATL1 mRNA levels were determined by qRT-PCR 10 
days after transfection. All values are normalized to control sgRNA. mRNA expression values were first normalized 
to PUM1 and ACTB levels Data are represented as mean ± SD, n=2 (each with 3 technical replicates). ** represents 
p<0.01, * represent p<0.05. 
Next, I wanted to check whether introduction of methylation would suffice to suppress GLYATL1 
expression in resistant cell lines. For this purpose, doxycycline-inducible MCF7 LTED cells 
stably overexpressing dCas9-Q147L were transfected with sgRNAs. Three individual sgRNAs 
significantly downregulated GLYATL1 expression.(Figure 35a).  Downregulation of GLYATL1 
was found to confer LTED cells a proliferative disadvantage as seen in retarded growth of LTED 
cells tranfected either with sgRNA 1# or sgRNA 3# compared to control sgRNA (Figure 35b,c). 
 
Figure 35: Effect of epigenetic editing on GLYATL1 expression in MCF7 LTED cells. (a)  MCF7 LTED cells 
stably expressing inducible dCas9 fused to M.SssI (Q147L) were transfected with sgRNAs targeting CpGs of 
GLYATL1 and control sgRNA. GLYATL1 mRNA levels were determined by qRT-PCR 7 days after transfection. 
(b,c) Cell numbers were determined via microscopy-based nuclei count at different time-points over a course of 1 
week following transfection with two individual sgRNAs and control sgRNA.  All values of mRNA expression are 
normalized to control sgRNA. mRNA expression values were first normalized to PUM1 and ACTB levels. Data are 
represented as mean ± SD, n=2 (each with 3 technical replicates) All values for proliferation assays were normalized 
to seeding controls. n=1 (with 5 technical replicates). ** represents p<0.01, * represents p<0.05. 
I also wanted to investigate whether methylation would have a similar effect also in MCF7 
TAMR cells. For this purpose, doxycycline-inducible MCF7 TAMR cells stably overexpressing 
dCas9-Q147L were transfected with two individual sgRNAs (sgRNA 1# and 2#), which had 
been found to be effective in inducible LTED cells. Results indicate a significant downregulation 
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in GLYATL1 expresssion after 7 days of transfection (Figure 36a). Interestingly, proliferation 
assay of TAMR cells over a week after transfection revealed that the decrease in GLYATL1 
expression levels rendered these cells more susceptible to tamoxifen treatment (4-OHT) as they 
proliferated less in the presence of tamoxifen compared to cells transfected with the same 
sgRNA but treated with vehicle control (EtOH) or the cells transfected with control sgRNA 
(Figure 36b,c). This finding further confirmed that downregulation of GLYATL1 results in re-
sensitization of resistant cells to endocrine therapy, in particular to tamoxifen exposure. 
 
Figure 36: Effect of epigenetic editing on GLYATL1 expression in MCF7 TAMR cells. MCF7 TAMR cells 
stably expressing inducible dCas9 fused to M.SssI (Q147L) were transfected with two individual sgRNAs targeting 
CpGs of GLYATL1 and control sgRNA. (a) GLYATL1 mRNA levels were determined by qRT-PCR 7 days after 
transfection. (b,c) Cell numbers were determined via microscopy-based nuclei count at different time-points over a 
course of 1 week following transfection with two individual sgRNAs and treatment with either 4-OHT or vehicle 
control (EtOH). All values of mRNA expression are normalized to control sgRNA. mRNA expression values were 
first normalized to PUM1 and ACTB levels. Data are represented as mean ± SD, n=2 (each with 3 technical 
replicates). All values for proliferation assays were normalized to seeding controls. n=1 for proliferation assay (with 
5 technical replicates). *** represents p<0.001. 
4.1.6.2 Regulation by HER2 
Investigation of public breast cancer patient datasets (Collins, 2007; Curtis et al., 2012) and of 
the breast cancer cell line panel of 42 individual cell lines representing different molecular 
subtypes showed that GLYATL1 expression is higher in luminal, however, also in HER2-
enriched subtypes (Figure 12). This finding led to the hypothesis that HER2 might play a role in 
regulation of GLYATL1. In order to test this hypothesis, first I analyzed the mRNA expression 
levels of ERBB2 in the MCF7 cell line repertoire and compared these with expression levels of 
GLYATL1. Both genes showed a similar trend in expression as they both were upregulated in 
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TAMR, LTED and LTEDTAMR cells, LTED having the highest expression levels for both 
genes (Figure 37a,b). Next, RNA interference targeting ERBB2 was applied to assess a putative 
role of ERBB2 in the regulation of GLYATL1. Knockdown of ERBB2 in both TAMR and LTED 
cells of MCF7 origin resulted in significant downregulation of GLYATL1, suggesting an 
involvement of ERBB2 in the regulation of GLYATL1 (Figure 37c,d). 
 
Figure 37: Effect of ERBB2 knockdown on GLYATL1 expression. Levels of ERBB2 (a) and GLYATL1 (b) 
mRNA expression in MCF7 cell line repertoire were determined by qRT-PCR. MCF7 TAMR (c) and LTED cells 
(d) were transfected with siERBB2 and non-targeting control siRNA (siCTRL).  GLYATL1 mRNA levels were 
determined by qRT-PCR 72h after transfection.  All values of mRNA expression are normalized to parental MCF7 
(a,b) or siCTRL (c,d). mRNA expression values were first normalized to PUM1 and ACTB levels. Data are 
represented as mean ± SD , n=3 (each with 3 technical replicates). ** represents p<0.01, * represents p<0.05. 
4.1.6.3 Regulation by transcription factors 
Next step was to investigate the involvement of transcription factors associated with luminal 
subtype in regulation of GLYATL1 expression. For this, I chose to focus on ESR1 and GATA3. I 
also included EP300 as it was shown to code for a transcription factor with a predicted binding 
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site in the promoter region of GLYATL1 based on UCSC Genome Browser (Kent et al., 2001) 
(Figure 38a).  I went to check the expression levels of these genes in resistant MCF7 cells 
compared to parental. RNA-sequencing data revealed that both ESR1 and EP300 were 
downregulated in TAMR cells whereas LTED cells had elevated expression of these genes. 
GATA3, on the other hand, was found to be downregulated in both TAMR and LTED cells.   
 
 
Figure 38: Transcription factor occupancy of GLYATL1 promoter. (a) Transcription factors with potential 
binding sites for GLYATL1 promoter were assessed based TF-ChIP data of UCSC Genome Browser (Kent et al., 
2001). Expression levels for (b) ESR1, (c) GATA3, (d) EP300 in resistant MCF7 cells were determined via RNA-
Sequencing. All values are represented as relative values normalized to their respective WT.  
Knockdown of each transcription factor resulted in a significant decrease in GLYATL1 
expression levels in both MCF7 TAMR and LTED cells, apart from siGATA3 in MCF7 LTED 
cells (Figure 39). 
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Figure 39: Effect of transcription factor knockdown on GLYATL1 expression. MCF7 TAMR and LTED cells 
were transfected with siESR1 (a,d), siGATA3 (b,e), siEP300 (c,f) and non-targeting control siRNA (siCTRL).  
GLYATL1 mRNA levels were determined by qRT-PCR 72h after transfection.  All values of mRNA expression are 
normalized to siCTRL. mRNA expression values were first normalized to PUM1 and ACTB levels. Data are 
represented as mean ± SD,  n=3 (each with 3 technical replicates). *** represents p<0.001, ** represents p<0.01, * 
represents p<0.05. 
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Taken altogether, these results suggest that GLYATL1 is an ER-responsive gene with 
implications of methylation, HER2, luminal pioneer factor GATA3 and histone acetyltransferase 
p300 playing a role in regulating its transcription. 
4.2 Part II: Establishing CRISPR/dCas9-mediated Epigenetic 
Editing Methodology to Modulate the Epigenetic Landscape of 
Endocrine Therapy Resistant Breast Cancer 
4.2.1 CRISPR/dCas9-mediated targeted epigenetic editing 
 
Epigenetic editing can be defined as any alteration on epigenetic level which in turn can be 
exploited to regulate expression of specific genes. Genome can be epigenetically interfered by 
complexes comprised of specific DNA recognition domains such as zinc finger, transcription 
activator-like (TAL) effector or CRISPR/dCas9 and chromatin modifying enzyme with catalytic 
activity (Kungulovski & Jeltsch, 2016). In this study I aimed to utilize epigenetic interference 
tools based on the CRISPR/dCas9 system with deactivated Cas9 (dCas9) coupled to catalytic 
domains of DNA or histone modifying enzymes. to induce epigenetic changes at specific 
genomic loci implicated in endocrine therapy resistance.. For this approach, I adopted a hit-and-
run approach in which the cells were transiently transfected with both a sgRNA plasmid and 
another plasmid encoding dCas9 fused with an effector domain (epi-effector). All dCas9-effector 
domain constructs I used contain a self-cleavable mCherry reporter tag and were provided by 
Mihaly Koncz (MTA-SZBK) or Marianne Rots (UMCG). The general experimental procedure 
involved transfection for 48h, collection and validation of epigenetic interference at the mRNA 
level (TaqMan) and re-seeding of cells to assess potential long term effects. Transient 
transfection efficiency of dCas9 constructs were modest for MCF7 cells (approximately 30% for 
parental MCF7 and 40% for MCF7 LTED) (Figure 40a,b). I also utilized cells stably transduced 
with doxycycline-inducible dCas9 fused to catalytic domain of an epigenetic modifier where 
upon doxycycline induction the cells were only transfected with sgRNA plasmids (thereby 
increasing the transfection efficiency) (Figure 40c).  
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Figure 40: Transfection efficiency of dCas9-effector domain plasmids and sgRNA plasmid. Transfection 
efficiency of dCas9 plasmids were determined by mCherry
+
 cells in flow cytometry in (a) MCF7 parental  and (b) 
LTED cells. (c) sgRNA plasmid transfection efficiency was determined via GFP
+
 cells in flow cytometry upon 
transfection with a similar-sized plasmid (pmaxGFP). Flow cytometry dot blot gating was done according to the 
transfection reagent control.  LTX only:Transfection reagent control.  
In order to develop the epigenetic interference method in the context of endocrine therapy 
resistance, I chose target genes SLC9A3R1 and CD44 based on recent findings from project 
partner Dr. Luca Magnani’s lab (ICL) and prior knowledge, respectively, and BAMBI based on 
RNA-seq data of resistant cell line repertoire (Refer to Part I).  
4.2.1.1 SLC9A3R1 
The first target gene I investigated is SLC9A3R1 (Solute Carrier Family 9 (Sodium/Hydrogen 
Exchanger), Isoform 3 Regulatory Factor 1). This gene was identified in a published study, 
where enhancer ranking of metastatic versus primary breast tumors had been performed based on 
H3K27ac ChIP-Seq (Patten et al., 2018). Among the ranked enhancers, that of SLC9A3R1 was 
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found to be clonal in metastatic tumors compared to primary ones. SLC9A3R1 encodes for 
NHERF-1, a PDZ-scaffold protein that is involved in the regulation of major cancer signaling 
pathways such as PDGFR/EGFR, PI3K/PTEN/AKT and Wnt/β-catenin (Vaquero et al., 2017). 
The PDZ2 domain of SLC9A3R1 was found to be related with metastasis and invadopodia-
dependent invasion (Cardone et al., 2012). The expression of SLC9A3R1 was significantly 
upregulated in MCF7 LTED cells compared to their sensitive counterparts (Figure 42a). 
Knowing the exact location of the enhancer for SLC9A3R1 -which is located in the first intron- 
enabled us to tackle with the epigenetic regulation of this gene. For this purpose, I designed 
sgRNAs targeting promoter and enhancer regions (Figure 41). I used PRDM9 (H3K4 
methyltransferase) or DOT1L (H3K79 methyltransferase) fused with dCas9 in combination with 
two sgRNAs (sgRNA 2# and 3#) targeting upstream of the CGI to increase gene expression 
since H3K4me3 and H3K79me are activating histone markers. Both constructs indeed resulted in 
increased gene expression in MCF7 cells compared to dCas9 (with no effector domain) 
transfected cells. The increase in gene expression was found to be significantly upregulated after 
12 days of transfection with both constructs (Figure 42b,c).  
 
Figure 41: Designed sgRNAs for SLC9A3R1. Schematic depiction of location of sgRNAs designed to target 
SLC9A3R1 promoter and enhancer regions (Patten et al., 2018) with CRISPR/dCas9-mediated epigenetic editing 
with their genomic locations. Arrows point the PAM sequence and indicate the directionality of sgRNA binding. 
Arrow on the genome depicts TSS: transcription start site, CGI:CpG island, DHS:DNase I-hypersensitive site. 
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Figure 42: Effect of dCas9-p300 on SLC9A3R1 expression. (a) Levels of SLC9A3R1 expression were determined 
by qRT-PCR. (b) MCF7 cells were transfected with either dCas9 (with no effector domain) or dCas9-p300 in 
combination with two sgRNAs targeting promoter region of SLC9A3R1.  (c) MCF7 cells were transfected with 
either dCas9 (with no effector domain) or dCas9-p300 in combination with four sgRNAs targeting enhancer region 
of SLC9A3R1.  SLC9A3R1 mRNA levels were determined by qRT-PCR 2 days and 12 days after transfection. All 
values of mRNA expression are normalized to dCas9+sgRNA. mRNA expression values were first normalized to 
PUM1 and ACTB levels. Data are represented as mean ± SD, n=3 (each with 3 technical replicates). * represents 
p<0.05. 
Furthermore, I wanted to see the effect of targeting both promoter and enhancer region with 
dCas9 fused to p300 (H3K27 acetyltransferase) since H3K27ac is known to be an activating 
histone mark for promoters and enhancers (Hilton et al., 2015a). This approach resulted in the 
significant upregulation of SLC9A3R1 when promoter and enhancer region were targeted 
simultaneously compared to targeting either alone (Figure 43). 
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Figure 43: Effect of combinatorial targeting of promoter and enhancer with dCas9-p300 on SLC9A3R1 
expression. MCF7 cells were transfected with either dCas9 (with no effector domain) or dCas9-p300 in 
combination with either two sgRNAs targeting promoter region of SLC9A3R1, four sgRNAs targeting enhancer 
region of SLC9A3R1 or both.  SLC9A3R1 mRNA levels were determined by qRT-PCR 48h after transfection. All 
values of mRNA expression are normalized to their respective dCas9+sgRNA combination. mRNA expression 
values were first normalized to PUM1 and ACTB levels. Data are represented as mean ± SD, n=3 (each with 3 
technical replicates). * represents p<0.05. 
I also wanted to check whether introducing methylation would alter the expression of this gene. 
For this purpose, I used dCas9-M.SssI(Q147L) construct. Coupling dCas9-M.SssI(Q147L) with 
sgRNA 2# and 3# yielded a significant downregulation in MCF7 WT cells which persisted even 
after 15 days post-transfection (Figure 44). 
 
Figure 44: Effect of methylation on SLC9A3R1 expression in MCF7 cells. MCF7 cells were transfected with 
either dCas9 (with no effector domain) or dCas9-M.SssI(Q147L) in combination with two sgRNAs targeting 
promoter region. SLC9A3R1 mRNA levels were determined by qRT-PCR 48h and 15 days after transfection. All 
values of mRNA expression were normalized to dCas9+sgRNA. mRNA expression values were first normalized to 
PUM1 and ACTB levels. Data are represented as mean ± SD, n=2 (each with 3 technical replicates). * represents 
p<0.05. 
Taken altogether, these results indicate that it is possible to modulate SLC9A3R1 expression by 
CRISPR/dCas9-mediated epigenetic editing in a hit-and-run approach. 
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4.2.1.2 CD44 
I selected CD44 as a second gene to investigate in the context of endocrine therapy resistance. 
CD44 is known to be associated with invasiveness and stemness due to the fact that it is a target 
gene of Wnt signaling pathway(Orian-Rousseau, 2015). Recently it has been shown in Dr. 
Magnani’s lab that long term estrogen deprivation leads to an increase in the CD44hi population 
in MCF7 cells (Hong et al., 2018) (Figure 45a,b). This finding led to the hypothesis that CD44 
might be related to resistance acquisition especially in LTED cells. Given this knowledge, I was 
interested to see whether it is possible to fine-tune CD44 expression in MCF7 and MCF7 LTED 
cells using different epigenetic effectors fused to dCas9 in combination with sgRNAs targeting 
the promoter region of the CD44 gene (kindly provided by Marianne Rots´ lab) (Figure 45c).  
 
Figure 45: Increased CD44 levels in MCF7 LTED cells and designed sgRNAs for the promoter region of 
CD44. CD44 mRNA and protein levels in LTED cells were determined by qRT-PCR (a) and flow cytometry (b), 
repectively. (c) Schematic depiction of location of sgRNAs designed to target CD44 promoter region with 
CRISPR/dCas9-mediated epigenetic editing with their genomic locations. Arrows point the PAM sequence and 
indicate the directionality of sgRNA binding. Arrows on the genome depict TSS. CGI:CpG island. All values of 
mRNA expression are normalized to parental MCF7. mRNA expression values were first normalized to PUM1 and 
ACTB levels. Data are represented as mean ± SD, n=3 (with 3 technical replicates). ** represents p<0.01. 
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In order to achieve this, first I decided to utilize dCas9-p300 aiming to increase gene expression. 
Targeting CD44 promoter region with four individual sgRNAs yielded a significant upregulation 
in CD44 expression 48h post-transfection (Figure 46a). Furthermore, one of the sgRNAs 
(sgRNA 3#) was proven to be also effective in significantly increasing gene expression when 
used in combination with dCas9-DOT1L (Figure 46b). 
 
Figure 46: Effect of dCas9-p300 and dCas9-DOT1L on CD44 expression in MCF7 cells. MCF7 cells were 
transfected with either dCas9 (with no effector domain) or dCas9-p300 in combination with four individual sgRNAs 
targeting promoter region. (b) MCF7 cells were transfected with either dCas9 (with no effector domain) or dCas9-
DOT1L in combination with a sgRNA targeting promoter region. CD44 mRNA levels were determined by qRT-
PCR 48h after transfection. All values of mRNA expression are normalized to dCas9+sgRNA. mRNA expression 
values were first normalized to PUM1 and ACTB levels. Data are represented as mean ± SD, n=2 (with 3 technical 
replicates). *** represents p<0.001, ** represents p<0.01, * represents p<0.05. 
For downregulation of CD44, I chose histone methyltransferase G9a (fused to dCas9) which is a 
writer of methylation on H3K9 and H3K27(Mozzetta et al., 2014) both of which are repressive 
histone marks. Targeting two regions in the promoter resulted in downregulation in CD44 
expression in MCF7 parental cells even after 15 days post-transfection. This decrease in gene 
expression corroborated with CD44 protein levels as shown in surface staining results of CD44 
in dCas9-G9a transfected cells compared to dCas9 (with no effector domain) transfected cells in 
combination with two individual sgRNAs (Figure 47). 
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Figure 47: Effect of dCas9-G9a on CD44 expression in MCF7 cells. MCF7 cells were transfected with either 
dCas9 (with no effector domain) or dCas9-G9a in combination with two individual sgRNAs targeting promoter 
region. CD44 mRNA levels were determined by qRT-PCR (a) and CD44 protein levels were determined by flow 
cytometry 15 days after transfection. All values of mRNA expression are normalized to dCas9+sgRNA. mRNA 
expression values were first normalized to PUM1 and ACTB levels. Data are represented as mean ± SD, n=2 (with 3 
technical replicates) * represents p<0.05. 
Alternatively, utilizing dCas9-G9a approach for downregulation of CD44 was adopted also in 
MCF7 LTED cells in an attempt to see whether downregulation of CD44 would re-sensitize 
these cells to endocrine therapy conditions (estrogen deprivation in particular).  Here four 
individual sgRNAs yielded a significant decrease in CD44 expression 48h after transfection with 
the dCas9-G9a construct (Figure 48a). Two of these sgRNAs (sgRNA 4# and sgRNA 8#) were 
effective in downregulating CD44 after 7 days as shown in MCF7 LTED cells with inducible 
stable dCas9-G9a expression (Figure 49b). Furthermore, these two sgRNAs resulted in a 
significant decrease in proliferation of LTED cells, rendering them more susceptible to estrogen–
deprivation conditions compared to controls transfected with a non-targeting control sgRNA 
(Figure 49c,d). 
These results showcase the ability of an engineered CRISPR/dCas9 system to stably fine-tune 
the expression of CD44 by editing the epigenetic landscape of the promoter in both sensitive and 
resistant cell lines. These findings also hint at the possibility of its utilization to alter the gene 
expression by modifying the epigenetic layer to achieve re-sensitization to endocrine therapy in 
resistant cell line. 
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Figure 48: Effect of dCas9-G9a on CD44 expression in MCF7 LTED cells. (b) MCF7 LTED cells stably 
expressing dCas9-G9a were induced with doxycycline 24h prior to transfection with two individual sgRNAs 
targeting promoter region of CD44 or ctrl sgRNA. CD44 mRNA levels were determined by qRT-PCR after 48h (a) 
and 7 days (b) of transfection. Cell numbers (MCF7 LTED cells with inducible stable expression of dCas9-G9a) 
were determined via microscopy-based nuclei count over 7 days of transfection with either sgRNA 4# (c) or sgRNA 
8# (d). All mRNA expression values are normalized to either dCas9+sgRNA (a) or ctrl sgRNA (b). mRNA 
expression levels were first normalized to PUM1 and ACTB levels. All values for proliferation assays were 
normalized to seeding controls. Data are represented as mean ± SD, n=2 (each with 3 technical replicates), n=2 for 
proliferation experiments (each with 4 technical replicates). 
4.2.1.3 BAMBI 
CD44 is considered to be a target of the Wnt signaling pathway. Several publications indicate the 
involvement of Wnt signaling in endocrine therapy resistance and its contribution to a more 
aggressive phenotype. Hence, I wondered whether altering the activation status of the Wnt 
signaling pathway would have an impact in the context of endocrine therapy resistance. I re-
assessed the RNA-sequencing data of the wildtype and resistant MCF7 cell lines, searching for 
differentially regulated genes more upstream in the Wnt signaling cascade.  
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Among genes involved in Wnt signaling, mRNA expression of BMP and activin bound inhibitor 
(BAMBI) was significantly increased in both MCF7 TAMR and LTED compared to their 
parental MCF7. This increase was verified via qRT-PCR (Figure 49a). BAMBI was also found to 
be upregulated in T47D resistant cell lines in both treatment conditions (Figure 49b). BAMBI is 
involved in the canonical Wnt pathway, where it can relay Wnt signaling at the beginning of the 
cascade by binding and enhancing the interaction between the Wnt receptor Frizzled and its co-
receptor LRP5/6. Next, I wanted to check the correlation of BAMBI expression with overall 
patient survival in two independent public datasets. The TCGA breast cancer dataset showed a 
trend for high BAMBI expression being correlated with poor patient survival in all subtypes 
(Figure 49c). When I looked at the overall survival of patients belonging to luminal A subtype 
specifically, the trend got more pronounced indicating a significant negative correlation between 
BAMBI expression and survival (Figure 49d). The METABRIC dataset showed a similar trend 
significantly for all subtypes (Figure 49e).     
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Figure 49: BAMBI expression in MCF7 and T47D cell line repertoire and correlation with overall patient 
survival. BAMBI mRNA levels were determined by qRT-PCR in MCF7 (a) and T47D (b) cells. Quartile-based 
overall survival analysis of TCGA dataset comparing high versus low BAMBI expression for all subtypes (c) and for 
luminal A subtype (d). (e) Quartile-based overall survival analysis of METABRIC dataset of low versus high 
BAMBI expression (for each quartile n=492). mRNA expression values are normalized to levels of respective WT. 
mRNA expression levels were first normalized to PUM1 and ACTB levels, n=3 (each with 3 technical replicates). ** 
represents p<0.01, * represents p<0.05. 
 
Figure 50: Designed sgRNAs for BAMBI. Schematic depiction of location of sgRNAs designed to target BAMBI 
promoter region with CRISPR/dCas9-mediated epigenetic editing with their genomic locations. Arrows point the 
PAM sequence and indicate the directionality of sgRNA binding. Arrow on the genome depicts TSS. CGI:CpG 
island. 
Given this information, I regarded BAMBI to be an interesting target to follow up and designed 
and tested six sgRNAs targeting the promoter region of BAMBI (including the CpG island at the 
promoter) with the help of Vinona Wagner, a master student (Figure 50). For upregulation of 
BAMBI, dCas9-p300 was chosen. Two individual sgRNAs (sgRNA 1# and sgRNA 6#) were 
effective in significant upregulation of BAMBI 48h post-transfection (Figure 51a). Interestingly, 
CD44 expression was found to be increased (approximately 2.5 fold with sgRNA 1#) as well 
when BAMBI was manipulated by CRISPR/dCas9-mediated epigenetic editing (Figure 51b). 
MCF7 cells stably expressing inducible dCas9 fused to the catalytic domain of p300 showed that 
these two individual sgRNAs are indeed effective in upregulating BAMBI after 10 days of 
transfection. Here, the effect of sgRNA 1# was found to be significant (Figure 51c). 
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Figure 51: Effect of dCas9-p300 on BAMBI expression in MCF7 cells. MCF7 cells were transfected with either 
dCas9 (with no effector domain) or dCas9-p300 in combination with two individual sgRNAs targeting promoter 
region of BAMBI. Doxycycline- induced MCF7 cells stably expressing dCas9-p300 were transfected with two 
individual sgRNAs. BAMBI (a,c) and CD44 (b). mRNA levels were determined by qRT-PCR 48h (a,b) and 10 days 
(c) after transfection. All values of mRNA expression are normalized to either dCas9+sgRNA (a,b) or ctrl sgRNA 
(c). mRNA expression values were first normalized to PUM1 and ACTB levels. Data are represented as mean ± SD, 
n=2 (with 3 technical replicates). *** represents p<0.001, * represents p<0.05. 
Alternatively, I also wanted to assess the involvement of methylation on BAMBI expression due 
to the existence of a CpG island at its promoter. For this purpose, I treated parental MCF7 cells 
with DNMT1 inhibitor 5-Aza-dC and checked BAMBI mRNA levels after 72h. BAMBI 
expression was indeed found upregulated upon global DNA demethylation (Figure 52a). Given 
this information, MCF7 cells stably expressing doxycycline-inducible dCas9-TET1 were 
transfected with sgRNAs targeting BAMBI promoter. BAMBI expression was found to be 
increased with all sgRNAs tested after 10 days (Figure 52b). Remarkably, CD44 expression was 
also increased with all the sgRNAs, verifying once more the close correlation between Wnt 
signaling and CD44 expression (Figure 52c). Here, the upregulating effect of sgRNA 1# and 
sgRNA 5# were found to be significant for both genes. 
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Figure 52: Effect of demethylation on BAMBI expression in MCF7 cells. (a) MCF7 cells were treated with either 
5 μM 5-Aza-dC or vehicle control (water) for 72h. Total RNA was extracted and BAMBI expresssion levels were 
determined via qRT-PCR. Doxycycline- induced MCF7 cells stably expressing dCas9-TET1 were transfected with 
six individual sgRNAs targeting the promoter region of BAMBI. BAMBI (b) and CD44 (c) mRNA levels were 
determined by qRT-PCR 48h after transfection. All values of mRNA expression are normalized to either vehicle 
control (a) or ctrl sgRNA (b,c). mRNA expression values were first normalized to PUM1 and ACTB levels. Data are 
represented as mean ± SD, n=3 (with 3 technical replicates). ** represents p<0.01, * represents p<0.05. 
For downregulation of BAMBI, dCas9-G9a was used since it was found to be effective in 
downregulating CD44. Indeed, BAMBI expression in MCF7 LTED cells was found to be 
significantly decreased after 48h of transfection when the promoter region was targeted with two 
individual sgRNAs (sgRNA 4# and sgRNA 6#) (Figure 53a). BAMBI expression remained 
significantly downregulated even after 11 days of transfection (Figure 53b). CD44 levels were 
concordantly and significantly decreased as well (Figure 53c). 
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Figure 53: Effect of dCas9-G9a on BAMBI expression in MCF7 LTED cells. MCF7 LTED cells transfected with 
either dCas9 (with no effector domain) or dCas9-p300 in combination with two individual sgRNAs targeting 
promoter region of BAMBI. (a) BAMBI mRNA levels were determined by qRT-PCR 48h after transfection. BAMBI 
(b) and CD44 (c) expression levels were determined by qRT-PCR after 11 days of transfection. All values of mRNA 
expression are normalized to dCas9+sgRNA. mRNA expression values were first normalized to PUM1 and ACTB 
levels. Data are represented as mean ± SD, n=2 (with 3 technical replicates). ** represents p<0.01, * represents 
p<0.05. 
Utilizing MCF7 LTED cells stably expressing inducible dCas9 fused to the catalytic domain of 
either wild-type G9a or catalytically inactive mutant G9a, I could verify the significant 
downregulation of BAMBI, and concordantly CD44, with the same sgRNAs after 7 days of 
transfection. Here, BAMBI and CD44 expression were found to be significantly decreased in 
MCF7 LTED cells expressing dCas9-G9a
WT
, but not in MCF7 LTED cells expressing dCas9-
G9a
mut
, hinting at the fact that the effect of downregulation comes indeed from the 
methyltransferase activity of G9a (Figure 54a-d). Next step was to assess the effect of BAMBI 
downregulation on the proliferation of LTED cells. LTED cells stably expressing dCas9-G9a
WT
 
proliferated significantly less when transfected with sgRNA 4# and sgRNA 6# compared to their 
non-targeting sgRNA transfected counterparts suggesting a re-sensitization to estrogen 
deprivation conditions (Figure 53 e,f). 
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Figure 54: Effect of epigenetic editing on BAMBI expression in MCF7 LTED cells with inducible stable 
expression of dCas9 fused to wild-type or mutant G9a. Cells were induced with doxycycline 24h prior to 
transfection with two individual sgRNAs targeting promoter region of BAMBI or ctrl sgRNA. BAMBI (a,c) and 
CD44 (b,d) mRNA levels were determined by qRT-PCR after 7 days of transfection in cells expressing either wild-
type of mutant G9a fused to dCas9, respectively. Cell numbers (MCF7 LTED cells with inducible stable expression 
of dCas9-G9a) were determined via microscopy-based nuclei count over 7 days of transfection with either sgRNA 
4# (e) or sgRNA 6# (f). All values are normalized to ctrl sgRNA. mRNA expression levels were first normalized to 
PUM1 and ACTB levels. All values for proliferation assays were normalized to seeding controls. Data are 
represented as mean ± SD, n=2 (each with 3 technical replicates), n=2 for proliferation experiments (each with 4 
technical replicates). 
Taken altogether, these results showcase the ability, flexibility and stability of hit-and-run 
CRISPR/dCas9-mediated epigenetic editing in fine-tuning expression of target genes as depicted 
here on four independent examples (GLYATL1, SLC9A3R1, CD44 and BAMBI). Moreover, these 
findings provide insights regarding the components that might play a role in epigenetic 
regulation of these genes and additional proof that epigenetic regulation indeed constitutes an 
integral part of regulation of transcription. 
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5. Discussion 
Breast cancer is the second leading cause of cancer-related death in women (Siegel et al., 2019) 
Due to its heterogeneity, it is really challenging to come up with a generalized therapy against 
breast cancer. Even though majority of breast cancer cases are ER-positive and therefore can 
benefit from endocrine therapy, intrinsic or acquired resistance results in relapse for these 
patients in the long term. Resistance to endocrine therapy still remains a major clinical 
predicament for luminal breast cancer cases.  
Recently, endocrine therapy occurrence is pertained to alterations in epigenetic layer as well as 
genetic composition (Magnani et al., 2013; Nguyen et al., 2015). Epigenetic reprogramming 
plays an integral role in adaptation to environmental changes such as drug treatment.  This 
phenomena has been proposed as a mechanism to render the sensitive cells refractory to 
treatment.  In this study, we tried to shed some light on this elusive manner by recapitulating 
endocrine therapy resistance in vitro and profiling the resistant cells of two different origin 
(MCF7 and T47D) in order to uncover several layers of transcriptional regulation, namely 
transcriptome, methylome and chromatin accessibility.  
5.1 Validation of in vitro models 
 
MCF7 cell lines having been made resistant against endocrine therapies (i.e., 4OH-tamoxifen, 
LTED) and the wildtype MCF7 cells were profiled for changes in transcriptomes and chromatin 
accessibility using RNA-Seq and ATAC-Seq, respectively. This revealed genes that were 
affected at RNA and chromatin levels, respectively. ACSL4 and ELF5 were among the top 
upregulated and GREB1 and PGR among the top downregulated genes in the cell line models of 
endocrine resistance, each mimicking different endocrine therapy conditions (TAMR, LTED and 
LTEDTAMR). These genes provided a proof of concept as they had previously been implicated 
in endocrine therapy resistance: ACSL4 was shown to be responsible for downregulation of ERα 
in triple-negative MDA-MB-231 cells. Knock-down of ACSL4 restored ERα expression, 
rendering these cells susceptible to tamoxifen treatment both in vitro and in vivo (Orlando et al., 
2015). ACSL4 was also found to induce proliferation and invasion of prostate cancer cells and 
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was involved in hormonal resistance since it induces proliferation in the absence of androgens 
which makes it a candidate for castration-resistant prostate cancer (X. Wu et al., 2015). ELF5 
was found to be upregulated in in vitro-generated tamoxifen resistant cell lines and methylation 
status of the ELF5 promoter was closely linked to its transcription as ELF5 promoter was less 
methylated in relapse breast cancer patients compared to primary tumors (Fitzgerald et al., 2016). 
GREB1, an ERα co-factor, silencing by histone methyltransferase EZH2 was suggested as an 
underlying reason for tamoxifen resistance (Y. Wu et al., 2018). It has been shown in literature 
that ER+/PR+ breast tumors respond to endocrine therapy better than ER+/PR- tumors (Cui et 
al., 2005). The loss of progesterone receptor is linked to HER2 overexpression and associated 
with high relapse risk (Sun et al., 2016). Hence, the cell line models having been generated 
and/or analyzed in the course of this study seem to be valid in vitro models for endocrine 
resistance. 
5.2 GLYATL1 depletion leads to partial re-sensitization to 
endocrine therapy conditions  
 
GLYATL1 was one of the top upregulated genes in resistant MCF7 cell lines. This gene was also 
upregulated in resistance acquisition model derived from another luminal subtype model cell line 
T47D. This finding led to the hypothesis that GLYATL1 might indeed be important for endocrine 
therapy resistance development for the luminal subtype and not be a cell line-dependent effect. 
In order to understand whether GLYATL1 is necessary for resistance to endocrine therapy, RNA 
interference experiments were performed using MCF7 and T47D cell lines that were either 
parental wildtype cells or had induced therapy-resistance. Loss of GLYATL1 expression resulted 
in reduced cell viability of tamoxifen-resistant (TAMR) and estrogen-deprivation resistant 
(LTED) cells, under tamoxifen exposure and estrogen-deprivation, respectively. MCF7 
LTEDTAMR were re-sensitized to both estrogen deprivation and tamoxifen exposure as they 
proliferated significantly less in both conditions (Figure 15). T47D resistant cells reacted to 
GLYATL1 loss in a similar fashion, indicating this gene’s importance in a cell-independent 
manner (Figure 16). These results suggested that loss/downregulation of GLYATL1 might indeed 
contribute to re-sensitization of resistant cells to endocrine therapy conditions. 
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According to literature, GLYATL1 codes for an N-acyltransferase enzyme which catalyzes the 
addition of an acyl group to L-Glutamine (H. Zhang et al., 2007). The gene was found to be 
significantly upregulated in tumor versus normal tissues of colon, prostate and breast cancer 
among 14 different cancer entities in respective TCGA datasets. GLYATL1 is suggested as a 
biomarker for prostate cancer due to its significant upregulation in two independent datasets 
comparing primary prostate cancer samples to healthy control (Barfeld et al., 2014). All these 
findings are very well in line with my findings obtained in loss-of-function experiments and 
helped to prioritize this gene and protein, as the data suggests GLYATL1 to be involved in the 
acquisition and/or maintenance of endocrine therapy resistance of breast cancer. 
5.3 GLYATL1 overexpression confers endocrine therapy 
resistance  
 
In order to unravel the necessity of GLYATL1 for initiation of therapy resistance I next utilized 
an overexpression model of GLYATL1 in breast cancer cell lines. Exposing wildtype MCF7 cell 
lines stably overexpressing GLYATL1 to treatment media mimicking different endocrine 
therapy conditions for a period of one week indicated that GLYATL1 is indeed able to confer 
resistance to endocrine therapy conditions, especially tamoxifen treatment, since overexpressing 
cells were able to proliferate better compared to their empty vector control under tamoxifen 
treatment (Figure 19). However, this effect was observed to be milder for T47D cells under 
tamoxifen exposure. For T47D cells, overexpression of GLYATL1 was found to be conferring a 
proliferative advantage under estrogen deprivation conditions (Figure 20). This can be explained 
by the fact that for T47D cell line repertoire, GLYATL1 expression is highest in T47D LTED 
cells compared to parental control (Figure 11c) and therefore this gene might be more 
fundamental for overcoming the lack of estrogen in T47D cells.  
5.4 GLYATL1 overexpression counteracts induction of cell cycle 
arrest and apoptosis in endocrine therapy-sensitive cells 
 
Induction of cell cycle arrest and/or apoptosis are two of the hallmark effects of endocrine 
therapy (Amaral et al., 2013; Moriai et al., 2009; Otto et al., 1996). Hence, I analyzed the effects 
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of GLYATL1 on the cell cycle and late apoptotic index within MCF7 cells overexpressing the 
protein. And indeed, cells under endocrine therapy had a higher cell-cycle activity as measured 
by the fraction of cells in S-phase while the fraction of cells in late apoptosis was reduced. 
Interestingly, a similar reduction of cells in late apoptosis was observed in T47D cells under the 
same experimental conditions, however, there was no significant change in cell cycle progression 
in these cells (Figures 21 & 22). These findings suggest that GLYATL1 might confer resistance 
through inducing cell-cycle progression and/or inhibiting apoptosis. These results also hint at the 
fact that overexpression of the same gene may lead to different mechanisms in two independent 
biological entities.  
5.5 GLYATL1 is involved in histone acetylation 
 
Recently, GLYATL1 has been proposed to code for a histone acetyltransferase (Vecellio et al., 
2014) and nomenclatured as an epigenetic writer (Keating et al., 2018). GLYATL1 has an 
established status as a mitochondrial enzyme. Therefore it primarily localizes to mitochondria 
(H. Zhang et al., 2007). To our knowledge, there are no publications indicating a nuclear 
localization for GLYATL1 to this date. Before further investigation of its putative role in histone 
acetylation, I wanted to check the cytosolic and nuclear fractions of GLYATL1 overexpressing 
cells. This led to the finding of GLYATL1 localizing both in cytoplasm and nucleus in MCF7 
and T47D cell lines overexpressing GLYATL1 (Figure 27). Such localization has also been 
suggested in the GeneCards and the compartments database (Binder et al., 2014; Database 
GeneCards, 2017). Ectopic overexpression of proteins may lead to their artificial localization 
within cells (Simpson et al., 2000). Hence, nuclear localization of GLYATL1 should also be 
verified in resistant cell lines expressing elevated levels endogenously. However, GLYATL1 is 
found to be present in the nucleus also for cells transduced with the empty vector (without 
GLYATL1 ORF) which suggests nuclear localization even in the absence of overexpression 
(Figure 27). These results thus suggested that GLYATL1 could indeed play a role also in the 
nucleus.  
mRNA expression levels of HAT family members were elevated in both in vitro resistance 
model cell lines revealing an upregulation of KAT2A and KAT2B for all resistant MCF7 cell lines 
and KAT6A and KAT6B in the resistant T47D cell lines. KAT2A was found to be increased 
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moderately in TAMR and LTEDTAMR cells (Figure 24). KAT2A(GCN5) and KAT2B(PCAF) 
are responsible for introduction of acetylation on H3K9 and H3K14 residues (Krebs et al., 2011; 
Z. Nagy & Tora, 2007). These HATs take part in multi-subunit HAT complexes hATAC and 
SAGA in a mutually exclusive fashion (Spedale et al., 2012).  
KAT6A (MOZ) is implicated in acetylation of H3K9 residue as Moz-deficient mice displayed 
hypoacetylation of H3K9ac in Hox gene loci (Voss et al., 2009). Moreover, both KAT6A and 
KAT6B have been shown to be involved in the acetylation of H3K9 and H3K14 and to act as 
writers and readers of these modifications (Dreveny et al., 2014; Voss et al., 2009). KAT6Á and 
KAT6B exhibit tumorigenesis-inducing properties since their chemical inhibition in lymphoma 
led to tumor growth arrest (Baell et al., 2018). KAT6B (MORF) is implicated in prostate cancer 
cell proliferation through the PI3K-AKT signaling axis (He et al., 2013). It has been shown to 
introduce H3K23ac mark in small cell lung cancer (Simó-Riudalbas et al., 2015). Recent 
findings also annotate KAT6A as a novel epigenetic activator of ERα promoter (Yu et al., 2017). 
Taken altogether, increased KAT2A and KAT2B in MCF7 cells as well as increased KAT6A and 
KAT6B within T47D suggest elevated levels of H3K9ac and H3K14ac marks in the affected 
cells. Accordingly, levels of both acetylation marks were found to be increased in resistant 
MCF7 cells. Additionally, GLYATL1 overexpressing MCF7 cells had higher levels of H3K9ac 
and H3K14ac, suggesting a link between GLYATL1 expression and acetylation of these marks in 
the histone tail (Figure 28). I further confirmed the connection between GLYATL1 and histone 
modifications in RNAi experiments where knockdown of GLYATL1 resulted in a significant 
reduction of H3K9ac and H3K14ac in MCF7 TAMR and LTED cells where GLYATL1 was 
found to be upregulated (Figure 29). This novel finding draws attention to a previously unknown 
involvement of GLYATL1 in the acetylation of H3K9ac and H3K14ac via KAT2B in the context 
of endocrine therapy resistance.  
In addition, GLYATL1 knockdown led to a significant decrease in KAT2B expression in MCF7 
LTED cells, while a concomitant increase in KAT2A expression was observed. An opposite trend 
was detected for GLYATL1 overexpressing cells where KAT2B expression was downregulated. 
There, KAT2A was found to be increased in mRNA level (Figure 30). These results suggest a 
correlation between GLYATL1 and KAT2B while corroborating with previous findings indicating 
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mutual exclusivity of these two GNAT family member HATs (Krebs et al., 2011; Spedale et al., 
2012).  
Histone modifications are crucial determinants of gene transcription. The epigenetic make-up of 
histone marks, the so-called ´histone code´, influences the epigenetic landscape cross-talking 
with DNA methylation status, thereby altering the chromatin architecture to allow or restrict 
binding of factors of the transcriptional machinery to certain genomic regions (Carlberg et al., 
2018). Investigation of changes in histone code is a crucial step in elucidating epigenetic 
reprogramming.    
A recent study on mouse embryonic stem cells further confirmed the co-occurrence of active 
histone marks H3K9ac & H3K14ac and revealed the occupancy of bivalent promoters by these 
two marks (Karmodiya et al., 2012). It was also argued in the same publication that these two 
marks can be used to distinguish active enhancers from poised ones, an attribute associated with 
the H3K27ac mark. Additionally, it was shown that H3K14ac also occupies some inactive 
promoters, adding a controversial layer to designated feature of histone acetylation as a 
transcriptional activation mark (Karmodiya et al., 2012). ChIP-seq of these two histone marks 
would elucidate the genomic regions that they are enriched in as well as the spectrum of their 
target genes. Correlation of these genes with the available transcriptomic data would further 
validate their contribution to epigenetic reprogramming in the context of endocrine therapy 
resistance.   
The increase in ZMYND8 mRNA levels in resistant MCF7 and T47D cell lines (Figure 26) 
supported the finding of the increase in H3K14ac, since ZMYND8 is identified as epigenetic 
reader of dual mark H3K4me1-H3K14ac (Li et al., 2016; Savitsky et al., 2016). In another 
publication, ZMYND8 is annotated as a direct target gene of hypoxia inducible factor-1 (HIF-1) 
and HIF-2 and to encode an epigenetic reader of histone marks H3K36me/me2, H3K14ac and 
H4K16ac (Y. Chen et al., 2018). Taken altogether, ZMYND8 proves to be an interesting target 
linking histone acetylation and breast cancer progression. 
This study only focuses on alterations in two histone marks, H3K9ac and H3K14ac in resistant 
MCF7 cell lines. However, the increase in pan acetylation of H3 hints at the possibility that other 
H3 residues such as H3K18, H3K23 and H3K27 might be acetylated more as well (Figure 25). 
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The increase of KAT6A and KAT6B in T47D resistant cell lines highlights the possibility of 
elevated H3K9ac and H3K14ac also for this resistance model.  Further investigation of the 
“acetylome” in both resistant cell lines will provide more information regarding the importance 
of histone acetylation in the context of endocrine therapy resistance.   
Moreover, a recent publication highlights the gene fusion between GLYATL1 and TAF6L [TAF6-
like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor] in breast cancer 
which can also account for its contribution to histone acetylation (Yoshihara et al., 2015). This 
fusion could be assessed in endocrine therapy resistant cell lines compared to sensitive ones by 
fluorescence in situ hybridization (FISH) using available probes to investigate the existence or 
enrichment of such a fusion.   
5.6 GLYATL1 expression correlates with poor prognosis in breast 
cancer patients 
 
Cell lines provide the opportunity to work in depth on different cancer entity models. However, 
they may not reflect what is actually happening in patients. In the case of a highly heterogeneous 
disease as breast cancer, it is extremely important to investigate clinical implications of in vitro 
findings. Overall survival analysis for GLYATL1 expression on the TCGA breast cancer dataset 
showed that GLYATL1 expression was negatively correlated with survival. This finding 
demonstrates the clinical relevance of GLYATL1 in the context of patient survival. However, this 
does not necessarily give any information about its potential role in endocrine therapy resistance 
due to the lack of matched primary and relapsed tumor material. Investigation of the patient data 
from METABRIC dataset after filtering for ER+ and tamoxifen-treated patients indicated that 
higher GLYATL1 expression was found to be correlated with poor recurrence-free patient 
survival which corroborates previous findings (Á. Nagy et al., 2018) (Figures 13). An 
independent cohort of breast cancer patients revealed a negative correlation of GLYATL1 
expression with recurrence-free survival as GLYATL1 expression was found to be significantly 
increased in relapsed patients (Cortazar et al., 2018; Pawitan et al., 2005) (Figure 14). 
Additionally, overall survival analysis for ZMYND8, epigenetic reader of H3K14ac mark, shows 
a significant negative correlation between ZMYND8 expression and patient survival in TCGA 
breast cancer dataset (Á. Nagy et al., 2018) (data not shown). Together, these previous findings 
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support a tumor promoting role GLYATL1 has which is associated with therapy resistance, tumor 
recurrence and patient survival. My data adds functional information to this association 
suggesting that GLYATL1 is directly involved in the disease process. 
A deeper look at the subtype specificity of GLYATL1 expression revealed the HER2-enriched 
subtype to be the molecular subtype with the most abundant GLYATL1 expression in the 
METABRIC dataset. The basal subtype was the lowest among other subtypes in both datasets 
investigated suggesting that expression of GLYATL1 might be related to one of the three 
receptors (ER, PR, HER2) which the basal subtype lacks (Figure 12b,12c).  
5.7 GLYATL1 expression is regulated by HER2 and luminal 
transcription factors 
 
It has been shown that endocrine therapy resistance can be a result of activation of alternative 
growth factor pathways (Araki & Miyoshi, 2018). ERBB2 upregulation or amplification is 
observed in several endocrine therapy resistance models (Grabinski et al., 2014; Houston et al., 
1999), and also in the two independent in vitro resistance cell line models generated and used in 
this study. In the light of this information, the effect of ERBB2 on GLYATL1 expression was 
assessed by RNA interference. Knockdown of ERBB2 in MCF7 resistant cell lines resulted in a 
significant decrease in GLYATL1 mRNA levels (Figure 37). This suggested that GLYATL1 
expression might be partly regulated by HER2 in resistant MCF7 cell line model.  
Investigating the transcription factors that might bind to the promoter region of GLYATL1 from 
UCSC Genome Browser revealed TFs encoded by ESR1, GATA3, EP300 as potential TFs 
driving the transcription of this gene (Kent et al., 2001) (Figure 38). Following up on this lead, 
knockdown experiments on each transcription factor indicated that GLYATL1 expression was 
significantly downregulated when ESR1 and EP300 was knocked down for both MCF7 TAMR 
and LTED cells whereas knockdown of GATA3 led to significant reduction in GLYATL1 mRNA 
levels only in MCF7 TAMR cells (Figure 39). 
These findings hint at GLYATL1 being an estrogen receptor-responsive gene. Regulation by 
ER, HER2, EP300 and GATA3 might provide an explanation for the increased levels of 
GLYATL1 expression in luminal as well as in HER2-enriched subtypes of breast cancer cell lines 
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and patients. Regulation by the estrogen-receptor was confirmed by the significant increase in 
growth of MCF7 cells overexpressing GLYATL1 when grown in estrogen-supplemented media 
as compared to cells that were grown in media supplemented with EtOH, the vehicle for 4-OHT 
(Figure 19a, 19b). ChIP-seq/PCR experiments for ERα, p300 and GATA3 occupancy on the 
GLYATL1 promoter could further validate these findings. Moreover, other transcription factors 
such as FOXA1 and FOXA2 (as suggested by UCSC Genome Browser) (Figure 38) could also 
be investigated to assess their role in regulation of GLYATL1. 
 
Taken altogether, these discoveries exhibit novel insights into the regulation of this relatively 
unstudied gene. It might be surprising that ERα can apparently regulate the expression of a tragte 
gene even in estrogen deprived conditions (LTED). However, it has been shown before that 
ligand–independent activation of ERα is one of the hallmarks of endocrine therapy resistance 
(Ding et al., 2003). In fact, the increase in ERBB2 mRNA levels suggests an activation of HER2 
signaling which can induce phosphorylation and binding of ERα to its estrogen-responsive 
elements (ERE) in the genome. In the case of tamoxifen resistance, this leads to substitution of 
corepressor- ERα complexes bound to tamoxifen with phosphorylated ERα-activator complexes 
leading to conversion of tamoxifen into an agonist from its conventional antagonist role on tumor 
growth (Shou et al., 2004). Moreover, RNA-seq results indicate an increase in ESR1 expression 
in MCF7 LTED cells and both in T47D TAMR and LTED cells which can support cross-talk 
between ERα- and HER2 which could thus constitute an integral part in resistance acquisition. 
ESR1 levels in MCF7 TAMR and LTEDTAMR cells, on the other hand, were found to be 
decreased compared to parental MCF7. This draws attention to the possibility of GLYATL1 
expression being regulated also by other mechanisms such as the epigenetic layer.  
5.8 GLYATL1 is regulated by methylation 
 
Epigenetic regulation gained much recognition recently since it has been associated with 
adaptation to any changes in the milieu such as constant exposure to drugs. Changes in DNA 
methylation patterns and the histone code, therefore the whole chromatin architecture, favor 
expression of certain genes while hindering expression of some others resulting in a phenotype 
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differing from the original status (i.e. resistant versus sensitive). For this reason, uncovering the 
changes in the epigenetic layer was essential to discern the role of epigenetics in endocrine 
therapy resistance. Methylome profiling of MCF7 resistant cell line repertoire showed that there 
are CpGs significantly differentially hypomethylated in the promoter region of GLYATL1 in 
resistant cells compared to parental (Figure 31). This finding led to the hypothesis that this gene 
might be regulated also by methylation. Treating endocrine therapy sensitive MCF7 cells with a 
DNA methylation inhibitor (5-Aza-dC) resulted in a significant increase in GLYATL1 expression 
(Figure 32a). In fact, the change in gene expression was similar to the change between resistant 
and sensitive MCF7 cells, hinting at the fundamental role methylation plays in regulating this 
gene’s expression (Figure 11). 
Recognition of the epigenetic layer as an integral part in regulation of gene expression resulted in 
approaches to manipulate the epigenetic states in order to modulate aberrant gene expression. 
Administration of epigenetic drugs (HDAC inhibitors etc.) can be shown as an example. 
However, these drugs lack specificity since they act on the whole epigenome which constitutes a 
major drawback (Marchion & Münster, 2007). Therefore, the need for a more targeted and 
specific approach has arisen. A modified version of the revolutionary genome editing method 
CRISPR/Cas9 offered a solution for this predicament. In this CRISPR/dCas9-mediated 
epigenetic editing approach, a catalytically dead Cas9 (unable to cut) fused to the catalytic 
domain of desired epigenetic modifier (HAT, DNMT, HMT, HDAC etc.) with a sgRNA 
targeting a specific region of the genome gives opportunity to modulate the epigenetic 
composition of a region of choice in a very specific manner (Dominguez et al., 2016; Vojta et al., 
2016).  
5-Aza-dC treatment was an example for administration of epigenetic drugs. In order to 
circumvent any non-specific effect of global DNA hypomethylation a CRISPR/dCas9-mediated 
epigenetic approach has been adopted. With this method, dCas9 fused to the catalytic domains of 
either TET1 (DNA demethylase) or M.SssI-Q147L (reduced activity mutant of prokaryotic 
DNMT) was utilized in combination with sgRNAs targeting CpGs that have been identified in 
Illumina EPIC 850k methylation array analysis. Recently it has been shown that a 10% activity 
mutant of M.SssI-derived DNMT (Q147L) is effective in introducing targeted methylation in a 
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more specific manner compared to its eukaryotic counterparts (Lei et al., 2017) and I tus chose to 
use this protein in my study.  
Targeting differentially methylated CpGs in parental MCF7 cells stably expressing dCas9-TET1 
led to an upregulation in GLYATL1 expression as assessed 10 days after transfection with 
sgRNAs, thereby validating the importance of methylation (Figure 34). However it is important 
to note that the upregulation achieved was less than the upregulation in resistant cell lines. This 
hints at the existence of putative other CpGs regulating the expression of GLYATL1. Indeed there 
is a CpG island upstream of GLYATL1 that might be responsible for regulation of this gene along 
with others (such as neighbor gene and family member GLYATL2). Detailed scrutinization of 
EPIC array data would reveal whether there are any probed CpGs differentially methylated in 
this CpG island, providing new target regions to fine-tune GLYATL1 expression. 
Hypomethylation of the promoter region in resistant cell lines might also allow binding of 
transcription factors such as ERα, GATA3 and p300 which I found to have implications on 
regulation of transcription of GLYATL1. 
In contrast, deploying dCas9-Q147L construct led to a decreased expression of GLYATL1 in both 
TAMR and LTED cells targeting the same CpGs (Figure 35 & 36). In the case of 
downregulation of GLYATL1 in TAMR, sgRNAs used were shown to re-sensitize resistant cells 
to tamoxifen treatment as they proliferated less in the presence of tamoxifen compared to vehicle 
control and transfection with control sgRNA (Figure 36b, 36c). These findings are in line with 
the effect of re-sensitization effect of GLYATL1 knockdown in MCF7 TAMR cells (Figure 15b).  
5.9 GLYATL1 as a link between metabolism and epigenetics 
GLYATL1 encodes for an enzyme that uses  L-Glutamine as  substrate (H. Zhang et al., 2007). 
Elevated levels of this enzyme in both resistant cell line models (MCF7 and T47D) suggest an 
increase in glutamine levels in resistant cells compared to their parental counterparts. Recently 
there has been growing number of publications indicating a close interplay between glutamine 
metabolism and epigenetic reprogramming (Z. Chen et al., 2015; Cluntun et al., 2017). Many  
metabolites (e.g. Acetyl-CoA, NAD/NADH, SAM/SAH, ATP) that are crucial for histone 
modification are products of metabolic processes and it has been shown that availability of these 
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metabolites influence the epigenetic composition of the cell, and therefore its chromatin 
architecture (Katada et al., 2012; Phang et al., 2013).  
Here, I have shown that increased GLYATL1 is contributing to elevated H3K9ac and H3K14ac 
in MCF7 resistant cells. It can be argued that this increase can be closely related with metabolic 
rewiring towards glutamine metabolism in resistant cells. Furthermore, a deeper look at the 
RNA-Seq data reveals an increase in ATP citrate synthase (ACLY) mRNA levels in resistant 
MCF7 cells compared to sensitive counterpart (data not shown). ACLY encodes for an enzyme 
that catalyzes synthesis of acetyl-CoA. This can be seen as further evidence for elevated histone 
acetylation since acetyl-CoA accumulation in the cell might be sensed by HATs (Katada et al., 
2012; Shi & Tu, 2015). Even though the metabolomics were not investigated in this study, it is 
important to note that GLYATL1 might be an ideal example linking metabolism to epigenetic 
reprogramming in the context of endocrine therapy resistance. Further investigation to validate 
the proposed alterations in metabolism and increased intracellular acetyl-CoA availability would 
provide invaluable insights to better understand the cross-talk between the metabolic and the 
epigenetic landscapes of endocrine therapy resistant breast cancer.    
5.10 CRISPR/dCas9-mediated epigenetic editing is effective in fine 
tuning target genes  
 
CRISPR/dCas9-mediated epigenetic editing allows alteration of gene expression while providing 
insights about into the epigenetic layer regulating it.  This system offers the advantage and 
flexibility to fine-tune expression of a gene targeting the same region with different effector 
domains fused to dCas9 or utilizing the same effector domain to up- or down-regulate the same 
gene targeting different genomic regulatory regions. This flexibility offers an alternative to the 
use of two different approaches such as RNA interference and overexpression to investigate the 
function of a gene. CRISPRa (CRISPR activation) and CRISPRi (CRISPR interference) 
approaches can be shown as good examples in which dCas9 is fused to either an artificial 
transcriptional activator or a repressor, in order to achieve transcriptional activation and 
silencing, respectively (Sanson et al., 2018). 
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In this study, a hit-and-run CRISPR/dCas9-mediated epigenetic editing approach was established 
to investigate the involvement of target genes in endocrine therapy resistance in luminal breast 
cancer. This has been achieved either via transient transfection of the cells with two plasmids, 
one encoding dCas9 fused to catalytic domain of chosen effector domain and another other 
encoding sgRNA, or transient transfection of doxycycline-inducible cells stably overexpressing 
dCas9-effector domain with sgRNA plasmids. The latter approach was adopted in an attempt to 
increase the transfection efficiency which is modest for a two plasmid transient transfection 
system in the cell lines of interest and was mostly utilized to assess functional effects of 
epigenetic editing on target genes. (Figure 40).  
Epigenetic editing has gained substantial interest recently. Several studies exhibit examples of 
this approach and its implications in the stable modulation of gene expression and epigenetic 
reprogramming (Cano-Rodriguez et al., 2016; Hilton et al., 2015b)  Reprogramming mouse 
primary T-cells by dCas9-p300 induced expression of FOXP3 is one example to such studies. In 
that study, dCas9-p300 construct and sgRNA were stably integrated into the genome and led to a 
substantial increase (approximately 500-fold) in FOXP3 gene expression which could explain 
the effect to achieve stable reprogramming (Okada et al., 2017).  
The changes that are presented in my study are rather modest compared to the ones exemplified 
in the literature. This can be explained by the transient transfection approach I adopted (Figure 
40). Transfection efficiencies could well account for the moderate expression changes. The effect 
size might thus be masked by untransfected cells in the bulk population. This was circumvented 
in part using doxycycline-inducible expression of dCas9-effector domain in target cells. 
Inducible expression of dCas9 was chosen to negate any non-specific binding of constitutively 
expressed dCas9 protein to genome even in the absence of sgRNA as previously shown 
(Galonska et al., 2018).  
The endogenous epigenetic landscape of target gene is yet another and very important limiting 
factor for the efficacy of any CRISPR/dCas9-mediated epigenetic editing. dCas9 is a rather large 
molecule and sterical hindrance introduced by the target region such as existing CpG 
methylation or respressive histone marks restrict its binding, therefore lowering its effectivity to 
introduce epigenetic marks to desired loci. This has been demonstrated in a recent study where 
demethylation of a target region prior to introduction of activating histone marks resulted in 
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improved and stable upregulation or target genes (Cano-Rodriguez et al., 2016). Combination of 
more than one sgRNA might also help improving targeting efficiency as indicated in a recent 
publication where a pool of sgRNAs in combination with dCas9-p300 resulted in a significantly 
higher upregulation of target gene expression compared to singular targeting in a hit-and-run 
approach (Hilton et al., 2015b; Vojta et al., 2016).  
Remarkably, even though the effect sizes in the up- or down-regulation of target genes were 
modest, the epigenetic alterations were found to be stable and remained significant even long 
after transfection (up to 15 days) suggesting that these marks were maintained during several cell 
cycles (Figure 44 & 47). Impressively, the effect of introducing H3K9me/me2 or H3K27me/me2 
with dCas9-G9a proved to exert improved downregulation of BAMBI (and Wnt target gene 
CD44) as shown after 11 days of transfection compared to the effect size 48h post-transfection 
(Figure 53). Utilizing inducible stable cell lines improved the effect size in terms of stability as 
shown in the long-term effects of epigenetic editing for almost all target genes (Figures 34, 35b, 
36, 48b, 52, 54). This further proved that increased transfection efficiency leads to improved 
alteration of gene expression.  
Off-target effects remain an infamous drawback of the CRISPR/dCas9 system and this does not 
change for the re-purposed CRISPR/dCas9-mediated epigenetic editing approach. Even though 
the Cas9 variant used here is catalytically inactive, sufficient sequence identity of sgRNAs with 
other than the intended target region in the genome would alow binding of dCas9 and could lead 
to off-target effects. This needs to be taken into consideration even though off-target binding of 
the Cas9 protein has been reported to have limited impact on the expression of non-targeted 
genes, (Y. Fu et al., 2013; Galonska et al., 2018; Pattanayak et al., 2013)In order to minimize 
off-target effects several sgRNAs were designed for the target genes targeting the region of 
interest (mainly being a gene regulatory sequence such as promoter, CpG island, enhancer). The 
effect of the effector domains in this study presented were achieved with at least two individual 
sgRNAs targeting different parts of the region of interest. Moreover, the off-target effects of a 
hit-and-run approach is likely to be considerably less than stable expression of a dCas9 variant 
and sgRNAs since the occupancy of genomic regions by dCas9 occurs only for a limited time. 
Without a question, further experiments such as ChIP-seq for the dCas9 protein to pinpoint 
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potential other binding sites in the whole genome would be the ultimate experiment to 
interrogate off-target binding.  
It is also important to note that the baseline expression level of a target gene influences the extent 
its expression can be manipulated. This can be seen in the example of SLC9A3R1. This gene is 
highly expressed in MCF7 cells. The increase in MCF7 LTED cells is 1.2 fold compared to 
parental (Figure 41a). Epigenetic editing of this gene using the dCas9-p300 construct resulted in 
a moderate increase, increasing the expression just to the levels of LTED cells. Nevertheless, the 
increase in gene expression was found to be statistically significant and remained upregulated 
even after 12 days of transient transfection (Figure 42). 
What was more interesting regarding SLC9A3R1 was the availability of combinatorial targeting 
of both promoter and enhancer region using dCas9-p300 since the H3K27ac mark is associated 
with active promoters and enhancers. The enhancer region for the gene was uncovered as a result 
of a recent study conducted by a collaborator where clonality of enhancers in primary versus 
metastatic breast cancer was assessed via H3K27ac ChIP-seq (Patten et al., 2018). Here the 
combinatorial targeting of the promoter and enhancer led to a significantly stronger increase in 
gene expression compared to targeting of either regulatory element individually (Figure 43).  
Further experiments on functional effect of SLC9A3R1 manipulation in both sensitive and 
resistant cell lines will likely reveal its contribution to endocrine therapy resistance while 
providing insights regarding epigenetic regulation of this gene. 
5.11 Wnt signaling pathway: BAMBI –CD44 axis 
 
Wnt signaling has been implicated to play a role in endocrine therapy resistance. Knockdown of 
a long non-coding RNA was shown to cause a reduction in Wnt pathway activation, thereby 
rendering tamoxifen-resistant MCF7 cells sensitive to tamoxifen exposure (H. Liu et al., 2016). 
Increased Wnt pathway activity in another in vitro-generated MCF7 tamoxifen resistance model 
could be reversed by inhibition of the pathway (Loh et al., 2013).  
CD44, a target gene of Wnt signaling pathway, encodes for a cell surface glycoprotein that is 
involved in cell adhesion and migration. Higher expression of this gene has been linked to a 
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more aggressive and invasive phenotype (Orian-Rousseau, 2015; Senbanjo & Chellaiah, 2017). 
Recent findings indicate an elevation in the percentage of cell expressing high CD44 levels 
(CD44
high
) in MCF7 cells under estrogen deprivation conditions (Hong et al., 2018). CD44 is 
also shown to be a marker for a subset of breast cancer stem cells (CD44
high
 CD24
low
) (Yan et al., 
2015).  
Indeed MCF7 LTED cells are shown to express more CD44 both at mRNA and protein levels 
(Figure 45). In light of this finding, CD44 was chosen as a target gene for epigenetic editing 
experiments. The experiments presented in this study demonstrated that the expression of the 
CD44 gene can be strongly modified by a hit-and-run CRISPR/Cas9-based epigenetic editing 
approach (Figures 46, 47, 48). This change in expression was found to be stable even 7-15 days 
post transfection (Figures 47, 48).  
Moreover, reduction in CD44 levels as shown in inducible MCF7 LTED cells stably expressing 
dCas9-G9a resulted in re-sensitization of these cells to estrogen deprivation conditions 
manifested as retardation in proliferation (Figure 48). This finding strongly suggests the 
involvement of CD44 in the maintenance of endocrine therapy resistance in MCF7 LTED cell 
line model.  
CD44 marks the endpoint of a signaling pathway, namely Wnt signaling as it is one of the target 
genes that gets transcribed upon Wnt stimulation (Zeilstra et al., 2008). Therefore it was 
intriguing to check whether activation status of Wnt pathway is linked to elevated CD44 levels in 
endocrine therapy resistance. RNA-sequencing data of in vitrogenerated cell linesoriginating 
from two different luminal breast cancer cell lines revealed that BAMBI was differentially 
regulated in resistant cell lines. Its expression was found to be increased in both MCF7 and 
T47D TAMR as well as LTED cells (Figure 49). A negative correlation between BAMBI 
expression and overall patient survival in two independent publicly available breast cancer 
dataset pointed tothe clinical significance of this gene in the context of breast cancer (Figure 49).  
Epigenetic experiments targeting the BAMBI promoter was effective in modulating its expression 
using dCas9-p300 for upregulation and dCas9-G9a for downregulation (Figures 51, 52, 53, 54). 
Alteration of expression changes induced by epigenetic editing proved to be stable over time. 
Intriguingly, BAMBI expression was increased (up to 3-fold) with all individual sgRNAs 
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targeting its promoter in inducible MCF7 cells stably expressing dCas9-TET1, strongly 
suggesting methylation as a regulatory mechanism for the expression of this gene. Changes in 
BAMBI expression upon epigenetic editing was closely correlated with alteration of CD44 
expression, confirming the status of CD44 as a target gene of Wnt pathway as BAMBI acts as the 
activator of canonical Wnt signaling pathway (Lin et al., 2008).     
Downregulation of BAMBI by dCas9-G9a led to a stable decrease in the expression of both 
BAMBI and CD44 expressions. Impressively, reduction in CD44 levels was even stronger upon 
regulation of BAMBI compared to targeting the CD44 promoter directly using the same dCas9 
variant (Figures 48b, 54b). This hints at the fact that targeting a signaling molecule at the 
beginning of a signaling cascade might have a bigger impact than targeting a downstream 
molecule of the same signaling cascade. Moreover, a comparison between doxycycline-inducible 
MCF7 LTED cells stably expressing dCas9-G9a
WT
 and dCas9-G9a
mut
 revealed that 
downregulation of BAMBI and CD44 was achieved only in dCas9-G9aWT cells, validating the 
effect on expression reduction is indeed mediated by the methyltransferase activity of G9a 
(Figure 54). Here it is important to note a limitation of this study as validation of the introduced 
epigenetic marks by bisulfite sequencing (for DNA methylation) and ChIP-qPCR (for histone 
modifications) following epigenetic editing is still missing and should be done in the future. 
Proliferation assays ın MCF7 LTED cells stably expressing dCas9-G9aWT demonstrated that the 
reduction of BAMBI expression by two individual sgRNAs resulted in growth retardation, in 
other words the re-sensitization of LTED cells to estrogen deprivation (Figure 54). The effect 
observed was reminiscent of the CD44 reduction effect in the same cell line. This finding once 
again suggested an involvement of Wnt signaling in the maintenance of endocrine therapy 
resistance, in particular the resistance to aromatase inhibition. Recently it has been demonstrated 
that the activation of CD44 and Wnt signaling might confer a positive feedback loop, as CD44 
overexpression was also shown to increase activation of the Wnt pathway (Schmitt et al., 2015). 
Either way, activation status of Wnt pathway and CD44 remain to be important players of 
endocrine therapy resistance. 
BAMBI had been initially classified as a pseudoreceptor and inhibitor of the Transforming 
Growth Factor-β (TGF-β) pathway. Owing to its homology with the TGF-β receptor as well as 
its lack of an intracellular domain, BAMBI could scavenger TGF-β ligands and attenuate TGF-β 
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signaling (Onichtchouk et al., 1999). Downregulation of BAMBI could potentially lead to 
activation of the TGF-β signaling pathway while causing a reduction in Wnt signaling at the 
same time. The TGF- β pathway is known for its dual and context dependent role in being either 
pro- or anti-tumorigenic (Buck & Knabbe, 2006). However, it has been implicated in a more 
metastatic, invasive and stem-like phenotype in breast cancer (Buck & Knabbe, 2006; Shipitsin 
et al., 2007). Therefore, it is important to check the status of TGF-β signaling when 
epigenetically interfering with BAMBI. 
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5.12 Conclusions and Outlook  
 
In conclusion, this study identifies GLYATL1 as a novel gene with functional relevance in 
endocrine therapy resistance in luminal breast cancer along with its involvement in histone 
acetylation of H3K9 and H3K14 residues. Expression of GLYATL1 was found to be regulated by 
several factors including methylation, growth factor signaling pathway and luminal transcription 
factors.  
As an outlook, interaction partners of GLYATL1 could be detected via mass spectrometry and 
signaling pathways that GLYATL1 is part of could be unraveled via Reverse Phase Protein 
Array (RPPA). Additionally, elucidating the proposed link between glutamine metabolism and 
GLYATL1 might directly connect epigenetics and metabolism. These information could provide 
further insights to better understand how or why this rather overlooked protein is involved in 
endocrine therapy resistance in breast cancer and reveal its vulnerabilites for future therapeutic 
approaches. 
This study denotes the efficiency and flexibility of established hit-and-run CRISPR/dCas9-
mediated epigenetic editing with four different examples as target genes; GLYATL1, SLC9A3R1, 
CD44 and BAMBI. It was shown to be possible to fine-tune the expression of all target genes 
utilizing dCas9 fused to different variants of effector domains depending on the epigenetic 
landscape of the target gene of interest. 
This study has also shown that the epigenetic landscapes and expression of the BAMBI and 
CD44 genes are involved in the maintenance of resistance to endocrine therapy in ER-positive 
breast cancer. This hints at a general involvement of the Wnt signaling pathway in therapy 
resistance. 
As an outlook to this part of my study, it would be interesting to show the activation of the Wnt 
pathway upon epigenetic editing of BAMBI either via nuclear translocation of β–catenin or 
utilizing luciferase activity of Wnt reporter cell lines. Phenotypical assays associated with 
activated Wnt signaling such as migration and invasion could be also of interest to showcase 
functional effect of epigenetic editing on Wnt pathway components.                      
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Abbreviations 
4-OHT  4-Hydroxytamoxifen 
5-Aza-dC 5-Aza-2′-deoxycytidine 
AI  Aromatase inhibitor 
AKT  Serine/Threonine Kinase 1 
ANK  Ankyrin 
ATAC  Assay for Transposase-Accessible Chromatin 
ATP  Adenosine triphosphate  
BAMBI  BMP and activin membrane bound inhibitor 
BCA  Bicinchoninic acid protein assay 
BCa  Breast cancer 
BL  Basal-like 
BRCA  Breast cancer 
BSA  Bovine Serum Albumin 
Cas9  CRISPR associated protein 9 
CDK  Cycling dependent kinase 
cDNA  Complementary deoxyribonucleic acid 
CGI  CpG island 
ChIP  Chromatin immunoprecipitation 
CO2  Carbon dioxide 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeat   
CRISPRa CRISPR activation 
CRISPRi CRISPR interference 
CTRL  Control 
CYP2D6 Cytochrome P450 Family 2 Subfamily D Member 6 
dCas9  Dead Cas9 
DMEM  Dulbecco´S Modified Eagle´s Medium 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
Abbreviations 
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DNMT  DNA methyltransferase 
DOT1L  DOT1 Like Histone Lysine Methyltransferase 
E2  Estrogen 
EDTA  Ethylenediaminetetraacetic acid 
EdU  5-Ethynyl-2'-deoxyuridine 
EGFR  Epidermal growth factor receptor  
ER-  Estrogen receptor  negative 
ER+  Estrogen receptor positive 
ERBB2  Erb-B2 Receptor Tyrosine Kinase 2 
ERα  Estrogen receptor-alpha 
ESR1  Estrogen Receptor 1 
EtOH  Ethanol 
FACS  Fluorescence-activated cell sorting 
FBS  Fetal Bovine Serum 
FISH  Fluorescence in situ hybridisation 
FITC  Fluorescein isothiocyanate 
G9a  Histone-lysine N-methyltransferase EHMT2 
G9a  Histone-lysine N-methyltransferase EHMT2 
GATA3  5-Ethynyl-2'-deoxyuridine 
GLYATL1 Glycine-N-acyltransferase-like 1 
GNAT  GCN5-Related N-Acetyltransferases 
HAT  Histone acetyltransferase 
HDAC  Histone deacetylase 
HER2  Human Epidermal Growth Factor Receptor 2 
HMT  Histone methyltransferase 
IHC  Immunohistochemistry 
JNK  c-Jun N-terminal kinase 
LAR  Luminal androgen receptor 
LTED  Long term estrogen deprivation  
M  Mesenchymal 
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MAPK  Mitogen-Activated Protein Kinase 
METABRIC Molecular Taxonomy of Breast Cancer International Consortium 
mRNA  Messenger ribonucleic acid 
mTOR  Mechanistic Target Of Rapamycin Kinase  
NAD  Nicotinamide adenine dinucleotide 
NADH  Nicotinamide adenine dinucleotide + hydrogen 
NaF  Sodium Fluoride 
ORF  Open reading frame 
OS  Overall survival 
PAM  Protospacer adjacent motif 
PBS  Phosphate buffered saline 
PE  Phycoerythrin 
PFA  Paraformaldehyde 
PI  Propidium iodide 
PI3K  Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 
PI3KCA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha  
PR  Progesterone receptor 
PUM1  Pumilio RNA Binding Family Member 1 
PVDF  Polyvinylidene fluoride 
qRT-PCR Quantitative reverse transcriptase polymerase chain reaction 
RFS  Recurrence-free survival 
RIPA  Radio-immuno precipitation assay 
RNA  Ribonucleic acid 
RNAi  Ribonucleic acid interference 
RPPA  Reverse phase protein array 
RT  Room temperature 
RTCA  Real time cell analyzer 
SAM  S-Adenosyl methionine 
SD  Standard deviation 
SDS PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
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SEM  Standard error of mean 
SERD  Selective estrogen receptor downregulator 
SERM  Selective estrogen receptor modulator 
SET  Su(var)3-9, Enhancer-of-zeste and Trithorax 
sgRNA  Single guide RNA 
siRNA  Small interfering ribonucleic acid  
SLC9A3R1 Solute Carrier Family 9 (Sodium/Hydrogen Exchanger), Isoform 3 Regulatory Factor 1 
TAMR  Tamoxifen resistant 
TBST  Tris buffered saline with Tween 20 
TCGA  The cancer genome atlas 
TEMED Tetramethylethylenediamine 
TET  Ten-eleven Translocation 
TGFβ  Transforming growth factor β 
TNBC  Triple negative breast cancer 
TP53  Tumor protein 53 
TSS  Transcription start site 
UCSC  University of California, Santa Cruz 
Wnt  Wingless-type MMTV integration site family 
WT  Wild type 
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